UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
     
þ   ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2008
OR
     
o   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________ to _________
Commission file number: 333-123081
HEALTH BENEFITS DIRECT CORPORATION
(Exact Name of Registrant as Specified in Its Charter)
     
Delaware   98-0438502
     
(State or Other Jurisdiction of
Incorporation or Organization)
  (I.R.S. Employer
Identification No.)
     
150 N. Radnor-Chester Road
Suite B-101
Radnor, Pennsylvania
  19087
     
(Address of Principal Executive Offices)   (Zip Code)
(484) 654-2200
 
Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act: None.
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, par value $0.001 per share
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. o  Yes    þ  No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. o  Yes    þ  No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes  þ    No  o
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer  o Accelerated filer  o   Non-accelerated filer  o
(Do not check if a smaller reporting company)
Smaller reporting company  þ
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
Yes  o    No  þ
The aggregate market value of common stock, par value $0.001 per share, held by non-affiliates at June 30, 2008 (the last business day of the registrant’s most recently completed second fiscal quarter) was $14,773,055. Such aggregate market value was computed by reference to the closing price of the common stock of the registrant on the Over-the-Counter Bulletin Board on June 30, 2008.
As of March 20, 2009, there were 41,279,645 shares of the registrant’s common stock, par value $0.001 per share, outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
None.
 
 

 


 

TABLE OF CONTENTS
         
    Page  
 
       
PART I
    4  
    12  
    13  
    13  
 
       
PART II
    15  
    16  
    F-1  
    98  
    98  
    98  
 
       
PART III
    100  
    104  
    115  
    118  
    120  
    122  
  EX-3.7
  Exhibit 10.31
  Exhibit 21
  Exhibit 23.1
  Exhibit 31.1
  Exhibit 31.2
  Exhibit 32.1

2


 

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS
Certain of the statements contained in this Annual Report on Form 10-K, including in the Business description, the “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in this report are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements herein include, among others, statements addressing management’s views with respect to future financial and operating results and costs associated with the Company’s operations and other similar statements. Various factors, including competitive pressures, market interest rates, changes in insurance carrier mix, regulatory changes, customer and insurance carrier defaults or insolvencies, litigation, acquisition of businesses that do not perform as we expect or that are difficult for us to integrate or control, adverse resolution of any contract or other disputes with customers and insurance carriers, or the loss of one or more key insurance carrier relationships, could cause actual outcomes and results to differ materially from those described in forward-looking statements.
The words “may,” “will,” “expect,” “intend,” “anticipate,” “estimate,” “believe,” “continue” and similar expressions may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. While we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report on Form 10-K, we caution you that these statements are based on a combination of facts and factors currently known by us and projections of the future about which we cannot be certain. Many factors, including general business and economic conditions, affect our ability to achieve our objectives. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report on Form 10-K will prove to be accurate. In addition, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, if at all. We may not update these forward-looking statements, even though our situation may change in the future.

3


 

PART I
ITEM 1. BUSINESS.
Overview
     We were originally incorporated under the laws of the state of Nevada on October 21, 2004 as Darwin Resources Corp., an exploration stage company engaged in mineral exploration. On November 22, 2005, Darwin Resources Corp. merged with and into its newly-formed wholly-owned subsidiary, Darwin Resources Corp., a Delaware corporation, solely for the purpose of changing its state of incorporation from Nevada to Delaware. On November 23, 2005, HBDC II, Inc., a newly-formed wholly-owned subsidiary of Darwin Resources Corp., was merged with and into Health Benefits Direct Corporation, a privately-held Delaware corporation, and the name of the resulting entity was changed from Health Benefits Direct Corporation to HBDC II, Inc. Following the merger, Darwin Resources Corp. changed its name to Health Benefits Direct Corporation and we began operations in our current form.
     We operate though three distinct businesses in two business segments: our Telesales business segment, which is comprised of our Telesales business and our Insurint business, and the Atiam business segment.
     Telesales specializes in the direct marketing of health and life insurance and related products to individuals and families. Telesales has developed proprietary technologies and processes to connect prospective insurance customers with Telesales’ agents and service personnel using an integrated on-line platform with call center follow up. Telesales employs licensed agents supported by tele-application, customer service and technology employees for the purpose of providing immediate information to prospective customers and selling insurance products. Telesales receives commission and other fees from the insurance companies on behalf of which it sells insurance products for the sale of such products. During the first quarter of 2009 we ceased marketing and selling activities in Telesales and sold the majority of our call center-produced agency business to eHealth Insurance Services, Inc. (“eHealth”).
     Insurint™ is a proprietary, professional-grade, web-based agent portal that aggregates real-time quotes and underwriting information from multiple highly-rated carriers of health and life insurance and related products. We market Insurint using a Software as a Service (SaaS) model instead of software licensing model, which offers easy web-based distribution and pay-as-you-go pricing. We market primarily to insurance agents, agencies, and other organizations selling health insurance products to families and individuals. Unlike existing health insurance quote engines, Insurint also enables an agent to input responses to a set of questions about the health of proposed insureds to place an insurance policy faster and more accurately. In addition, Insurint offers a suite of sales tools that agents can use to increase their overall sales production.
     Atiam is a provider of comprehensive, web-based insurance administration software applications. Atiam’s flagship software product is InsPro, which was introduced 2004. Atiam’s clients include insurance carriers and third party administrators. Atiam realizes revenue from the sale of software licenses, application service provider fees, software maintenance fees and consulting and implementation services. We acquired Atiam on October 1, 2007.

4


 

Telesales
     Telesales is an independent agency, selling health and life insurance and related products on behalf of a number of nationally-branded, highly-rated insurance carriers. The primary product we sell on behalf of insurance carriers is major medical health insurance for individuals and families. We also sell short-term medical policies (term shorter than one year), health savings accounts and term life insurance. We believe these additional products represent significant cross-sell opportunities to our existing client base with minimal acquisition cost.
     Our service is free to consumers and our principal source of revenue is commissions paid to us by our insurance carrier partners as compensation for policies sold. Our commissions are based on a percentage of the premium amount collected by a carrier during the period that a customer maintains coverage under a policy. These commissions include first year commissions and renewal commissions. First year commission rates are significantly higher than renewal commission rates. We also are eligible for incentive bonuses based on our ability to meet pre-determined criteria established by our insurance carriers. The amounts of commissions and incentive bonuses for which we are eligible vary, often significantly, by carrier and product. Our licensed agents assist consumers in sorting through the complicated process of selecting and obtaining health or life insurance or related products.
     During the first quarter of 2009, we ceased the direct marketing and sale of health and life insurance and related products to individuals and families in our Telesales call center. We continue to sell health and life insurance and related products to individuals and families through our non employee Insurance Specialist Group, Inc. (“ISG”) agents. Our Telesales business segment eliminated 43 positions, including all of our licensed employee sales agents and certain of our Telesales service and support personnel, and we eliminated another 20 positions in Telesales through attrition.
     On February 20, 2009, we completed the sale of our Telesales call center-produced agency business to eHealth, an unaffiliated third party.
     Pursuant to the terms of the sale, we transferred to eHealth broker of record status and the right to receive commissions on certain of the in-force individual and family major medical health insurance policies and ancillary dental, life and vision insurance policies issued by Aetna, Inc., Golden Rule, Humana, PacifiCare, Inc., Assurant and United Healthcare Insurance Co. on which we were designated as broker of record. We still retain of the right to receive commission of certain policies and products, including the agency business generated through our ISG agents, all short term medical products and all business produced through carriers other than the specified carriers mentioned above. In addition, we also transferred to eHealth certain lead information relating to health insurance prospects. Going forward, eHealth has agreed to pay us a portion of each commission payment received by eHealth relating to the transferred policies for the duration of each policy, for so long as eHealth remains broker of record on such policy.
     In addition, we will continue to receive a portion of all first year and renewal commissions received by eHealth from policies sold through certain referral sites that result from leads delivered by us to eHealth. We are entitled to receive these payments under the terms of a Marketing and Referral Agreement, with eHealth, which is scheduled to terminate on August 20, 2010.

5


 

     As a result of the above transactions, management anticipates a significant decline in future Telesales revenues as a result of the cessation of direct marketing and sales in Telesales and the eHealth transaction. Revenue from the five insurance carriers subject to the eHealth transactions accounted for 66% of the Company’s total revenue for the year ended December 31, 2008. We believe the reduction in future revenues will be mitigated by significant reductions in future expenses.
Insurint
      Principal Products and Services
     Insurint™ is a web based tool that provides insurance agents and brokers with an all-in-one, real time quoting engine and on-demand customer relationship management, or CRM, platform. It helps insurance agents and brokers streamline their sales and marketing activities and increases agent productivity, which ultimately strengthens the customer relationship. Insurint utilizes a Software as a Service (SaaS) model instead of software licensing model, which offers easy web-based access and pay-as-you-go pricing. Currently, we recognize revenue based on both one time setup and recurring monthly access fees.
     During 2008 we earned $97,177 in revenue from Insurint™.
     There are more than one million independent insurance agents licensed to sell health and life insurance to individuals and groups in the United States. The vast majority of these agents use a combination of manual quoting methods (such as rating tables from different carriers), legacy software tools (such as stand-alone CRM software) and hard copies of underwriting guides to address their customer’s needs and manage their business. While Insurint™ is designed for the use of independent insurance agents, it may also be used by insurance company’s direct sales departments, or captive agents. We believe there is a significant opportunity for Insurint™, based on this tool’s unique strengths as described below, to provide a large number of these agents with a comprehensive, end-to-end solution that meets all of their quoting, underwriting, CRM and marketing needs, allowing them to improve their efficiency and maximize their productivity:
    Insurint™ is a one-stop platform from which an agent may choose from a variety of health and life insurance products and carriers. Insurint™ allows the insurance sales agent to cross sell products or bundle quotes across different product lines.
 
    Insurint™ provides real-time information and underwriting intelligence to help agents build their business, while saving time and taking the hassle out of quoting and comparing individual plans.
 
    Insurint™ provides seamless integration of the quoting engine with CRM features, which helps an agent to be more efficient with his or her sales, marketing and customer management activities. Insurint™ can also enable an agent to make service calls to his or her customers, thus improving customer service and providing another selling opportunity for the agent.
 
    Insurint™ provides an integrated web sharing tool, InsurintConnect, which allows the agent to share the sales process and presentation with the client, thereby involving the client in the sale, and helping them move from multiple plan choices to a logical conclusion to meet their coverage needs.

6


 

    Insurint™ provides a brandable, flexible technology framework, which can be customized to the needs of agencies of all sizes, and may integrate with any existing telephony and/or CRM solution they may already employ.
      Marketing, Sales and Operations
     Insurint’s marketing utilizes aggregator and affinity relationships, which seeks co-marketing opportunities that create synergies between products and organizations, email promotions and presentations at important industry events. Insurint’s marketing message and graphical treatment is centered on an evolutionary concept, and is positioning itself as the “Next Stage in the Evolution of Insurance Technology.” Insurint’s sales team provides both personalized and group demonstrations to agents, agencies and carriers looking to learn more about Insurint™.
     Insurint currently has several key vendor agreements and relationships, which provide functionality for portions of Insurint™’s quoting engine. The unanticipated loss of the functionality of portions of Insurint’s quoting engine, which are provided by key vendors, would result in an interruption of Insurint™’s product delivery to its customers until such time that Insurint integrated replacement functionality from alternative vendors or sources. The loss of such functionality could result in the loss of existing customers and revenue. To mitigate the negative impact of the potential loss of such functionality Insurint has contractual agreements with key vendors, which include performance standards and minimum contractual time periods. Insurint monitors these key vendor relationships, their performance of services and periodically evaluates alternative vendors and services.
     Insurint depends on various hosting and technology vendors, which provide services critical to Insurint’s delivery of products and services to Insurint’s customers. Such hosting and technology services can be replaced with comparable services from other vendors on short notice.
Atiam Business Segment
     We acquired Atiam Technologies, L.P. on October 1, 2007 and now operate this business as our Atiam business segment. Atiam and its predecessor Systems Consulting Associates, Inc. (“SCA”) was founded in 1986 by Robert J. Oakes as a programming and consulting services company. In 1988 SCA entered into a long-term contract with Provident Mutual Insurance Company to develop, maintain, install, support, and enhance IMACS, which was an insurance direct marketing and administration software system. IMACS was the precursor of InsPro. Atiam dedicated four years, from 2001 to 2005, to developing Atiam’s principal product InsPro, which is a comprehensive, scalable, and modular web-based insurance marketing, claims administration, and policy servicing platform.
      Principal Products and Services
     Our Atiam business segment offers InsPro on a licensed and an ASP (Application Service Provider) basis. InsPro is an insurance administration and marketing system that supports group and individual business lines, and efficiently processes agent, direct market, worksite and web site generated business.
     During 2008, we earned 87% of Atiam’s revenues from our four largest Atiam clients as follows; client #1 $2,885,388, client #2 $786,740, client #3 $576,399 and client #4 $552,138.

7


 

     InsPro incorporates a modular design, which enables the customer to purchase only the functionality needed, thus minimizing the customer’s implementation cost and time necessary to implement InsPro. InsPro can be rapidly tailored to the requirements of a wide range of customers from the largest insurance companies and marketing organizations to the smallest third party administrators, operating in environments ranging from a single server environment to the mainframe installations. InsPro currently supports a wide range of distribution channels, including the Internet, traditional direct marketing, agent-booked, individual and group plans, worksite, and association booked business, and supports underwritten as well as guaranteed products including long term care, Medicare supplement, critical illness, long and short term disability, whole and term life, comprehensive major, hospital indemnity accidental death and dismemberment.
     An InsPro software license entitles the purchaser a perpetual license to a copy of the InsPro software installed at a single client location, which may be used to drive a production and model office instance of the application. The ASP Hosting Service enables a client to lease the InsPro software, paying only for that capacity required to support their business. ASP clients access an instance of InsPro installed on Atiam owned servers located at Atiam’s offices or at a third party’s site.
     Software maintenance fees apply to both licensed and ASP clients. Maintenance fees cover periodic updates to the application and the InsPro Help Desk.
     Consulting and implementation services are generally associated with the implementation of an InsPro instance for either an ASP or licensed client, and cover such activity as InsPro installation, configuration, modification of InsPro functionality, client insurance plan set-up, client insurance document design, and system documentation.
      Sales, Marketing and Operations
     Atiam markets its products and services directly to prospective insurance carriers and third party administrators via trade shows, advertising in industry publications and direct mail.
     Atiam delivers services to its clients, which include InsPro system implementation, legacy system migration to InsPro, InsPro application management, web development, InsPro help desk and 24x7 hosting service support.
Competition
      Telesales
     The individual health and life insurance agency market is highly competitive and has few barriers to entry. We anticipate that competition in this market will continue to intensify. We are not aware of any insurance sales agency that utilizes an interactive insurance marketplace substantially similar to ours. However, significant competition exists from companies engaging in traditional and Internet-only sales. These competitors include large and small insurance carriers, agencies that operate on a national and regional basis and individual agents. We also anticipate substantial new competition in this market, including from competitors with an interactive insurance marketplace substantially similar to ours.

8


 

     Many of our competitors are more established than we are, and have significantly greater financial, technical, marketing, and other resources than we do. Many of our competitors have greater name recognition and a larger customer base than we do. These competitors may be able to respond more quickly to new or changing opportunities and customer requirements and may be able to undertake more extensive promotional activities and offer more attractive terms to insurance carriers.
     During the first quarter of 2009 we ceased marketing and selling activities in Telesales and sold our call center-produced agency business to eHealth Insurance Services, Inc.
      Insurint
     The life and health insurance field agent tool market is fragmented, but also very competitive, and is characterized by rapidly changing consumer demand and technological change. We believe Insurint’s competitors fall into three categories, which are:
    Direct competitors, who provide web based tools targeting the life and health insurance agent’s desktop, which includes Norvax, Quotit and HealthConnect;
 
    The insurance agent’s insurance agencies and their technology partners, who provide internally developed web based tools;
 
    Indirect competitors, who provide web based tools targeting insurance agents selling insurance products other than primarily health insurance, such as Agencyworks’ InsureSocket Brokerage, Connecture’s InsureConnect, iPipeline, which all target life insurance agents, Ebix (for Life and Property and casualty insurance agents), and iBommerang, which provides co-browsing for insurance agents.
     Insurint’s major competitors in the agent quoting and sales software market for individual major medical products are Norvax, which was founded in 2001 and has created a recognized brand, and Quotit, which was founded in 1999 and has strong relationships with more than 120 insurance carriers in health, life, dental and vision insurance markets.
      Atiam
     The market for insurance policy administration systems and services are very competitive, rapidly evolving, highly fragmented and subject to rapid technological change. Many of our competitors are more established than we are and have greater name recognition, a larger customer base and greater financial, technical and marketing resources than Atiam’s.
     Atiam is focused on the senior health, disability, affinity and association segments. Atiam competes with such concerns as International Business Machines Corporation (Genelco Software), Computer Sciences Corporation (FutureFirst), LifePro, and Fiserv Inc. (ID3), as well as with such smaller enterprises as Management Data, Inc. To compete we use best practice technologies and methods incorporated into InsPro, which provides customers with a user-friendly, flexible, modular and cost-effective insurance administrative software system. We also compete on price with a typical InsPro software license fee ranging from $500,000 to $750,000, compared to $800,000 to $900,000 from our competitors. InsPro’s modular design, scalability and ASP hosting service option makes it a compelling insurance administrative system from

9


 

small third party administrators to the largest insurance carriers.
Employees
     As of December 31, 2008, we had 120 employees, which included 118 full-time and 2 part-time employees. None of our employees are members of any labor union and we are not a party to any collective bargaining agreement. We believe that the relationship between our management and our employees is good.
Intellectual Property and Proprietary Rights
     We rely on a combination of trademark, copyright and trade secret laws in the United States and other jurisdictions as well as confidentiality procedures and contractual provisions to protect our proprietary technology and our brand. We also have filed patent applications that relate to certain of our technologies and business processes.
Governmental Regulation
     Our Telesales activities are subject to governmental regulation at both the state and federal level. Our non-insurance activities are subject to governmental regulation much like many other non-insurance companies. Our Telesales insurance carrier partners also are subject to governmental regulation at both the state and federal level. In addition, there are still relatively few laws or regulations specifically addressing our Internet activities. As a result, the manner in which existing laws and regulations could be applied to the Internet in general, and how they relate to our businesses in particular, is unclear in many cases. Such uncertainty arises under existing laws regulating matters including user privacy, defamation, pricing, advertising, taxation, gambling, sweepstakes, promotions, content regulation, quality of products and services, and intellectual property ownership and infringement.
     We expect to post privacy policy and practices concerning the use and disclosure of any user data on our websites. Failure to comply with posted privacy policies, Federal Trade Commission requirements, or other domestic or international privacy-related laws and regulations could result in governmental proceedings. There are multiple legislative proposals before federal and state legislative bodies regarding privacy issues. It is not possible to predict whether or when such legislation may be adopted, and certain proposals, if adopted, could harm our business through a decrease in use and revenue.
     Our Telesales direct marketing operations are or may become subject to additional federal and state “do not call” laws and requirements. In January 2003, the Federal Trade Commission amended its rules to provide for a national “do not call” registry. Under these federal regulations, consumers may have their phone numbers added to the national “do not call” registry. Generally, we are prohibited from calling any consumer whose telephone number is listed in the registry unless the consumer has requested or initiated the contact or given his or her prior consent. Enforcement of the Federal “do not call” provisions began in the fall of 2003, and the rule provides for fines of up to $11,000 per violation and other possible penalties. Our current business model relies heavily on outbound calls from our contact centers to consumers. The federal regulations and similar state laws may restrict our ability to effectively market to new consumers the products we sell on behalf of our insurance carrier partners. Furthermore, compliance with these rules may prove difficult, and we may incur penalties for improperly conducting our marketing activities.

10


 

Corporate Information
     We were incorporated under the laws of the state of Nevada on October 21, 2004 as Darwin Resources Corp., or Darwin-NV, an exploration stage company engaged in mineral exploration. On November 22, 2005, Darwin-NV merged with and into its newly-formed wholly-owned subsidiary, Darwin Resources Corp., a Delaware corporation, or Darwin-DE, solely for the purpose of changing the company’s state of incorporation from Nevada to Delaware. On November 23, 2005, HBDC II, Inc., a newly-formed wholly-owned subsidiary of Darwin-DE, was merged with and into Health Benefits Direct Corporation, a privately-held Delaware corporation engaged in direct marketing and distribution of health and life insurance and related products primarily over the Internet, and the name of the resulting entity was changed from Health Benefits Direct Corporation to HBDC II, Inc. Following this merger, Darwin-DE changed its name to Health Benefits Direct Corporation and, as a result, HBDC II, Inc. became our wholly-owned subsidiary.
     Our principal executive offices are located at 150 N. Radnor-Chester Road, Suite B-101, Radnor, Pennsylvania 19087. Our telephone number is (484) 654-2200. Our website address is www.healthbenefitsdirect.com. The principal offices of our wholly-owned subsidiary, HBDC II, Inc., are located at 2200 S.W. 10th Street, Deerfield Beach, Florida 33442. The principal offices of our wholly-owned subsidiary, Insurint Corporation are located at 2200 S.W. 10th Street, Deerfield Beach, Florida 33442 and its web site is www.insurint.com . The principal offices of our wholly-owned subsidiary, Atiam, are located at 130 Baldwin Tower, Eddystone, PA 19022 and its web site is www.atiam-tech.com .
Investor Information
     All periodic and current reports, registration statements and other material that we are required to file with the Securities and Exchange Commission (“SEC”), including our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) of the Securities Exchange Act of 1934, are available free of charge through our investor relations page at www.healthbenefitsdirect.com . Such documents are available as soon as reasonably practicable after electronic filing of the material with the SEC. Our Internet websites and the information contained therein or connected thereto are not intended to be incorporated into this Annual Report on Form 10-K.
     The public may also read and copy any materials filed by the Company with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Washington, DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site, www.sec.gov, which contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.
Executive Officers of the Registrant
     The following table sets forth the name, age, and title of persons currently serving as our executive officers. Our executive officers are appointed by, and serve at the discretion of, our board of directors.

11


 

             
Name   Age   Position
Anthony R. Verdi
    60     Acting Principal Executive Officer, Chief Financial Officer and Chief Operating Officer
Robert J. Oakes
    50     President and Chief Executive Officer of Atiam Technologies, LLC
     Anthony R. Verdi has served as our Chief Financial Officer and Assistant Secretary since November 2005, as our Chief Operating Officer since April 2008 and from June 20, 2008 as acting Principal Executive Officer. From 2001 until November 2005, Mr. Verdi has provided consulting services to life, health and property and casualty insurance company agency and venture capital clients. From December 1998 until March 2001, Mr. Verdi served as Chief Operating Officer of Provident and Chief Financial Officer of HealthAxis. From January 1990 until December 1998 Mr. Verdi served as Chief Financial Officer of Provident American Corporation. From July 1986 until January 1990, he was the Vice President and Controller of InterCounty Hospitalization and Health Plans, a nonprofit group medical insurer. From April 1971 until July 1986, he served in various finance and accounting capacities for the Academy Insurance Group, ultimately serving as the Assistant Controller.
     Robert Oakes has served as the President and Chief Executive Officer of our Atiam Technologies LLC subsidiary since our acquisition of the subsidiary on October 1, 2007. From 1986 until 2007 Mr. Oakes was President and Chief Executive Officer of the general partner of Atiam Technologies L.P., a software development and servicing company that developed, expanded and serviced products to serve the insurance and financial services markets. Mr. Oakes founded Atiam in 1986 and led the company’s effort to design and develop its flagship product, InsPro .
ITEM 2. PROPERTIES.
     We do not own any real property. We currently lease approximately 50,000 square feet of office space in Deerfield Beach, Florida under a lease agreement with 2200 Deerfield Florida LLC. The lease expires on March 31, 2016 and we have the option to extend the term for two additional 36-month periods, as well as the right to terminate the lease within the first five years. The monthly rent increases every 12 months, starting at $62,500 and ending at approximately $81,550.
     We also lease 7,414 square feet of office space in Radnor, Pennsylvania. We lease this office space under a lease agreement with Radnor Properties-SDC, L.P. The term of the lease commenced on November 1, 2006, and will expire on March 31, 2017. The monthly base rent increases every 12 months, starting at approximately $13,466 and ending at approximately $21,531. Under the terms of the lease agreement, rent is waived for the first five months of the lease term with respect to 5,238 square feet and for the first 12 months for the remaining 2,176 square feet.
     We also sublease approximately 14,000 square feet of office space located in New York, New York. We sublease this office space under a sublease agreement with World Travel Partners I, LLC. The initial term of the sublease terminates on December 30, 2010. The monthly base rent increases every 12 months, starting at approximately $25,250 and ending at approximately $28,420.
     We also lease approximately 13,600 square feet of space in Eddystone, Pennsylvania. We lease this office space under a lease agreement with BPG Officer VI Baldwin Tower L.P.

12


 

The term of this lease commenced on August 1, 2007, and will expire on December 31, 2012. The monthly rent increases every 12 months, starting at approximately $8,500 and ending at approximately $23,900.
ITEM 3. LEGAL PROCEEDINGS.
     On August 7, 2008, a former employee of the Company (the “Plaintiff”) filed a putative collective action in the United States District Court for the Southern District of Florida, case no. 08-CV-61254-Ungaro-Simonton, alleging that the Company and a co-defendant, who is an officer of the Company, unlawfully failed to pay overtime to its insurance sales agents in violation of the Fair Labor Standards Act (“FLSA”). Plaintiff purported to bring claims on behalf of a class of current and former insurance sales agents who were classified as non-exempt by the Company and compensated at an hourly rate, plus commissions (“Agents”). On October 16, 2008, the Court conditionally certified a collective action under the FLSA covering all Agents who worked for the Company within the last three years. Plaintiff and all Agents who opt to participate in the collective action seek payment from the Company of compensation for all overtime hours worked at the rate of one and one-half times their regular rate of pay, liquidated damages, attorneys’ fees, costs, and interest. On March 2, 2009, the parties reached an agreement to settle this case. That settlement will be submitted to the Court for necessary approval.
     On August 28, 2008, a former employee of the Company (the “Plaintiff”) filed a national class action complaint in the Seventeenth Judicial Circuit of Florida, Broward County, case no. 062008 CA 042798 XXX CE, alleging that the Company breached a contract with employees by failing to provide certain commissions and/or bonuses. The complaint also contains claims for an accounting and for declaratory relief relating to the alleged compensation agreement. Plaintiff purports to bring these claims on behalf of a class of current and former insurance sales agents. Plaintiff seeks payment from the Company of all commissions allegedly owed to him and the putative class, triple damages, attorneys’ fees, costs, and interest. The Company filed a motion to dismiss the complaint, which has not yet been heard by the court. The Company believes that these claims are without merit and intends to vigorously defend the litigation.
     We are also involved in various investigations, claims and lawsuits arising in the normal conduct of our business, none of which, in our opinion, will harm our business. We cannot assure that we will prevail in any litigation. Regardless of the outcome, any litigation may require us to incur significant litigation expense and may result in significant diversion of our attention.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
     We held our annual meeting of shareholders on October 2, 2009. The following nominees were elected to our board of directors at our annual meeting. The number of votes for each nominee is set forth below:
                 
    Number of    
    Shares Voted in   Number of Shares
    Favor   Withheld
Donald R. Caldwell
    26,730,713       217,597  
Alvin H. Clemens
    26,524,713       423,597  
John Harrison
    26,876,713       71,597  
Warren V. Musser
    26,798,713       149,597  
Robert J. Oakes
    26,881,713       66,597  
Sanford Rich
    26,826,713       121,597  
L.J. Rowell
    26,831,713       116,597  
Paul Soltoff
    26,708,713       239,597  
Frederick C. Tecce
    26,703,713       244,597  
Anthony R. Verdi
    26,878,713       69,597  
Edmond Walters
    26,831,713       116,597  

13


 

     In addition, each of the following two proposals was approved at the annual meeting. The number of votes for each proposal is set forth below:
                         
    For   Against   Abstain
Proposal to ratify the appointment of Sherb & Co., LLP as the Company’s independent registered public accountants for the fiscal year ending December 31, 2008
    26,527,029       358,148       63,133  
 
                       
Proposal to approve the adoption of the Health Benefits Direct Corporation 2008 Equity Compensation Plan
    15,208,466       499,015       191,289  
There were no broker non-votes with respect to the election of directors and the proposal to ratify the appointment of Sherb & Co., LLP as the Company’s independent registered public accountants for the fiscal year ending December 31, 2008. There were 9,874,540 broker non-votes with respect to the proposal to approve the adoption of the Health Benefits Direct Corporation 2008 Equity Compensation Plan .

14


 

PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.
Market Information
     The following table sets forth the high and low bid prices for our common stock for the periods indicated, as reported by the OTCBB. The prices state inter-dealer quotations, which do not include retail mark-ups, mark-downs or commissions. Such prices do not necessarily represent actual transactions.
                 
    High   Low
2007:
               
First quarter, ended March 31, 2007
  $ 3.26     $ 2.55  
Second quarter, ended June 30, 2007
  $ 2.93     $ 2.20  
Third quarter, ended September 30, 2007
  $ 2.40     $ 1.75  
Fourth quarter, ended December 31, 2007
  $ 2.60     $ 1.65  
 
               
2008:
               
First quarter, ended March 31, 2008
  $ 1.90     $ 0.70  
Second quarter, ended June 30, 2008
  $ 1.02     $ 0.41  
Third quarter, ended September 30, 2008
  $ 0.70     $ 0.21  
Fourth quarter, ended December 31, 2008
  $ 0.40     $ 0.06  
 
               
2009
               
First quarter through March 30, 2009
  $ 0.16     $ 0.05  
Holders of Record
     Based on information furnished by our transfer agent, as of December 31, 2008, we had approximately 137 holders of record of our common stock.
     Our common stock has been quoted on the OTCBB since December 13, 2005 under the symbol HBDT.OB. Prior to that date, there was no active market for our common stock. Based on information furnished by our transfer agent, as of February 6, 2009, we had approximately 132 holders of record of our common stock. We have not declared any cash dividends on our common stock during the last two fiscal years.

15


 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
OVERVIEW
Health Benefits Direct Corporation operates through two business segments.
The Atiam business segment, or Atiam, is a provider of comprehensive, web-based insurance administration software applications. Atiam’s flagship software product is InsPro, which was introduced in 2004. Atiam’s clients include insurance carriers and third party administrators. Atiam realizes revenue from the sale of software licenses, application service provider fees, software maintenance fees and consulting and implementation services.
The Telesales business segment, or Telesales, specializes in the direct marketing of health and life insurance and related products to individuals and families. Telesales has developed proprietary technologies and processes to connect prospective insurance customers with Telesales’ agents and service personnel using an integrated on-line platform with call center follow up. Telesales employs licensed agents supported by tele-application, customer service and technology employees for the purpose of providing immediate information to prospective customers and selling insurance products. Telesales receives commission and other fees from the insurance companies for the sale of their products.
During the first quarter of 2009, we ceased the direct marketing and sale of health and life insurance and related products to individuals and families in our Telesales call center. We continue to sell health and life insurance and related products to individuals and families through our non-employee ISG agents. Our Telesales business segment eliminated 43 positions, including all of its licensed employee sales agents along with other Telesales service and support personnel, and eliminated another 20 positions in Telesales through attrition.
On February 20, 2009, we entered into a Client Transition Agreement with eHealth, pursuant to which we transferred to eHealth certain lead information relating to health insurance prospects and broker of record status and the right to receive commissions on certain of the in-force individual and family major medial health insurance policies and ancillary dental, life and vision insurance policies issued by Aetna, Inc., Golden Rule Insurance Company, Humana, Inc., PacifiCare, Inc., Time Insurance Company (marketed under the name Assurant Health) and United Healthcare Insurance Co. on which we were designated as the broker of record as of that date. Certain policies and products were excluded from the transaction, including our agency business generated through our ISG agents, all short term medical products and all business produced through carriers other than the specified carriers. As consideration for such transfer, eHealth agreed to pay us approximately $1,280,000 in cash and to assume certain of our liabilities relating to historical commission advances on the transferred policies in an aggregate amount of approximately $1,385,000. eHealth has also agreed to pay us a portion of each commission payment received by eHealth relating to a transferred policy for the duration of the policy, provided that eHealth remains broker of record on such policy. Additionally, eHealth agreed to construct one or more websites for the purpose of selling health insurance products and to pay us a portion of all first year and renewal commissions received by eHealth from policies sold through such websites that result from marketing to prospects using leads that we delivered to eHealth.

16


 

Management anticipates a significant decline in future Telesales revenues as a result of the cessation of direct marketing and sales in Telesales and the eHealth transaction. Revenue from the five insurance carriers covered by the eHealth transaction accounted for 66% of our total revenue for 2008 and 85% of our Telesales segment. Management believes the reduction in future revenues will be mitigated by significant reductions in future expenses.
We have not yet completed a determination of the impairment of long term assets as a result of the cessation of direct marketing and sales and eHealth transaction. The long term assets, which may be impaired, and their net book value as of December 31, 2008, include property and equipment net of depreciation of approximately $434,067, internet domain name www.healthbenefitsdirect.com of $22,389, intangible assets net of accumulated amortization acquired from ISG, including the value of purchased commission override revenue of $227,779 and value of acquired carrier contracts and agent relationships of $1,032,294. We anticipate completing an impairment determination during the first quarter of 2009.
CRITICAL ACCOUNTING POLICIES
The following is a discussion of our critical accounting policies and methods. Critical accounting policies are defined as those that are both important to the portrayal of our financial condition and results of operations and are reflective of significant judgments and uncertainties made by management that may result in materially different results under different assumptions and conditions. Note 2 to the consolidated financial statements for the year ended December 31, 2008 includes further information on the significant accounting policies and methods used in the preparation of our consolidated financial statements.
The preparation of financial statements in conformity with U.S. generally accepted accounting principals requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate the application of these estimates, including those related to the recoverability of investments, useful lives of intangible assets, valuation of goodwill, product development costs, revenue recognition and deferred revenue and accounting for income taxes. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual amounts could differ significantly from these estimates.

17


 

Revenue Recognition Policy
Our Telesales segment generates revenues primarily from the receipt of commissions paid to us by insurance companies based upon the insurance policies sold to consumers through our service. These revenues are in the form of first year, bonus and renewal commissions that vary by company and product. We recognize commission revenue from the sale of primarily health insurance, after we receive notice that the insurance company has received payment of the related premium. First year commission revenues per policy can fluctuate due to changing premiums, commission rates, and types or amount of insurance sold. We receive bonuses based upon individual criteria set by insurance companies. We recognize bonus revenues when we receive notification from the insurance company of the bonus due to us. Bonus revenues are typically higher in the fourth quarter of our fiscal year due to the bonus system used by many health insurance companies, which pay greater amounts based upon the achievement of certain levels of annual production. Revenues for renewal commissions are recognized after we receive notice that the insurance company has received payment for a renewal premium. Renewal commission rates are significantly less than first year commission rates and may not be offered by every insurance company. We also generate revenue from the sale of leads to third parties. Such revenues are recognized when we receive notification from those sources of the revenue due to us. Our revenue recognition accounting policy has been applied to all periods presented in this report. The timing between when we submit a consumer’s application for insurance to the insurance company and when we generate revenues has varied over time. The type of insurance product, the insurance company’s premium billing and collection process, and the insurance company’s backlog are the primary factors that impact the length of time between submitted applications and revenue recognition. Any changes in the amount of time between submitted application and revenue recognition, which will be influenced by many factors not under our control, will create fluctuations in our operating results and could affect our business, operating results and financial condition.
The Company also generates revenue from the sub-lease of our leased New York City office and a portion of our leased Deerfield Beach Florida office, which are both leased under operating leases. The terms of the Company’s sub-lease of our New York City office is under similar terms as our lease. The Company sub-leases portions of our Deerfield Beach office to two unaffiliated parties through January 31, 2010. Sub-lease revenue includes base rent, additional rent representing a portion of occupancy expenses under the terms of the sub-leases and certain technology and facility services provided. We recognize sub-lease revenue when lease rent payments are due in accordance with the sub-lease agreements in accordance with SFAS No. 13 “Accounting for Leases.” Recognition of sub-lease revenue commences when control of the facility has been given to the tenant. We record a provision for losses on accounts receivable equal to the estimated uncollectible amounts. This estimate is based on our historical experience and a review of the current status of the Company’s receivables.
Our Atiam business segment offers InsPro on a licensed and an application service provider, or ASP, basis. An InsPro software license entitles the purchaser to a perpetual license to a copy of the InsPro software installed at a single client location, which may be used to drive a production and model office instance of the application. The ASP hosting service enables a client to lease the InsPro software, paying only for that capacity required to support their business. ASP clients access an instance of InsPro installed on Atiam owned servers located at Atiam’s offices or at a third party’s site.
Software maintenance fees apply to both licensed and ASP clients. Maintenance fees cover periodic updates to the application and the InsPro Help Desk.

18


 

Consulting and implementation services are generally associated with the implementation of an InsPro instance for either an ASP or licensed client, and cover such activity as InsPro installation, configuration, modification of InsPro functionality, client insurance plan set-up, client insurance document design, and system documentation.
The Company recognizes revenues in accordance with AICPA Statement of Position (SOP) 97-2, Software Revenue Recognition , as amended by SOP 98-9 (Modification of SOP 97-2, Software Revenue Recognition, With Respect to Certain Transactions). Revenue from software license agreements is recognized when persuasive evidence of an agreement exists, delivery of the software has occurred, the fee is fixed or determinable, and collectibility is probable. The Company considers fees relating to arrangements with payment terms extending beyond one year to not be fixed or determinable and revenue for these arrangements is recognized as payments become due from the customer. In software arrangements that include more than one InsPro module, the Company allocates the total arrangement fee among the modules based on the relative fair value of each of the modules.
License revenue allocated to software products generally is recognized upon delivery of the products or deferred and recognized in future periods to the extent that an arrangement includes one or more elements to be delivered at a future date and for which fair values have not been established. Revenue allocated to maintenance agreements is recognized ratably over the maintenance term and revenue allocated to training and other service elements is recognized as the services are performed.
The unearned portion of Atiam business segment revenue has been included in the consolidated balance sheet as a liability for deferred revenue.
Under the criteria set forth in SOP 98-1, “Accounting for the Costs of Computer Software Developed or Obtained for Internal Use” capitalization of software development costs begins upon the establishment of technological feasibility of the software. The establishment of technological feasibility and the ongoing assessment of the recoverability of these costs require considerable judgment by management with respect to certain external factors, including, but not limited to, anticipated future gross product revenues, estimated economic life, and changes in software and hardware technology. Capitalized software development costs are amortized utilizing the straight-line method over the estimated economic life of the software not to exceed three years. We regularly review the carrying value of software development assets and a loss is recognized when the unamortized costs are deemed unrecoverable based on the estimated cash flows to be generated from the applicable software.
We review the carrying value of property and equipment and intangible assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparison of its carrying amount to the undiscounted cash flows that the asset or asset group is expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the property, if any, exceeds its fair market value.

19


 

Effective January 1, 2006, we adopted the provisions of SFAS No. 123(R), “Share-Based Payment,” under the modified prospective method. SFAS No. 123(R) eliminates accounting for share-based compensation transactions using the intrinsic value method prescribed under APB Opinion No. 25, “Accounting for Stock Issued to Employees,” and requires instead that such transactions be accounted for using a fair-value-based method. Under the modified prospective method, we are required to recognize compensation cost for share-based payments to employees based on their grant-date fair value from the beginning of the fiscal period in which the recognition provisions are first applied. For periods prior to adoption, the financial statements are unchanged, and the pro forma disclosures previously required by SFAS No. 123, as amended by SFAS No. 148, will continue to be required under SFAS No. 123(R) to the extent those amounts differ from those in the Statement of Operations.
ACQUISITION OF ATIAM
We acquired Atiam on October 1, 2007. The results of Atiam’s operations prior to our October 1, 2007 acquisition have been excluded from our financial statements. The results of our Atiam business segment have been included in the Company’s statement of operations as of October 1, 2007. Thus Atiam segment’s results from operations for years ended December 31, 2008 and 2007 are not comparable. The Company accounted for the acquisition of Atiam using the purchase method of accounting in accordance with Statement of Financial Accounting Standards No. 141 “Business Combinations”. Our calculation for the consideration paid for Atiam in connection with the Bilenia Agreement and the Atiam Merger Agreement in the aggregate was $3,080,744 and consisted of the following:
         
Cash payments to sellers
  $ 1,350,000  
Fair value of common stock issued to sellers
    1,650,006  
Estimated direct transaction fees and expenses
    80,738  
 
     
Estimated purchase price
  $ 3,080,744  
 
     
We estimated the fair values of Atiam’s assets acquired and liabilities assumed at the date of acquisition as follows:
         
Cash
  $ 608,534  
Accounts receivable
    643,017  
Prepaid expenses & other assets
    22,623  
Property and equipment, net
    158,819  
Other assets
    3,401  
Intangible assets
    2,097,672  
Accounts payable
    (34,278 )
Accrued expenses
    (122,675 )
Income taxes payable
    (157,288 )
Deferred revenue
    (120,000 )
Long and short term capital lease obligations
    (19,081 )
 
     
 
  $ 3,080,744  
 
     

20


 

Intangible assets acquired from Atiam were assigned the following values: value of client contracts and relationships other than license with an assigned value of $1,089,223 amortized straight line over five years; value of purchased software for sale and licensing value with an assigned value of $644,449 amortized straight line over five years; and employment and non-compete agreements acquired with an assigned value of $364,000 amortized straight line over three years. Intangible assets acquired from Atiam had the following unamortized values as of December 31, 2008: value of client contracts and relationships other than license of $816,916; value of purchased software for sale and licensing value of $483,337; and employment and non-compete agreements acquired of $212,319.
RESULTS OF OPERATIONS FOR YEAR ENDED DECEMBER 31, 2008 COMPARED TO THE YEAR ENDED DECEMBER 31, 2007
Revenues
For the twelve months ended December 31, 2008, we earned revenues of $24,128,027 compared to $20,709,750 for the twelve months ended December 31, 2007, an increase of $3,418,277 or 17%. The increase in revenues is primarily attributable to an increase in Atiam segment revenues. We acquired Atiam on October 1, 2007. The results of Atiam’s operations prior to our October 1, 2007 acquisition have been excluded from our financial statements. The results of our Atiam business segment have been included in the Company’s statement of operations as of October 1, 2007. Thus Atiam segment’s results from operations for years ended December 31, 2008 and 2007 are not comparable. Telesales segment revenues declined due to lower periodic bonus revenue from carriers, which was caused by lower marketing and selling activity. Revenues include the following:
                 
    For the Twelve Months  
    Ended December 31  
    2008     2007  
 
               
Commission revenue from carriers excluding periodic bonuses and ISG
  $ 16,078,942     $ 16,043,563  
Periodic bonus revenue from carriers
    100,392       843,311  
ISG commission revenue
    1,404,244       1,821,958  
Lead sale revenue
    408,120       859,890  
Insurint technology fees
    97,177        
Sub-lease and other revenue
    460,640        
 
           
 
               
Telesales business segment
    18,549,515       19,568,722  
 
           
 
               
Consulting and implementation services
    3,889,069     $ 668,674  
ASP revenue
    1,123,943       244,854  
Sales of software licenses
    115,000       137,500  
Maintenance revenue
    450,500       90,000  
 
           
 
               
Atiam business segment
    5,578,512       1,141,028  
 
           
 
               
Total
  $ 24,128,027     $ 20,709,750  
 
           

21


 

    In 2008, we earned commission revenue from carriers, excluding periodic bonuses and ISG revenues, of $16,078,942 as compared to $16,043,563 in 2007.
    We had 31 licensed insurance agent employees at December 31, 2008 as compared to 118 at December 31, 2007. In March 2008, we closed our New York sales office, which accounted for approximately 20% of our sales activity for 2007. We also reduced sales and sales support staff in our Florida office. As a result of the closure, we terminated 34 licensed sales agents and eliminated eight open licensed sales positions, which were vacated subsequent to December 31, 2007. In October 2008, we further reduced our Telesales sales and sales support staff in our Florida office. In October 2008, we terminated 51 employees, including 22 agents. Management believes the reduction in future revenues will be mitigated by significant reductions in future expenses.
 
    Subsequent to December 31, 2008, we ceased the direct marketing and sale of health and life insurance and related products to individuals and families in our Telesales call center. We continue to sell health and life insurance and related products to individuals and families through our non-employee ISG agents. Our Telesales business segment eliminated 43 positions, which included all Telesales’ licensed employee sales agents along with other Telesales service and support personnel, and eliminated another 20 positions in Telesales through attrition. Management believes these reductions will result in the reduced expenses in excess of reduced revenue.
    In 2008, we earned periodic bonuses from carriers of $100,392 as compared to $843,311 in 2007. The Telesales segment receives bonuses from certain carriers, which are based primarily on the Telesales segment’s sales performance and criteria established by carriers and generally do not extend beyond the current calendar year. Accordingly, we cannot determine what criteria, if any, may be offered by its carriers pertaining to bonuses beyond the current calendar year. As a result of the cessation of direct marketing and sales in 2009, management does not anticipate receiving material periodic bonuses from carriers in the future.
 
    In 2008, we earned revenue of $1,404,244 relating to ISG as compared to $1,821,958 in 2007. ISG revenue declined as a result of reduced new sales, the lapse of inforce business and reduced commission overrides earned on the Telesales segment on new and inforce business. As a result of the transaction with eHealth in February 2009, management anticipates a significant decline in ISG commission revenue as a result of the elimination of commission overrides for all Telesales business.

22


 

    In 2008, we earned revenues of $408,120 relating to the sale of leads to third parties as compared to $859,890 in 2007. We re-sell certain leads that we purchase in order to recoup a portion of our lead cost. The primary reason for the decrease in lead sales revenue is a decrease in lead cost spending, which resulted in a reduced number of leads available for sale. As a result of the cessation of direct marketing in the first quarter of 2009, management does not anticipate receiving material lead revenue in the future.
 
    In 2008, we earned revenues of $97,177 relating to Insurint technology fees. Our Insurint subsidiary provides a proprietary, professional-grade, web based agent portal to support and assist insurance agents in the business of marketing and selling health insurance and related products. Insurint’s technology fees commenced in the second quarter of 2008.
 
    In 2008 we earned revenue of $460,640 relating to the sub-lease of a portion of our Florida office and our former New York sales office. Sub-lease revenue includes base rent, additional rent pertaining to utilities and occupancy costs and certain telephony, technology and facility services provided by us to certain of our sub-tenants.
    On February 21, 2008 the Company entered into a sub-lease agreement with a third party whereby the third party sub-leased approximately 5,200 square feet of our Deerfield Beach office space beginning March 1, 2008 through February 28, 2009. This sub-lease agreement was amended and restated on October 3, 2008 to increase the sub-leased square footage to 13,900 and extend the lease term through January 31, 2010.
 
    On October 1, 2008 the Company entered into a sub-lease agreement with a third party whereby the third party sub-leased approximately 8,000 square feet of our Deerfield Beach office space beginning October 15, 2008 through January 31, 2010. In accordance with this sub-lease agreement the Company recognizes base rent, additional rent representing a portion of certain actual occupancy expenses for our Deerfield Beach office and certain telephony, technology and facility services provided to our sub-tenant.
 
    On April 17, 2008 the Company entered into a sub-lease agreement with a third party whereby the third party will sub-lease our New York office space for the balance of the Company’s Sublease Agreement and pay the Company sub-lease payments essentially equal to the Company’s costs under the Sublease Agreement. The third party commenced paying sub-sublease payments to the Company in September 2008 however the third party failed to pay their December 2008, January and February 2009 rent when due. The Company is a beneficiary to a letter of credit in the amount of $151,503, which is available for the Company to draw against in the event of the third party’s failure to pay their rent when due. We have notified the third party that they have breached their lease and that we will make draws against the letter of credit for amounts past due.

23


 

Total Operating Expenses
Our total operating expenses in 2008 were $33,091,737 as compared to $35,037,791 for 2007, for a decrease of $1,946,054 or 6%. Total operating expenses consisted of the following:
                 
    For the Twelve Months  
    Ended December 31,  
    2008     2007  
 
               
Telesales business segment
  $ 26,781,420     $ 34,219,253  
Atiam business segment
    6,310,318       943,538  
 
           
 
               
Total
  $ 33,091,738     $ 35,162,791  
 
           
Telesales’ operating expenses consisted of the following:
                 
    For the Twelve Months  
    Ended December 31,  
    2008     2007  
 
               
Salaries, commission and related taxes
  $ 13,665,679     $ 17,077,101  
Lead, advertising and other marketing
    4,375,466       8,478,643  
Depreciation and amortization
    1,922,438       2,154,916  
Rent, utilities, telephone and communications
    3,319,088       2,658,471  
Professional fees
    1,672,450       1,915,223  
Loss on impairment of property and equipment
    88,922        
Loss on impairment of intangible asset
    380,711       125,000  
Other general and administrative
    1,356,666       1,809,899  
 
           
 
               
Total
  $ 26,781,420     $ 34,219,253  
 
           
    Salaries, commissions and related taxes declined in 2008 compared to 2007 as a result of employee workforce reductions.
 
    Our operating expenses for 2008 included approximately $3.0 million of non-recurring charges pertaining to severance, acceleration of equity compensation, expenses related to the closing of our New York office and litigation.

24


 

    Loss on impairment of property and equipment pertains to the closure of our Telesales New York sales office. During the first quarter of 2008 Telesales closed its sales office located in New York. As of March 31, 2008, we determined that all furniture and lease-hold improvements located at the New York sales office were impaired as a result of the office closure. During the first quarter of 2008, we recorded $88,922 expense to write-down the value of these assets to their net realizable value.
 
    Loss on impairment of intangible assets pertains to the following:
    During the first quarter of 2008, we determined that the portion of license fee paid by Telesales for a commission system together with capitalized costs incurred to implement the commission system was impaired as a result of the absence of definitive plans to implement this system for internal use in Telesales. We recorded a $295,633 expense in the first quarter of 2008 to write-off the value of this asset.
 
    As a result of Ivan Spinner’s termination of employment, we have determined that the value of an employment and non-compete agreement acquired pertaining to Mr. Spinner was impaired as of December 31, 2008 and recorded an impairment charge of $85,078 in loss on impairment of intangible assets.
We acquired Atiam on October 1, 2007. The results of Atiam’s operations prior to our October 1, 2007 acquisition have been excluded from our financial statements. The results of our Atiam business segment have been included in the Company’s statement of operations as of October 1, 2007. Thus Atiam segment’s results from operations for years ended December 31, 2008 and 2007 are not comparable. Atiam’s operating expenses consisted of the following:
                 
    For the Twelve Months  
    Ended December 31,  
    2008     2007  
 
               
Salaries, commission and related taxes
  $ 3,467,151     $ 467,066  
Lead, advertising and other marketing
    15,017       11,052  
Depreciation and amortization
    645,707       131,851  
Rent, utilities, telephone and communications
    190,626       62,264  
Professional fees
    1,276,052       146,884  
Other general and administrative
    715,765       124,421  
 
           
 
               
Total
  $ 6,310,318     $ 943,538  
 
           

25


 

Other income (expenses)
Interest income was attributable to interest-bearing cash deposits resulting from the capital raised in private placements. The decrease in interest income is the result of a decline in interest rates and to a lesser extent a decline in cash balances.
Interest expense pertains to imputed interest on certain employee obligations.
Net loss
As a result of these factors described above, we reported a net loss of $8,976,084 or $0.23 loss per share in 2008 as compared to a net loss of $14,136,599 or $0.43 loss per share in 2007.
Results of Operations for Telesales Business Segment
Revenues
In 2008, we earned revenues of $18,549,515 as compared to $19,568,722 in 2007, for a decrease of $1,019,207or 5%. Telesales segment revenues declined due to lower periodic bonus revenue from carriers, which was caused by lower marketing and selling activity. Revenues include the following:
                 
    For the Twelve Months  
    Ended December 31  
    2008     2007  
Commission revenue from carriers excluding periodic bonuses and ISG
  $ 16,078,942     $ 16,043,563  
Periodic bonus revenue from carriers
    100,392       843,311  
ISG commission revenue
    1,404,244       1,821,958  
Lead sale revenue
    408,120       859,890  
Insurint technology fees
    97,177        
Sub-lease and other revenue
    460,640        
 
           
 
               
Total
  $ 18,549,515     $ 19,568,722  
 
           
    In 2008, we earned commission revenue from carriers, excluding periodic bonuses and ISG revenues, of $16,078,942 as compared to $16,043,563 in 2007.
    We had 31 licensed insurance agent employees at December 31, 2008 as compared to 118 at December 31, 2007. In March 2008, we closed our New York sales office, which accounted for approximately 20% of our sales activity for 2007. We also reduced sales and sales support staff in our Florida office. As a result of the closure, we terminated 34 licensed sales agents and eliminated eight open licensed sales positions, which were vacated subsequent to December 31, 2007. In October 2008, we further reduced our Telesales sales and sales support staff in our Florida office and terminated 51 employees, including 22 agents. Management believes these reductions will result in the reduced expenses in excess of reduced revenue.

26


 

    Subsequent to December 31, 2008, we ceased the direct marketing and sale of health and life insurance and related products to individuals and families in our Telesales call center. We continue to sell health and life insurance and related products to individuals and families through our non-employee ISG agents. Our Telesales business segment eliminated 43 positions including all of its licensed employee sales agents, along with other Telesales service and support personnel, and eliminated another 20 positions in Telesales through attrition. Management believes these reductions will result in the reduced expenses in excess of reduced revenue.
    In 2008, we earned periodic bonuses from carriers of $100,392 as compared to $843,311 in 2007. The Telesales segment receives bonuses from certain carriers, which are based primarily on the Telesales segment’s sales performance and other criteria established by carriers and generally do not extend beyond the current calendar year. Accordingly, we cannot determine what criteria, if any, may be offered by its carriers pertaining to bonuses beyond the current calendar year. As a result of the cessation of direct marketing and sales in the first quarter of 2009, management does not anticipate receiving material periodic bonuses from carriers in the future.
 
    In 2008, we earned revenue of $1,404,244 relating to ISG as compared to $1,821,958 in 2007. ISG revenue declined as a result of reduced new sales, the lapse of inforce business and reduced commission overrides earned on the Telesales segment on new and inforce business. As a result of the transactions with eHealth in February 2009, management anticipates a significant decline in ISG commission revenue as a result of the elimination of commission overrides for all Telesales business.

27


 

    In 2008, we earned revenues of $408,120 relating to the sale of leads to third parties as compared to $859,890 in 2007. We re-sell certain leads that we purchase in order to recoup a portion of our lead cost. The primary reason for the decrease in lead sales revenue is a decrease in lead cost spending, which results in a reduced number of leads available for sale. As a result of the cessation of direct marketing in the first quarter of 2009, management does not anticipate receiving material lead revenue in the future.
 
    In 2008, we earned revenues of $97,177 relating to Insurint technology fees. Our Insurint subsidiary provides a proprietary, professional-grade, web based agent portal to support and assist insurance agents in the business of marketing and selling health insurance and related products. Insurint’s technology fees commenced in the second quarter of 2008.
 
    In 2008, we earned revenue of $460,640 relating to the sub-lease of a portion of our Florida office and our former New York sales office. Sub-lease revenue includes base rent, additional rent pertaining to utilities and occupancy costs and certain telephony, technology and facility services provided by us to certain of our sub-tenants.
    On February 21, 2008 the Company entered into a sub-lease agreement with a third party whereby the third party sub-leased approximately 5,200 square feet of our Deerfield Beach office space beginning March 1, 2008 through February 28, 2009. This sub-lease agreement was amended and restated on October 3, 2008 to increase the sub-leased square footage to 13,900 and extend the lease term through January 31, 2010.
 
    On October 1, 2008 the Company entered into a sub-lease agreement with a third party whereby the third party sub-leased approximately 8,000 square feet of our Deerfield Beach office space beginning October 15, 2008 through January 31, 2010. In accordance with this sub-lease agreement the Company recognizes base rent, additional rent representing a portion of certain actual occupancy expenses for our Deerfield Beach office and certain telephony, technology and facility services provided to our sub-tenant.
 
    On April 17, 2008 the Company entered into a sub-lease agreement with a third party whereby the third party will sub-lease our New York office space for the balance of the Company’s Sublease Agreement and pay the Company sub-lease payments essentially equal to the Company’s costs under the Sublease Agreement. The third party commenced paying sub-sublease payments to the Company in September 2008 however the third party failed to pay their December 2008, January and February 2009 rent when due. The Company is a beneficiary to a letter of credit in the amount of $151,503, which is available for the Company to draw against in the event of the third party’s failure to pay their rent when due. We have notified the third party that they have breached their lease and that we will make draws against the letter of credit for amounts past due.

28


 

Total Operating Expenses
Our Telesales segment’s total operating expenses in 2008 were $26,781,420 as compared to $34,219,253 in 2007, for a decrease of $7,437,833 or 22%. Total operating expenses consisted of the following:
    Salaries, commission and related taxes consisted of the following:
                 
    For the Twelve Months Ended  
    December 31,  
    2008     2007  
Salaries, wages and bonuses
  $ 8,192,550     $ 10,462,015  
Share based employee and director compensation
    1,516,686       1,751,556  
Commissions to employees
    1,928,889       2,634,257  
Commissions to non-employees
    371,441       398,900  
Employee benefits
    347,011       433,099  
Payroll taxes
    726,659       920,957  
Severance and other compensation
    505,610       365,651  
Directors’ compensation
    76,833       110,666  
 
           
 
               
Total
  $ 13,665,679     $ 17,077,101  
 
           
    Salaries and wages were $8,192,550 in 2008 as compared to $10,462,015 in 2007, for a decrease of $2,269,465 or 22%.
    This decrease is the result of the reduced personnel employed by the Telesales segment.
 
    The Telesales segment had 89 employees at December 31, 2008 as compared to 253 at December 31, 2007.
    In March 2008, we closed our New York sales office, which accounted for approximately 20% of our sales activity for 2007. We also reduced sales and sales support staff in our Florida office. As a result of the closure, we terminated 34 licensed sales agents and eliminated eight open licensed sales positions, which were vacated subsequent to December 31, 2007. In October 2008, we further reduced our Telesales sales and sales support staff in our Florida office and terminated 51 employees, including 22 agents. Management believes these reductions will result in the reduced expenses in excess of reduced revenue.

29


 

    Subsequent to December 31, 2008, we ceased the direct marketing and sale of health and life insurance and related products to individuals and families in our Telesales call center. We continue to sell health and life insurance and related products to individuals and families through our non-employee ISG agents. Our Telesales business segment eliminated 43 positions including all of its licensed employee sales agents along with other Telesales service and support personnel and eliminated another 20 positions in Telesales through attrition. Management believes these reductions will result in the reduced expenses in excess of reduced revenue.
    Share-based employee and director compensation expense was $1,516,686 in 2008 as compared to $1,751,556 in 2007.
    The decrease in 2008 as compared to 2007 was in part the result of an expense in 2007 pertaining to the modification of the expiration dates and vesting of two former executives’ options in the amount of $212,426 and vesting schedules of stock options issued in 2006.
 
    Share-based employee and director compensation consists of stock option and restricted stock grants, which are valued at fair-value on the date of the grant and expensed over the stock option’s vesting period or the duration of employment, whichever is shorter.
    Commissions to employees were $1,928,889 in 2008 as compared to $2,634,257 in 2007. This decrease was the result of a decrease in sales that resulted in lower sales commission expense.
 
    Commissions to non-employees were $371,441 in 2008 as compared to $398,900 in 2007. We pay commissions to non-employee ISG agents.
 
    Employee benefits expense was $347,011 in 2008 as compared to $433,099 in 2007. This decrease is the result of the reduced personnel employed by the Telesales segment. Our employee benefit cost consists of the company-paid portion of group medical, dental and life insurance coverage and partial matching of employee contributions to our 401(k) plan.
 
    Payroll taxes expense was $726,659 in 2008 as compared to $920,957 in 2007. The decrease was the result of lower salaries, wages, bonuses and commissions to employees.
 
    Severance and other compensation expense was $505,610 in 2008 as compared to $365,651 in 2007. The increase was the result of severance expense as a result of the termination of Ivan Spinner.

30


 

    Lead, advertising and other marketing was $4,375,466 in 2008 as compared to $8,478,643 in 2007, a decrease of $4,103,177 or 48%, due primarily to a decrease in the number of leads purchased in 2008 compared to 2007. Subsequent to December 31, 2008, we ceased the direct marketing and sale of health and life insurance and related products to individuals and families in its Telesales call center, which will result in the elimination of lead cost in the future.
    Depreciation and amortization expense consisted of the following:
                 
    For the Twelve Months Ended  
    December 31,  
    2008     2007  
Amortization of intangibles acquired as a result of the ISG acquisition
  $ 1,045,119     $ 1,287,397  
Amortization of software and website development
    198,181       223,081  
Amortization of internet domain name
    53,733       53,733  
Depreciation expense
    625,405       590,705  
 
           
 
               
Total
  $ 1,922,438     $ 2,154,916  
 
           
    In 2008, we incurred amortization expense of $1,045,119 as compared to $1,287,397 for the intangible assets acquired from ISG. The intangible assets acquired from ISG represent the value of purchased commission override revenue with an assigned value of $1,411,594 amortized over five years in proportion to expected future value, the value of acquired carrier contracts and agent relationships with an assigned value of $2,752,143 amortized over five years in proportion to expected future value and the value of employment and non-compete agreement acquired with an assigned value of $800,593 amortized on a straight line basis over a weighted average useful life of 3.2 years.
    As a result of Ivan Spinner’s termination of employment, we have determined the value of an employment and non-compete agreement acquired pertaining to Mr. Spinner impaired as of December 31, 2008 and recorded an impairment charge of $85,078 in loss of impairment of intangible asset.
    In 2008, we incurred depreciation expense of $625,405 as compared to $590,705 in 2007. The increase pertains to the impairment of furniture and equipment located at the Company’s former New York sales office.

31


 

    Rent, utilities, telephone and communications expenses consisted of the following:
                 
    For the Twelve Months Ended  
    December 31,  
    2008     2007  
Rent, utilities and other occupancy
  $ 2,609,673     $ 1,848,632  
Telephone and communications
    709,415       809,839  
 
           
 
               
Total
  $ 3,319,088     $ 2,658,471  
 
           
    In 2008, we incurred rent, utilities and other occupancy expense of $2,609,673 as compared to $1,848,632 in 2007. The increase was primarily attributable to a $629,326 accrual for the non-terminable lease for Telesales’ New York sales office. In March 2008, we closed our sales office located in New York. On April 17, 2008, we entered into a sub-lease agreement with a third party, whereby the third party will sub-lease our New York office space for the balance of our lease and pay us sub-lease payments essentially equal to the payments under the lease. The terms of the sublease agreement required us to make certain leasehold improvements. The third party commenced paying sub-lease payments to us in September 2008; however, the third party failed to pay its December 2008 and January and February 2009 rent when due. We are a beneficiary to a letter of credit in the amount of $151,503, which is available for us to draw against in the event of the third party’s failure to pay its rent when due. Effective December 31, 2008, we have accrued $629,396 related to the non-terminable lease for the abandoned facilities, which is net present value of our future lease payments due under the remaining sublease agreement term, plus management’s estimate of utility payments, which are estimated to be $773,311, less management’s estimate of future sub-lease revenue secured by the letter of credit, which is estimated to be $120,023.
 
    In 2008, we incurred telephone and communications expense of $709,415 as compared to $809,839 in 2007. The decrease was primarily attributable the closure of Telesales’ New York sales office reduced sales and sales support staff in our Florida office.
    In 2008, we incurred professional fees of $1,672,450 as compared to $1,915,223 in 2007 for a decrease of $242,774 or 13%. The decrease was primarily attributable to lower recruiting and technology outsourcing fees.

32


 

    During the first quarter of 2008, Telesales closed its sales office located in New York. As of March 31, 2008, we determined that all furniture and lease-hold improvements located at the New York sales office were impaired as a result of the office closure. During the first quarter of 2008, we recorded an $88,922 expense to write-down the value of these assets to their net realizable value in loss on impairment of property and equipment.
 
    Loss on impairment of intangible assets pertains to the following:
    During the first quarter of 2008, we determined that the portion of the license fee paid by Telesales for a commission system, together with capitalized costs incurred to implement the commission system, was impaired as a result of the absence of definitive plans to implement this system for internal use in Telesales. We recorded a $295,633 expense in the first quarter of 2008 to write-off the value of this asset.
 
    As a result of Ivan Spinner’s termination of employment, we have determined the value of an employment and non-compete agreement acquired pertaining to Mr. Spinner impaired as of December 31, 2008 and recorded an impairment charge of $85,078 in loss on impairment of intangible asset.
    Other general and administrative expenses consisted of the following:
                 
    For the Twelve Months Ended  
    December 31,  
    2008     2007  
Licensing and appointment fees
  $ 295,549     $ 440,240  
Travel and entertainment
    112,977       301,206  
Office expense
    353,519       824,181  
Other
    594,621       244,272  
 
           
 
               
Total
  $ 1,356,666     $ 1,809,899  
 
           
    We incur licensing and appointment costs associated with the licensing of our employee insurance agents. The reduction in licensing cost is primarily the result of the reduction in licensed employees.
    In March 2008, we closed our New York sales office and also reduced sales and sales support staff in our Florida office. As a result, we terminated 34 licensed sales agents and eliminated eight open licensed sales positions, which were vacated subsequent to December 31, 2007. In October 2008, we further reduced our Telesales sales and sales support staff in our Florida office and terminated 51 employees, including 22 agents.

33


 

    Subsequent to December 31, 2008, we ceased the direct marketing and sale of health and life insurance and related products to individuals and families in our Telesales call center. We continue to sell health and life insurance and related products to individuals and families through our non-employee ISG agents. Our Telesales business segment eliminated all of its licensed employee sales agents. We do not incur licensing and appointment fees for our non-employee ISG agents.
    In 2008, we had a decrease of $658,891, or 36%, in travel, entertainment and office expense as compared to 2007, due to the closing of the New York sales office and an overall reduction in travel.
 
    In 2008, we had an increase of $350,349 in other expense as compared to 2007, primarily due to estimated cost of settling certain litigation.
Loss from operations
As result of these factors described above, we reported a loss from operations of $8,231,905 in 2008 as compared to a loss from operations of $14,650,531 in 2007 in our Telesales business segment.

34


 

Results of Operations for the Atiam Business Segment
We acquired Atiam on October 1, 2007. The results of Atiam’s operations prior to our October 1, 2007 acquisition have been excluded from our financial statements. The results of our Atiam business segment have been included in the Company’s statement of operations as of October 1, 2007. Thus Atiam segment’s results from operations for years ended December 31, 2008 and 2007 are not comparable.
Revenues
For 2008, we earned revenues of $5,578,512, which consisted of the following:
                 
    For the Twelve Months  
    Ended December 31,  
    2008     2007  
 
               
Consulting and implementation services
  $ 3,889,069     $ 668,674  
ASP revenue
    1,123,943       244,854  
Sales of software licenses
    115,000       137,500  
Maintenance revenue
    450,500       90,000  
 
           
 
               
Total
  $ 5,578,512     $ 1,141,028  
 
           
In 2008, we earned revenues from seven clients as follows:
                 
    For the Twelve Months  
    Ended December 31,  
    2008     2007  
 
               
Client 1
  $ 2,885,388     $ 474,626  
Client 2
    786,740       344,863  
Client 3
    576,399       225,089  
Client 4
    552,138       96,450  
Clients 5, 6, 7
    777,847        
 
           
 
               
 
  $ 5,578,512     $ 1,141,028  
 
           
    Consulting and implementation services revenues are from seven InsPro clients. Implementation services provided to these clients included assisting clients in setting up their insurance products in InsPro, providing modifications to InsPro’s functionality to support the client’s business, interfacing InsPro with the client’s other systems, automation of client correspondence to their customers and data conversion from the client’s existing systems to InsPro.
 
    In 2008, we earned ASP revenue from five InsPro clients. ASP hosting service enables a client to lease the InsPro software, paying only for the capacity required to support its business. ASP clients access InsPro installed on Atiam owned servers located at Atiam’s offices or at a third party’s site.

35


 

    In 2008, we earned software license revenue from a single InsPro client.
 
    In 2008, we earned maintenance revenues from four clients.
Total Operating Expenses
Our Atiam business segment’s total operating expenses in 2008 were $6,310,318 and consisted of the following:
    Salaries, commission and related taxes consisted of the following:
                 
    For the Twelve Months  
    Ended December 31,  
    2008     2007  
Salaries, wages and bonuses
  $ 3,073,867     $ 410,962  
Employee benefits
    192,053       29,405  
Payroll taxes
    201,231       26,699  
 
           
 
               
Total
  $ 3,467,151     $ 467,066  
 
           
    The Atiam business segment had 31 employees at December 31, 2008.
    Lead, advertising and other marketing was $15,017 in 2008 as compared to $11,052 in 2007 and consisted primarily of marketing and conference fees.
 
    Depreciation and amortization expense consisted of the following:
                 
    For the Twelve Months  
    Ended December 31,  
    2008     2007  
Amortization of intangibles acquired as a result of the Atiam acquisition
  $ 468,081     $ 117,020  
Software development costs for external marketing
    43,574        
Depreciation expense
    134,052       14,831  
 
           
 
               
Total
  $ 645,707     $ 131,851  
 
           
    In 2008, we incurred amortization expense of $468,081 for the intangible assets acquired from Atiam. The Atiam acquisition was effective October 1, 2007. Intangible assets acquired from Atiam were assigned the following values:
    value of client contracts and relationships (other than licenses) with an assigned value of $1,089,223, amortized straight line over five years

36


 

    value of purchased software for sale and licensing value with an assigned value of $644,449, amortized on a straight line basis over five years
 
    employment and non-compete agreements acquired with an assigned value of $364,000, amortized on a straight line basis over three years.
    In 2008, we incurred amortization expense of $43,574 for software development cost for external marketing.
    In 2008, we incurred rent, utilities, telephone and communications expense, which consisted of the following:
                 
    For the Twelve Months  
    Ended December 31,  
    2008     2007  
Rent, utilities and other occupancy
  $ 126,844     $ 46,248  
Telephone and communications
    63,781       16,016  
 
           
 
               
Total
  $ 190,625     $ 62,264  
 
           
    In 2008, we incurred professional fees of $1,276,053, which pertain primarily to outsourced system development costs and to a lesser extent employee recruiting services.
 
    In 2008, we incurred other general and administrative expenses, which consisted of the following:
                 
    For the Twelve Months
Ended December 31,
    2008     2007  
 
               
Office expenses
  $ 23,367     $ 114,652  
Travel and entertainment
    113,217       21,894  
Computer processing, hardware, software and other
    579,181       (12,125 )
 
           
 
               
Total
  $ 715,765     $ 124,421  
 
           
    We incur travel and entertainment expenses in connection with marketing, sales and implementation of InsPro at client locations.
 
    We incur computer processing fees associated with ASP hosting services. Atiam has a hosting services contract with a third party, which can be terminated with notice and payment of a termination fee. This third party provides Atiam with hosting services for our client’s ASP production and test environments.

37


 

Loss From Operations
As a result of these factors described above, we reported a loss from operations of $731,806 in 2008 in our Atiam business segment.
LIQUIDITY AND CAPITAL RESOURCES
At December 31, 2008, we had a cash balance of $1,842,419 and working capital deficit of $(3,540,008).
On March 31, 2008, we entered into securities purchase agreements with certain institutional investors and completed a private placement of an aggregate of 6,250,000 shares of our common stock and warrants to purchase 6,250,000 shares of our common stock. Pursuant to the agreements we sold investment units at a per unit purchase price of $0.80. Each unit sold in the private placement consisted of one share of common stock and a warrant to purchase one share of common stock at an initial exercise price of $0.80 per share, subject to adjustment as provided therein. The gross proceeds from the private placement were $5,000,000 and we incurred $70,238 of legal and other expenses in connection with the private placement. We have and are using the net proceeds of the private placement for working capital purposes.
At December 31, 2008, we had a restricted cash balance of $1,150,000, which represents money market account balances pertaining to two letters of credit for the benefit of the landlords of our Florida and New York offices. The money market accounts are on deposit with the issuer of the letters of credit. We receive interest on the money market accounts.
Net cash used by operations was $8,354,232 in 2008 as compared to cash used by operations of $5,500,884 in 2007. In 2008, we used cash to fund:
    Our net loss of $8,976,084.
 
    Decreases in unearned commission advances of $5,428,424 relating to decreased commission payments from certain of our insurance carriers that advance our future commission revenue.
    We have agreements with certain of our insurance carriers whereby our insurance carriers advance our first year premium commissions before the commissions are earned. The unearned portion of premium commissions has been included in the consolidated balance sheet as a liability for unearned commission advances. These advance agreements represent a material source of cash to fund our operations. Unearned commission advances are recognized as commission revenue after we receive notice that the insurance company has received payment of the related premium. In the event that the insurance company does not receive payment of the related premium pertaining to a commission advance, the insurance company generally deducts the unearned commission advance from its commission payments to us.

38


 

    We have an advance agreement with Golden Rule that is contractually limited to a maximum of $9,000,000, can be terminated by either party at any time, and in the event of termination, our outstanding advance balance (including interest, if any) can be called by Golden Rule with seven days’ written notice. This advance agreement expired on December 31, 2008 and, as a result, Golden Rule will no longer advance first year premium commissions to us going forward. As of December 31, 2008, our outstanding advance balance with Golden Rule was $2,317,003. Subsequent to December 31, 2008 in connection with the eHealth transactions, eHealth paid Golden Rule a total of $966,097, which represented a partial repayment of our outstanding advance balance owed to Golden Rule. eHealth advanced these funds from amounts that otherwise would have been due to us from eHealth under the terms of the eHealth transaction. In addition, eHealth assumed approximately $794,000 of our outstanding advance balance with Golden Rule as of the date of the eHealth transaction.
 
    We have an advance agreement with Humana that allows the insurance carrier to terminate future advances and convert the outstanding advance balance into a promissory note, which, if not repaid within 30 days, would incur interest expense. As of December 31, 2008, our outstanding advance balance with Humana was $353,808. Subsequent to December 31, 2008 in connection with the eHealth transaction eHealth assumed $370,794 of the Company’s outstanding advance balance with Humana as of the date of the eHealth transaction. Effective January 31, 2009 Humana notified the Company that it will no longer advance first year premium commissions and charged back to the Company the remaining unearned commission advance as of January 31, 2009.
 
    As of December 31, 2008, our outstanding advance balance with Assurant was $236,064. Subsequent to December 31, 2008, in connection with the eHealth transaction, eHealth assumed approximately $220,000 of our outstanding advance balance with Assurant as of the date of the eHealth transaction.
    The payment of $157,288 of income tax liabilities assumed as a result of our acquisition of Atiam in 2007.
 
    Decreases in accounts payable of $570,313 in 2008, which is primarily the result of the payment of lead and marketing costs.
 
    Increases in accrued expense of $599,307 in 2008, which is primarily the result of increased professional services in the fourth quarter of 2008.
 
    Decreases in accounts receivable of $753,398 in 2008, which is the result of decreased commission payments from certain of our insurance carriers that advance us future commission revenue.

39


 

In addition to cash used in operating activities, we incurred $4,623,332 of non cash expenses and impairments in 2008, which were included in our net loss, including:
  Stock-based compensation and consulting expense of $1,516,686 and $1,772,031 in 2008 and 2007, respectively.
 
  Depreciation and amortization expense of $2,568,145 and $2,286,767 in 2008 and 2007, respectively.
 
  $135,401 loss on impairment of property and equipment pertaining to furniture and lease-hold improvements located at our former New York sales office.
 
  $380,711 loss on impairment of intangible assets, which included $295,633 of expense in 2008 to write-off the value of license fee and capitalized costs incurred to implement a commission system; and $85,078 as a result of Ivan Spinner’s termination of employment and impairment of acquired ISG employee contracts.
Net cash used by investing activities in 2008 was $760,558 as compared to $1,887,020 in 2007. Investing activities pertain to internal development of software for internal and external use and the purchase of property and equipment supporting current and future operations. Investing activities in 2007 included $1.35 million for the purchase of Atiam on October 1, 2007.
Net cash provided by financing activities in 2008 was $5,169,624 as compared to $10,863,708 in 2007.
    In the first quarter of 2008, we completed a private placement with certain institutional accredited investors and issued 6,250,000 shares of our common stock and warrants to purchase 6,250,000 shares of our common stock. Our gross proceeds were $5,000,000 and we incurred $70,238 of legal and other expenses in connection with the private placement.
 
    In the first quarter of 2007, we completed a private placement with certain institutional and individual accredited investors and issued 5,000,000 shares of our common stock and warrants to purchase 2,500,000 shares of our common stock. Gross proceeds were $11,250,000 and placement and other fees paid in connection with the private placement were $895,240.
 
    In 2008, our Atiam business segment has entered into several capital lease obligations to purchase equipment used for operations.

40


 

During the year ended December 31, 2008 we used $8,354,232 of cash to fund operations and $760,558 of cash to fund investing activities. As of December 31, 2008, we have funded our operating activities from the proceeds of the sale of our common stock; however, based on our most recent financial projections, we believe that our current level of liquid assets and our expected cash flows from operations may not be sufficient to finance our operations and financial commitments in the future. As a result, we have begun to reduce and expect to further reduce our cost structure. For example, during the first quarter of 2008, we closed our former New York sales office and reduced staffing at our Florida office in order to reduce expenses and our negative cash flow. During the third quarter of 2008, we sub-leased our former New York office and began receiving sub-lease rental revenue, which will offset the lease occupancy costs of the New York office. Subsequent to September 30, 2008, we further reduced our staffing and subleased a portion of its Florida office to further reduce our expenses and negative cash flow; however we anticipate that we will continue to use cash to fund operations for the foreseeable future. Management believes that our cash on hand together with the net proceeds of the January 2009 private placement and the recent sale of the Telesales agency business to eHealth will be sufficient to meet our cash requirements through at least the next 12 months.
Off-Balance Sheet Arrangements
We do not currently have any relationships with unconsolidated entities or financial partnerships, such as entities referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet or other contractually narrow or limited purposes.
The letters of credit pertaining to the lease for our Florida office and our New York office were collateralized in the form of a money market account, which as of December 31, 2008, had a balance of $1,150,000. This money market account is on deposit with the issuer of the letters of credit and is classified as restricted cash on our balance sheet. The terms of the money market account allow us to receive interest on the principal but prohibits us from withdrawing the principal for the life of the letters of credit.

41


 

Guarantee of Indebtedness by the Company to Third Parties Pertaining to Unearned Commission Advances Paid to Non-employee ISG Agents
The Company is a party to sales and marketing agreements whereby the Company has guaranteed the repayment of unearned commission advances paid directly from third parties including certain of the Company’s insurance carriers to the Company’s non-employee ISG agents. Under these agreements certain third parties pay commissions directly to the Company’s non-employee ISG agents and such payments include advances of first year premium commissions before the commissions are earned. Unearned commission advances from the Company’s insurance carriers to the Company’s non-employee ISG agents are earned after the insurance company has received payment of the related premium. In the event that the insurance company does not receive payment of the related premium pertaining to an unearned commission advance the third parties generally deduct the unearned commission advance from its commission payments to the Company’s non-employee ISG agents in the form of charge-backs. In the event that commission payments from these third parties to the Company’s non-employee ISG agents do not exceed the charge-backs these third parties may deduct the unearned commission advance to non-employee ISG agents from their payments to the Company or demand repayment of the non-employee ISG agents’ unearned commission balance from the Company. The current amount of the unearned commission advances these third parties to the Company’s non-employee ISG agents, which is the maximum potential amount of future payments the Company could be required to make to these third parties, is estimated to be approximately $643,000 as of December 31, 2008. As of December 31, 2008 the Company has recorded a liability of $76,651 in accrued expenses for the estimated amount the Company anticipates it will pay pertaining to these guarantees. Unearned commission advances from these third parties are collateralized by the future commission payments to the non-employee ISG agents and to the Company. The Company has recourse against certain non-employee ISG agents in the event the Company must pay the unearned commission advances.
License Agreement With Realtime Solutions Group
On May 31, 2006, we entered into a Software and Services Agreement (the “License Agreement”) with Realtime Solutions Group, L.L.C. (“Realtime”), under which Realtime granted us a worldwide, transferable, non-exclusive, perpetual and irrevocable license to use, display, copy, modify, enhance, create derivate works within, and access Realtime Solutions Group’s Straight Through Processing software (“STP”) and all associated documentation, source code and object code, for use in the marketing, promotion and sale of health benefits or insurance products.
As consideration for the grant of the rights and licenses under the License Agreement, we paid to Realtime a $10,000 nonrefundable cash deposit and upon delivery of the STP software and other materials we will pay a license fee in the form of 216,612 unregistered shares of our common stock. Concurrent with entering into the License Agreement, HBDC and Realtime entered into a Registration Rights Agreement that provides for piggyback registration rights for the to be issued shares.
The Company may unilaterally terminate the License Agreement, with or without cause, at any time on 30 calendar day prior written notice to Realtime. The license rights in the software granted under the License Agreement survive any termination of the License Agreement in perpetuity.
As of December 31, 2008 the Company has not taken delivery of the STP software or issued Common Stock in connection with the License Agreement.

42


 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
FINANCIAL STATEMENTS
TABLE OF CONTENTS
         
    Page  
    Number  
 
       
HEALTH BENEFITS DIRECT CORPORATION
       
 
       
    F-2  
    F-3  
    F-4  
    F-5  
    F-6  
    F-7  
    F-8  

F-1


 

MANAGEMENT’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States and include those policies and procedures that:
    Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;
 
    Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States;
 
    Provide reasonable assurance that our receipts and expenditures are being made only in accordance with authorization of our management and directors; and
 
    Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.
Because of its inherent limitations, such as resource constraints, human error, lack of knowledge or awareness and the possibility of intentional circumvention of these controls, internal control over financial reporting may not prevent or detect misstatements. Furthermore, the design of any control system is based, in part, upon assumptions about the likelihood of future events, which assumptions may ultimately prove to be incorrect. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.
Our management assessed the effectiveness of its internal control over financial reporting as of December 31, 2008. In making this assessment, management used the criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on its assessment, management has concluded that the Company’s internal control over financial reporting was effective as of December 31, 2008.
This Annual Report on Form 10-K does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to provide only management’s report in this Annual Report on Form 10-K.
         
     
  /s/ Anthony R. Verdi    
  Anthony R. Verdi   
  Chief Financial Officer and Chief Operating Officer
(Principal Executive Officer and Principal Financial Officer)

March 31, 2009 
 

F-2


 

         
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors
Health Benefits Direct Corporation and Subsidiaries
Radnor, Pennsylvania
We have audited the accompanying consolidated balance sheets of Health Benefits Direct Corporation and Subsidiaries as of December 31, 2008 and December 31, 2007, the related consolidated statements of operations, changes in shareholders’ equity and cash flows for the years ended December 31, 2008 and December 31, 2007. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall consolidated financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Health Benefits Direct Corporation and Subsidiaries as of December 31, 2008 and December 31, 2007, and the results of their operations and their cash flows for the years ended December 31, 2008 and December 31, 2007, in conformity with accounting principles generally accepted in the United States of America.
         
     
  /s/ Sherb & Co., LLP    
  Certified Public Accountants   
Boca Raton, Florida
March 26, 2009

F-3


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
                 
    December 31,     December 31,  
    2008     2007  
 
ASSETS
               
 
               
CURRENT ASSETS:
               
Cash
  $ 1,842,419     $ 5,787,585  
Accounts receivable, less allowance for doubtful accounts $2,173 and $59,106
    919,868       1,720,014  
State tax receivable
    31,290        
Deferred compensation advances
    36,186       578,372  
Prepaid expenses
    177,833       182,087  
Other current assets
    8,461       22,285  
 
           
 
               
Total current assets
    3,016,057       8,290,343  
 
               
Restricted cash
    1,150,000       1,150,000  
Property and equipment, net of accumulated depreciation $1,545,150 and $1,115,562
    1,163,948       1,592,480  
Intangibles, net of accumulated amortization $4,859,779 and $3,108,771
    3,198,407       5,095,960  
Other assets
    180,641       165,871  
 
           
 
               
Total assets
  $ 8,709,053     $ 16,294,654  
 
           
 
               
LIABILITIES AND SHAREHOLDERS’ EQUITY
               
 
               
CURRENT LIABILITIES:
               
Accounts payable
  $ 912,751     $ 1,483,064  
Accrued expenses
    2,030,948       1,406,641  
Current portion of capital lease obligations
    89,297       14,707  
Sub-tenant security deposit
    39,093        
Due to related parties
    4,315       28,500  
Unearned commission advances
    3,022,161       8,450,585  
Deferred revenue
    457,500       209,125  
Income tax payable
          157,288  
 
           
 
               
Total current liabilities
    6,556,065       11,749,910  
 
           
 
               
LONG TERM LIABILITIES:
               
Capital lease obligations
    209,511       44,241  
 
           
 
               
Total long term liabilities
    209,511       44,241  
 
           
 
               
SHAREHOLDERS’ EQUITY:
               
Preferred stock ($.001 par value; 10,000,000 shares authorized; no shares issued and outstanding)
           
Common stock ($.001 par value; 90,000,000 shares authorized; 41,279,645 and 34,951,384 shares issued and outstanding
    41,279       34,951  
Additional paid-in capital
    43,281,139       36,868,409  
Accumulated deficit
    (41,378,941 )     (32,402,857 )
 
           
 
               
Total shareholders’ equity
    1,943,477       4,500,503  
 
           
 
               
Total liabilities and shareholders’ equity
  $ 8,709,053     $ 16,294,654  
 
           
See accompanying notes to audited consolidated financial statements.

F-4


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
                 
    For the Years Ended  
    December 31,  
    2008     2007  
 
               
Revenues
  $ 24,128,027     $ 20,709,750  
 
               
Operating expenses:
               
Salaries, commission and related taxes
    17,132,830       17,544,167  
Lead, advertising and other marketing
    4,390,483       8,489,695  
Depreciation and amortization
    2,568,145       2,286,767  
Rent, utilities, telephone and communications
    3,509,713       2,720,735  
Professional fees
    2,948,503       2,062,107  
Loss on impairment of property and equipment
    88,922        
Loss on impairment of intangible asset
    380,711       125,000  
Other general and administrative
    2,072,431       1,934,320  
 
           
 
               
 
    33,091,738       35,162,791  
 
           
 
               
Loss from operations
    (8,963,711 )     (14,453,041 )
 
           
 
               
Other income (expense):
               
Loss on disposal of property and equipment
    (46,479 )     (2,592 )
Interest income
    73,913       350,707  
Interest expense
    (39,807 )     (31,673 )
 
           
 
               
Total other income (expense)
    (12,373 )     316,442  
 
           
 
               
Net loss
  $ (8,976,084 )   $ (14,136,599 )
 
           
 
               
Net loss per common share:
               
Net loss per common share — basic and diluted
  $ (0.23 )   $ (0.43 )
 
           
 
               
Weighted average common shares outstanding — basic and diluted
    39,734,505       33,006,127  
 
           
See accompanying notes to audited consolidated financial statements.

F-5


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
FOR THE YEARS ENDED DECEMBER 31, 2008 AND 2007
                                         
                         
    Common Stock, $.001                    
    Par Value                   Total
    Number of           Additional   Accumulated   Shareholders’
    Shares   Amount   Paid-in Capital   Deficit   Equity
 
                                       
Balance — December 31, 2006
    28,586,471     $ 28,586     $ 22,668,453     $ (18,266,258 )   $ 4,430,781  
Common stock issued in private placement
    5,000,000       5,000       10,349,760             10,354,760  
Common stock issued in SCA purchase
    739,913       740       1,649,266               1,650,006  
Common stock issued to directors as compensation
    75,000       75       161,175             161,250  
Modification of employee stock options
                212,426             212,426  
Issuance of restricted stock to employees
    250,000       250       (250 )            
Common stock issued upon exercise of warrants
    300,000       300       449,700             450,000  
Issuance of stock options
                             
Amortization of deferred compensation
                1,377,879             1,377,879  
Net loss for the period
                      (14,136,599 )     (14,136,599 )
     
Balance — December 31, 2007
    34,951,384       34,951       36,868,409       (32,402,857 )     4,500,503  
Common stock issued in private placement
    6,250,000       6,250       4,923,512             4,929,762  
Common stock issued to directors as compensation
    174,010       174       167,814             167,988  
Return of restricted stock from employees in payment of withholding tax
    (20,749 )     (21 )     (27,368 )           (27,389 )
Forfeiture of restricted stock
    (75,000 )     (75 )     75              
Amortization of deferred compensation
                1,348,697             1,348,697  
Net loss for the period
                      (8,976,084 )     (8,976,084 )
     
Balance — December 31, 2008
    41,279,645     $ 41,279     $ 43,281,139     $ (41,378,941 )   $ 1,943,477  
     
See accompanying notes to audited consolidated financial statements

F-6


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
                 
    For the Years Ended  
    December 31,  
    2008     2007  
Cash Flows From Operating Activities:
               
Net loss
  $ (8,976,084 )   $ (14,136,599 )
Adjustments to reconcile net loss to net cash used in operating activities:
               
Depreciation and amortization
    2,568,145       2,286,767  
Stock-based compensation and consulting
    1,516,686       1,772,031  
Loss on impairment of property and equipment
    88,922        
Loss on impairment of intangible assets
    380,711        
Loss on the disposal of property and equipment
    46,479        
Provision for bad debt
    46,748       (20,317 )
Changes in assets and liabilities:
               
Accounts receivable
    753,398       1,140,843  
State tax receivable
    (31,290 )      
Deferred compensation advances
    542,186       106,626  
Prepaid expenses
    4,254       (71,944 )
Other current assets
    13,824       (11,274 )
Other assets
    (14,770 )     (61,308 )
Accounts payable
    (570,313 )     288,532  
Accrued expenses
    599,301       (143,662 )
Sub-tenant security deposit
    39,093        
Due to related parties
    (24,185 )     (35,172 )
Unearned commission advances
    (5,428,424 )     3,295,468  
Deferred revenue
    248,375       51,837  
Income tax payable
    (157,288 )     37,288  
 
           
 
               
Net cash used in operating activities
    (8,354,232 )     (5,500,884 )
 
           
 
               
Cash Flows From Investing Activities:
               
Purchase of property and equipment
    (533,661 )     (555,787 )
Proceeds from the sale of property and equipment
    64,950        
Purchase of intangible assets and capitalization of software development
    (291,847 )     (1,331,233 )
 
           
 
               
Net cash used in investing activities
    (760,558 )     (1,887,020 )
 
           
 
               
Cash Flows From Financing Activities:
               
Capital leases obligations assumed
          19,081  
Gross proceeds from capital leases
    282,271       41,875  
Payments on capital leases
    (42,409 )     (2,008 )
Gross proceeds from sales of common stock
    5,000,000       11,250,000  
Gross proceeds from exercise of warrants
          450,000  
Placement and other fees paid in connection with offering
    (70,238 )     (895,240 )
 
           
 
               
Net cash provided by financing activities
    5,169,624       10,863,708  
 
           
 
               
Net increase (decrease) in cash
    (3,945,166 )     3,475,804  
 
               
Cash — beginning of the year
    5,787,585       2,311,781  
 
           
 
               
Cash — end of the year
  $ 1,842,419     $ 5,787,585  
 
           
 
               
Supplemental Disclosures of Cash Flow Information
Cash payments for income taxes
  $ 188,578     $  
 
           
 
               
Non cash investing and financing activities:
               
Common stock issued for the purchase of SCA
  $     $ 1,650,006  
 
           
See accompanying notes to audited consolidated financial statements.

F-7


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 1 — BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Organization
Health Benefits Direct Corporation (the “Company”, “we”, “us” or “our”) was incorporated under the laws of the state of Nevada on October 21, 2004 as Darwin Resources Corp., (“Darwin-NV”). On November 22, 2005, Darwin-NV merged with and into its newly-formed wholly-owned subsidiary, Darwin Resources Corp., a Delaware corporation (“Darwin-DE”), solely for the purpose of changing the Company’s state of incorporation from Nevada to Delaware. On November 23, 2005, HBDC II, Inc., a newly-formed wholly-owned subsidiary of Darwin-DE, was merged with and into Health Benefits Direct Corporation, a privately-held Delaware corporation (“HBDC”), and the name of the resulting entity was changed from Health Benefits Direct Corporation to HBDC II, Inc. Following the merger, Darwin-DE changed its name to Health Benefits Direct Corporation.
HBDC was formed in January 2004 for the purpose of acquiring, owning and operating businesses engaged in direct marketing and distribution of health and life insurance products, primarily utilizing the Internet. On September 9, 2005, HBDC acquired three affiliated Internet health insurance marketing companies, namely Platinum Partners, LLC, a Florida limited liability company, Health Benefits Direct II, LLC, a Florida limited liability company, and Health Benefits Direct III, LLC, a Florida limited liability company. HBDC issued 7,500,000 shares of its common stock and a warrant to purchase 50,000 shares of its common stock, in the aggregate, in exchange for 100% of the limited liability company interests of these companies.
The acquisition of HBDC by the Company was accounted for as a reverse merger because, on a post-merger basis, the former HBDC shareholders held a majority of the outstanding common stock of the Company on a voting and fully diluted basis. As a result, HBDC was deemed to be the acquirer for accounting purposes. Accordingly, the consolidated financial statements presented for the period ended December 31, 2005, are those of HBDC for all periods prior to the acquisition, and the financial statements of the consolidated companies from the acquisition date forward. The historical shareholders’ deficit of HBDC prior to the acquisition has been retroactively restated (a recapitalization) for the equivalent number of shares received in the acquisition after giving effect to any differences in the par value of the Company and HBDC’s common stock, with an offset to additional paid-in capital. The restated consolidated retained earnings of the accounting acquirer, HBDC, are carried forward after the acquisition.
The Company operates though two business segments, which are the Telesales Business Segment (“Telesales”) and the Atiam Business Segment (“Atiam”).

F-8


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 1 — BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Telesales specializes in the direct marketing of health and life insurance and related products to individuals and families. Telesales has developed proprietary technologies and processes to connect prospective insurance customers with Telesales’ agents and service personnel using an integrated on-line platform with call center follow up. Telesales employs licensed agents supported by tele-application, customer service and technology employees for the purpose of providing immediate information to prospective customers and selling insurance products. Telesales receives commission and other fees from the insurance companies on behalf of which it sells insurance products for the sale of such products. See Note 14 — Subsequent Events “Cessation of Direct Marketing and Sales in the Telesales Call Center, Transactions with eHealth and Reduction in Staffing”.
Atiam is a provider of comprehensive, web-based insurance administration software applications. Atiam’s flagship software product is InsPro, which was introduced in 2004. InsPro incorporates a modular design, which enables the customer to purchase only the functionality needed. Atiam’s clients include insurance carriers and third party administrators. Atiam realizes revenue from the sale of software licenses, application service provider fees, software maintenance fees and consulting and implementation services. See Note 5 — Atiam Acquisition and Note 16 Segment Information.
Basis of presentation
The consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”). The consolidated financial statements of the Company include the Company and its subsidiaries. All material inter-company balances and transactions have been eliminated.
For purposes of comparability, certain prior period amounts have been reclassified to conform to the 2008 presentation.
Use of estimates
The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates in 2008 and 2007 include the allowance for doubtful accounts, stock-based compensation, the useful lives of property and equipment and intangible assets, revenue recognition and deferred compensation advances to employees.
Cash and cash equivalents
The Company considers all liquid debt instruments with original matuirities of 3 months or less to be cash equivalents.

F-9


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 1 — BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Restricted cash
The Company considers all cash and cash equivalents held in restricted accounts pertaining to the Company’s letters of credit as restricted cash.
Accounts receivable
The Company has a policy of establishing an allowance for uncollectible accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Account balances deemed to be uncollectible are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. At December 31, 2008, the Company has established, based on a review of its outstanding balances, an allowance for doubtful accounts in the amount of $2,173.
Accounts receivable from the Company’s largest Atiam client as measured by receivable balance accounted for 30% and 13% of the Company’s total accounts receivable balance at December 31, 2008 and 2007, respectively. Accounts receivable from the Company’s largest insurance carrier accounted for 20% and 53% of the Company’s total accounts receivable balance at December 31, 2008 and 2007, respectively.
Fair value of financial instruments
The carrying amounts of financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued expenses and capital leases approximated fair value as of December 31, 2008 and December 31, 2007, because of the relatively short-term maturity of these instruments and their market interest rates.
Property and equipment
Property and equipment are carried at cost. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. In accordance with Statement of Financial Accounting Standards (SFAS) No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets” the Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable.

F-10


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 1 — BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Intangible assets
Intangible assets consist of assets acquired in connection with the acquisitions of Insurance Specialist Group, Inc. (“ISG”) and Atiam, costs incurred in connection with the development of the Company’s software and website and the purchase of internet domain names. See Note 3 — ISG Acquisition, Note 3 — Atiam Acquisition and Note 5 — Intangible Assets.
The Company’s Telesales segment capitalized certain costs valued in connection with developing or obtaining internal use software in accordance with American Institute of Certified Public Accountants Statement of Position 98-1, “Accounting for the Costs of Computer Software Developed or Obtained for Internal Use”. These costs, which consist of direct technology labor costs, are capitalized and amortized using the straight-line method over expected useful lives. Costs that the Company has incurred in connection with developing the Company’s websites and purchasing domain names are capitalized and amortized using the straight-line method over an expected useful life.
Under the criteria set forth in SOP 98-1, “Accounting for the Costs of Computer Software Developed or Obtained for Internal Use” capitalization of software development costs begins upon the establishment of technological feasibility of the software. The establishment of technological feasibility and the ongoing assessment of the recoverability of these costs require considerable judgment by management with respect to certain external factors, including, but not limited to, anticipated future gross product revenues, estimated economic life, and changes in software and hardware technology. Capitalized software development costs are amortized utilizing the straight-line method over the estimated economic life of the software not to exceed three years. We regularly review the carrying value of software development assets and a loss is recognized when the unamortized costs are deemed unrecoverable based on the estimated cash flows to be generated from the applicable software.

F-11


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 1 — BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
The Company’s Atiam segment capitalized certain costs valued in connection with developing or obtaining software for external use in accordance with Statement of Financial Accounting Standards (SFAS) No. 86, Accounting for the Costs of Computer Software to be Sold, Leased, or Otherwise Marketed. These costs, which consist of direct technology labor costs, are capitalized subsequent to the establishment of technological feasibility and until the product is available for general release. Both prior and subsequent costs relating to the establishment of technological feasibility are expensed as incurred. Development costs associated with product enhancements that extend the original product’s life or significantly improve the original product’s marketability are also capitalized once technological feasibility has been established. Software development costs are amortized on a straight-line basis over the estimated useful lives of the products not to exceed two years, beginning with the initial release to customers. The Company continually evaluates whether events or circumstances have occurred that indicate the remaining useful life of the capitalized software development costs should be revised or the remaining balance of such assets may not be recoverable. The Company evaluates the recoverability of capitalized software based on the net realizable value of its software products, as defined by the estimated future revenue from the products less the estimated future costs of completing and disposing of the products, compared to the unamortized capitalized costs of the products. As of December 31, 2008, management believes no revisions to the remaining useful life or additional write-downs of capitalized software development costs are required because the net realizable value of its software products exceeds the unamortized capitalized costs. Management’s estimates about future revenue and costs associated with its software products are subject to risks and uncertainties related to, among other things, market and industry conditions, technological changes, and regulatory factors. A change in estimates could result in an impairment charge related to capitalized software costs.
Impairment of long-lived assets
In accordance with Statement of Financial Accounting Standards (SFAS) No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets,” the Company periodically reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value.
Effective June 30, 2007, the Company executed a software license agreement with Atiam Technologies L.P., which granted the Company a non-exclusive perpetual and irrevocable license to use certain modules of Atiam’s policy insurance software, InsPro, for internal use in Telesales. As of March 31, 2008, we determined that the portion of license fee paid for the commission module, together with capitalized costs incurred to implement the commission module, was impaired as a result of the absence of definitive plans to implement this module for internal use in Telesales. The Company recorded a $295,633 expense in the 2008 to write-off the value of this asset.
During the first quarter of 2008, the Company closed its sales office located in New York. As of March 31, 2008, the Company determined that all furniture and lease-hold improvements located at the New York sales office were impaired as a result of the office closure. The Company recorded $88,922 expense to write-down the value of these assets to their net realizable value. During the third quarter of 2008 the Company sold all furniture and equipment located at the New York office and realized a loss of $92,374.

F-12


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 1 — BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
As a result of termination of Ivan Spinner’s employment the Company has determined the value of an employment and non-compete agreement acquired pertaining to Mr. Spinner impaired as of December 31, 2008 and recorded an impairment charge of $85,078.
Income taxes
The Company accounts for income taxes under the liability method in accordance with Statement of Financial Accounting Standards No. 109, “Accounting for Income Taxes” under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.
Loss per common share
In accordance with SFAS No. 128 “Earnings Per Share,” basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period. Diluted loss per common share is not presented because it is anti-dilutive. The Company’s common stock equivalents at December 31, 2008 include the following:
         
Options
    4,291,200  
Warrants
    13,636,686  
 
       
 
    17,927,886  
 
       
Revenue recognition
We follow the guidance of the Commission’s Staff Accounting Bulletin 104 for revenue recognition. In general, the Company records revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectibility is reasonably assured.

F-13


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 1 — BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Telesales segment revenue recognition
Our Telesales business segment generates revenue primarily from the receipt of commissions paid to the Company by insurance companies based upon the insurance policies sold to consumers by the Company. These revenues are in the form of first year, bonus and renewal commissions that vary by company and product. We recognize commission revenue primarily from the sale of health insurance, after we receive notice that the insurance company has received payment of the related premium. First year commission revenues per policy can fluctuate due to changing premiums, commission rates, and types or amount of insurance sold. Insurance premium commission revenues are recognized pro-rata over the terms of the policies. Revenues for renewal commissions are recognized after we receive notice that the insurance company has received payment for a renewal premium. Renewal commission rates are significantly less than first year commission rates and may not be offered by every insurance company or with respect to certain types of products. The unearned portion of premium commissions has been included in the consolidated balance sheet as a liability for unearned commission advances.
The length of time between when we submit a consumer’s application for insurance to an insurance company and when we recognize revenue varies. The type of insurance product, the insurance company’s premium billing and collection process, and the insurance company’s underwriting backlog are the primary factors that impact the length of time between submitted applications and revenue recognition. Any changes in the amount of time between submitted application and revenue recognition, which are influenced by many factors not under our control, create fluctuations in our operating results and could affect our business, operating results and financial condition.
The Company receives bonuses based upon individual criteria set by insurance companies, which vary over time and generally do not extend beyond the current calendar year. We recognize bonus revenues when we receive notification from the insurance company of the bonus due to us.
The Company receives fees for the placement and issuance of insurance policies that are in addition to, and separate from, any sales commissions paid by insurance companies. As these policy fees are not refundable and the Company has no continuing obligation, all such revenues are recognized on the effective date of the policies or, in certain cases, the billing date, whichever is later.

F-14


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 1 — BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
The Company also generates revenue from the sale of leads to third parties. Such revenues are recognized when the Company delivers the leads and bills the purchaser of the leads.
The Company also generates revenue from the sub-lease of our leased New York City office and a portion of our leased Deerfield Beach Florida office, which are both leased under operating leases. The terms of the Company’s sub-lease of our New York City office is under similar terms as our lease. The Company sub-leases portions of our Deerfield Beach office to two unaffiliated parties through January 31, 2010. Sub-lease revenue includes base rent, additional rent representing a portion of occupancy expenses under the terms of the sub-leases and certain technology and facility services provided. We recognize sub-lease revenue when lease rent payments are due in accordance with the sub-lease agreements in accordance with SFAS No. 13 “Accounting for Leases.” Recognition of sub-lease revenue commences when control of the facility has been given to the tenant. We record a provision for losses on accounts receivable equal to the estimated uncollectible amounts. This estimate is based on our historical experience and a review of the current status of the Company’s receivables.
See Note 14 — Subsequent Events.
Atiam segment revenue recognition
The Company’s Atiam business segment offers InsPro on a licensed and an application service provider (“ASP”) basis. An InsPro software license entitles the purchaser a perpetual license to a copy of the InsPro software installed at a single client location. Alternatively, ASP hosting service enables a client to lease the InsPro software, paying only for that capacity required to support their business. ASP clients access InsPro installed on Atiam owned servers located at Atiam’s offices or at a third party’s site.
Software maintenance fees apply to both licensed and ASP clients. Maintenance fees cover periodic updates to the application and the InsPro help desk.
Consulting and implementation services are generally associated with the implementation of an InsPro instance for either an ASP or licensed client, and cover such activity as InsPro installation, configuration, modification of InsPro functionality, client insurance plan set-up, client insurance document design and system documentation.
The Company recognizes revenues in accordance with AICPA Statement of Position (SOP) 97-2, Software Revenue Recognition , as amended by SOP 98-9 (Modification of SOP 97-2, Software Revenue Recognition, With Respect to Certain Transactions). Revenue from software license agreements is recognized when persuasive evidence of an agreement exists, delivery of the software has occurred, the fee is fixed or determinable, and collectibility is probable. The Company considers fees relating to arrangements with payment terms extending beyond one year to not be fixed or determinable and revenue for these arrangements is recognized as payments become due from the customer. In software arrangements that include more than one InsPro module, the Company allocates the total arrangement fee among the modules based on the relative fair value of each of the modules.

F-15


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 1 — BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
License revenue allocated to software products generally is recognized upon delivery of the products or deferred and recognized in future periods to the extent that an arrangement includes one or more elements to be delivered at a future date and for which fair values have not been established. Revenue allocated to maintenance agreements is recognized ratably over the maintenance term and revenue allocated to training and other service elements is recognized as the services are performed.
The unearned portion of Atiam’s revenue, which is revenue collected or billed but not yet recognized as earned, has been included in the consolidated balance sheet as a liability for deferred revenue.
Deferred compensation advances
The Company regularly advanced commissions to independent sales agents and sales employees, which are accounted for as deferred compensation advances. If the Company does not ultimately receive its revenue pertaining to the underlying product sales for which the Company has advanced commissions, the Company deducts such advanced commissions from the sales agent’s or sales employee’s current or future commissions. Deferred compensation advances are charged to expense when earned by the sales agent or sales employee, which approximates the Company’s recognition of earned revenue for the underlying product sales. The recoverability of deferred compensation advances is periodically reviewed by management and is net of management’s estimate for uncollectability. Management believes deferred compensation advances as reported are fully realizable.
Lead, advertising and other marketing expense
Lead expenses, which are costs incurred in Telesales, are paid referrals from third-party lead aggregators of individuals who have expressed an interest in purchasing insurance products. Advertising expense pertains to direct response advertising. Other marketing consists of professional marketing services. Lead, advertising and other marketing are expensed as incurred. See Note 14 — Subsequent Events.
Concentrations of credit risk
The Company maintains its cash and restricted cash in bank deposit accounts, which exceed the federally insured limits of $250,000 per account as of December 31, 2008. At December 31, 2008, the Company had approximately $1,209,000 in United States bank deposits, which exceeded federally insured limits. Effective October 3, 2008 through December 31, 2009, federally insured limits have been increased from $100,000 to $250,000 per account. The Company has not experienced any losses in such accounts through December 31, 2008.
During the year ended December 31, 2008, approximately 36% and 16% of the Company’s revenue was earned from each of the Company’s two largest insurance carriers. During the years ended December 31, 2007, approximately 50% and 16% of the Company’s revenue was earned from each of the Company’s two largest insurance carriers. See Note 14 — Subsequent Events.

F-16


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 1 — BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Stock-based compensation
The Company follows the provisions of SFAS No. 123(R), “Share-Based Payment,” under the modified prospective method. SFAS No. 123(R) requires stock based compensation transactions be accounted for using a fair-value-based method. Under the modified prospective method, the Company is required to recognize compensation cost for share-based payments to employees based on their grant-date fair value from the beginning of the fiscal period in which the recognition provisions are first applied.
Non-employee stock based compensation
The cost of stock based compensation awards issued to non-employees for services are recorded at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in Emerging Issues Task Force Issue (“EITF”) Issue No. 96-18, “Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services” (“EITF 96-18”).
Registration rights agreements
The Company has adopted View C of EITF 05-4 “The Effect of a Liquidated Damages Clause on a Freestanding Financial Instrument Subject” to EITF Issue No. 00-19 “Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled In, a Company’s Own Stock” (“EITF 05-4”). Accordingly, the Company classifies as liability instruments the fair value of registration rights agreements when such agreements (i) require it to file, and cause to be declared effective under the Securities Act, a registration statement with the Commission within contractually fixed time periods, and (ii) provide for the payment of liquidating damages in the event of its failure to comply with such agreements. Under View C of EITF 05-4, (i) registration rights with these characteristics are accounted for as derivative financial instruments at fair value and (ii) contracts that are (a) indexed to and potentially settled in an issuer’s own stock and (b) permit gross physical or net share settlement with no net cash settlement alternative are classified as equity instruments.
At December 31, 2008, the Company does not believe that it is probable that the Company will incur a penalty in connection with the registration rights agreement, which we entered into on March 31, 2008 in connection with the 2008 private placement. Accordingly, no liability was recorded as of December 31, 2008.

F-17


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 1 — BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Recent accounting pronouncements
The Company adopted the provisions of FASB Interpretation No. 48 “Accounting for Uncertainty in Income Taxes” on January 1, 2007. The adoption did not result in the recording of a liability for unrecognized tax benefits. The Company or one or more of its subsidiaries files income tax returns in the U.S. federal jurisdiction and various states and local jurisdictions. While the Company’s past tax returns are not currently under examination, generally all past returns are subject to examination by the relevant taxing authorities. The Company has not recorded any liability for uncertain tax positions since management believes the tax return position taken reflects the most likely outcome upon audit and that any audit adjustment would not result in any additional tax liability as a result of the Company’s material tax losses.
In February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities” (“SFAS No. 159”), which provides companies with an option to report selected financial assets and liabilities at fair value. SFAS No. 159 also establishes presentation and disclosure requirements designed to facilitate comparisons between companies that choose different measurement attributes for similar types of assets and liabilities. SFAS No. 159 is effective as of the beginning of an entity’s first fiscal year beginning after November 15, 2007. The Company believes that the adoption of SFAS No. 159 will not have a material effect on the Company’s financial statements.
In December 2007 FASB issued FAS 141(R) “Business Combinations” (“FAS 141 (R)”) and FAS 160 “Noncontrolling Interests in Consolidated Financial Statements” (“FAS 160”). These statements are effective for fiscal years, and interim periods within those fiscal years in case of FAS 160, beginning on or after December 15, 2008. Earlier adoption is prohibited. Together these statements revise the accounting rules with respect to accounting for business combinations. Specifically, the objective of FAS 141(R) is to improve the relevance, representational faithfulness and comparability of the information that the reporting entity provides in its financial reports about a business combination and its effects. This statement thus establishes principles and requirements for how the acquirer:
    Recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree;
 
    Recognizes and measures the goodwill acquired in the business combination or a gain from a bargain purchase; and
 
    Determines what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination.
The objective of FAS 160 is to improve the relevance, comparability, and transparency of the financial information that a reporting entity provides in its consolidated financial statements by establishing accounting and reporting standards that require:

F-18


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 1 — BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
    The ownership interests in subsidiaries held by parties other than the parent be clearly identified, labeled, and presented in the consolidated statement of financial position within equity, but separate from the parent’s equity.
 
    The amount of consolidated net income attributable to the parent and to the noncontrolling interest be clearly identified and presented on the face of the consolidated statement of income.
 
    Changes in a parent’s ownership interest while the parent retains its controlling financial interest in its subsidiary be accounted for consistently. A parent’s ownership interest in a subsidiary changes if the parent purchases additional ownership interests in its subsidiary or if the parent sells some of its ownership interests in its subsidiary. It also changes if the subsidiary reacquires some of its ownership interests or the subsidiary issues additional ownership interests. All of those transactions are economically similar, and this statement requires that they be accounted for similarly, as equity transactions.
 
    When a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary be initially measured at fair value. The gain or loss on the deconsolidation of the subsidiary is measured using the fair value of any noncontrolling equity investment rather than the carrying amount of that retained investment.
 
    Entities provide sufficient disclosures that clearly identify and distinguish between the interests of the parent and the interests of the noncontrolling owners.
Together these statements are not currently expected to have a significant impact on the Company’s consolidated financial statements. A significant impact may however be realized on any future acquisition(s) by the Company. The amounts of such impact cannot be currently determined and will depend on the nature and terms of such future acquisition(s), if any.
In March 2008, the FASB issued FASB No. 161, “Disclosures about Derivative Instruments and Hedging Activities,” which amends and expands the disclosure requirements of FASB No. 133, “Accounting for Derivative Instruments and Hedging Activities,” with the intent to provide users of financial statements with an enhanced understanding of; how and why an entity sues derivative instruments, how the derivative instruments and the related hedged items are accounted for and how the related hedged items affect an entity’s financial position, performance and cash flows. This statement is effective for financial statements for fiscal years and interim periods beginning after November 15, 2008. Management believes this statement has no impact on the consolidated financial statements of the Company.

F-19


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 1 — BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
In May 2008, the FASB issued SFAS 162, The Hierarchy of Generally Accepted Accounting Principles (“SFAS 162”) . SFAS 162 identifies the sources of accounting principles and the framework for selecting the principles used in the preparation of financial statements of nongovernmental entities that are presented in conformity with GAAP in the United States. Any effect of applying the provisions of SFAS 162 shall be reported as a change in accounting principle in accordance with SFAS 154, Accounting Changes and Error Corrections . SFAS 162 is effective 60 days following approval by the Securities and Exchange Commission of the Public Company Accounting Oversight Board amendments to AU Section 411, The Meaning of Present Fairly in Conformity with Generally Accepted Accounting Principles. Management does not anticipate that the adoption of SFAS 162 will have a material impact on the Company’s consolidated financial statements.
In June 2008, the FASB issued FASB Staff Position EITF 03-6-1, Determining Whether Instruments Granted in Share-Based Payment Transactions Are Participating Securities (“FSP 03-6-1”), which addresses whether instruments granted in share-based payment transactions are participating securities prior to vesting and, therefore, need to be included in earnings allocation in computing earnings per share under the two-class method. The statement is effective for financial statements issued for fiscal years beginning after December 15, 2008 and retrospective application is required for all periods presented. Management believes FSP 03-6-1 has no impact on the consolidated financial statements of the Company.
On September 12, 2008, the FASB issued FSP FAS 133-1 and FIN 45-4, Disclosures about Credit Derivatives and Certain Guarantees: An Amendment of FASB Statement No. 133 and FASB Interpretation No. 45; and Clarification of the Effective Date of FASB Statement No. 161 (“FSP FAS 133-1 and FIN 45-4”). FSP FAS 133-1 and FIN 45-4 (1) amends Statement of Financial Accounting Standards (“SFAS”) No. 133, Accounting for Derivative Instruments and Hedging Activities (“SFAS 133”), to require disclosures by sellers of credit derivatives, including credit derivatives embedded in a hybrid instrument; (2) amends FASB Interpretation No. 45, Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others , to require an additional disclosure about the current status of the payment/performance risk of a guarantee and (3) clarifies the FASB’s intent about the effective date of SFAS No. 161, Disclosures about Derivative Instruments and Hedging Activities — an amendment of FASB Statement No. 133 (“SFAS 161”). FSP FAS 133-1 and FIN 45-4 is effective for reporting periods ending after November 15, 2008. Management believes FSP FAS 133-1 and FIN 45-4 have no impact on the consolidated financial statements of the Company.
In October 2008 the FASB issued FASB Staff Position SFAS No. 157-3, “Determining the Fair Value of a Financial Asset When the Market for That Asset Is Not Active” (“FSP”). This FSP clarifies the application of SFAS No. 157 in an inactive market and provides an example to illustrate key considerations in determining the fair value of a financial asset when the market for that financial asset is not active. This FSP was effective October 10, 2008 and must be applied to prior periods for which financial statements have not been issued. The application of this FSP did not have a material impact to our consolidated financial statements.

F-20


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 1 — BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
On December 11, 2008, the FASB issued FSP FAS 140-4 and FASB Interpretation (“FIN”) 46(R)-8, Disclosures about Transfers of Financial Assets and Interests in Variable Interest Entities (“FSP FAS 140-4 and FIN 46(R)-8”). This FSP requires additional disclosures by public entities with continuing involvement in transfers of financial assets to special purpose entities and with variable interests in VIEs. FSP FAS 140-4 and FIN 46(R)-8 was effective for reporting periods ending after December 15, 2008. Management believes FSP FAS 140-4 and FIN 46(R)-8 have no material impact on the consolidated financial statements of the Company.
On January 12, 2009, the Financial Accounting Standards Board (“FASB”) issued FASB Staff Position (“FSP”) Emerging Issues Task Force (“EITF”) 99-20-1 , Amendments to the Impairment Guidance of EITF Issue No. 99-20 (“FSP EITF 99-20-1”). This FSP amends EITF Issue No. 99-20, Recognition of Interest Income and Impairment on Purchased Beneficial Interests and Beneficial Interests That Continue to Be Held by a Transferor in Securitized Financial Assets, by eliminating the requirement that a holder’s best estimate of cash flows be based upon those that a market participant would use. Instead, FSP EITF 99-20-1 eliminates the use of market participant assumptions and requires the use of management’s judgment in the determination of whether it is probable there has been an adverse change in estimated cash flow. This FSP was effective for reporting periods ending after December 15, 2008. Management believes FSP EITF 99-20-1 has no material impact on the consolidated financial statements of the Company.
Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.
NOTE 2 — ISG ACQUISITION
On April 3, 2006, the Company entered into a merger agreement (the “ISG Merger Agreement”) with ISG Merger Acquisition Corp., a Delaware corporation and a wholly-owned subsidiary of the Company (“Merger Sub”), ISG, and Ivan M. Spinner pursuant to which, among other things, Merger Sub merged with and into ISG (the “ISG Merger”). As consideration for the ISG Merger, the Company made a cash payment of $920,000 and issued 1,000,000 shares of its common stock to Mr. Spinner, the sole stockholder of ISG, in exchange for all of the outstanding stock of ISG. The ISG merger was completed on April 4, 2006.

F-21


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 2 — ISG ACQUISITION (continued)
The Company accounted for the acquisition of ISG using the purchase method of accounting in accordance with Statement of Financial Accounting Standards No. 141 “Business Combinations”. The Company’s purchase price for ISG in the aggregate was $5,154,329 and consisted of the following:
         
Cash payment to seller
  $ 1,135,000  
Fair value of common stock issued to seller
    3,310,806  
Discounted value of future fixed payments of employment agreement
    225,212  
Fair value of stock option issued to seller
    425,381  
Estimated direct transaction fees and expenses
    57,930  
 
     
 
       
Estimated purchase price
  $ 5,154,329  
 
     
The following table summarizes the estimated fair values of ISG’s assets acquired and liabilities assumed at the date of acquisition.
         
Cash
  $ 111,024  
Accounts receivable
    210,889  
Deferred compensation advances
    256,775  
Prepaid expenses and other assets
    957  
Property and equipment, net
    600  
Intangible assets
    4,964,330  
Accrued expenses
    (164,549 )
Unearned commission advances
    (225,697 )
 
     
 
       
 
  $ 5,154,329  
 
     
Intangible assets acquired from ISG were assigned the following values: value of purchased commission override revenue with an assigned value of $1,411,594 amortized over five years in proportion to expected future value; value of acquired carrier contracts and agent relationships with an assigned value of $2,752,143 amortized over five years in proportion to expected future value; and value of an employment and non-compete agreement acquired with an assigned value of $800,593 amortized straight line over the contractual period, which is a weighted average expected useful life of 3.1 years. Intangible assets acquired from ISG had the following unamortized values as of December 31, 2008: value of purchased commission override revenue of $227,779 and value of acquired carrier contracts and agent relationships of $1,032,294. As a result of Ivan Spinner’s termination of employment the Company has determined the value of an employment and non-compete agreement acquired pertaining to Mr. Spinner impaired as of December 31, 2008 and recorded an impairment charge of $85,078 in depreciation and amortization expense.
See Note 14 — Subsequent Events.

F-22


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
Note 3 — ACQUISITION OF ATIAM
On October 1, 2007, HBDC Acquisition, LLC (“HBDC Sub”), a Delaware limited liability company and wholly-owned subsidiary of the Company, entered into an Agreement to Transfer Partnership Interests (the “Bilenia Agreement”) with the former partners (the “Bilenia Partners”) of BileniaTech, L.P., a Delaware limited partnership (“Bilenia”), whereby HBDC Sub purchased all of the outstanding general and limited partnership interests of Atiam Technologies, L.P., a Delaware limited partnership, owned by the Bilenia Partners. Bilenia owned approximately 40% of Atiam Technologies, L.P. The execution of the Bilenia Agreement and the transfer of the Atiam partnership interests to HBDC Sub there under were conditions precedent to the closing of the Merger Agreement (as defined below) on October 1, 2007 (the “Closing Date”).
The aggregate amount paid by HBDC Sub to the Bilenia Partners for the Atiam partnership interests under the Bilenia Agreement was $1,000,000, consisting of $500,000 in cash and 224,216 shares of the Company’s common stock, which shares had an aggregate value of $500,000 based on the average closing price per share ($2.23) of Company Common Stock on The Over the Counter Bulletin Board (“OTCBB”) on the five consecutive trading days preceding the Closing Date.
On September 21, 2007, the Company entered into an Agreement and Plan of Merger (the “Atiam Merger Agreement”) by and among the Company, HBDC, System Consulting Associates, Inc., a Pennsylvania corporation (“SCA”), and the shareholders of SCA party thereto (the “Shareholders”). SCA owned approximately 60% of Atiam Technologies, L.P. The Company and SCA closed on the Merger on October 1, 2007.
The Atiam Merger Agreement provided for a business combination whereby SCA would be merged with and into HBDC Sub, with HBDC Sub continuing as the surviving corporation and as a wholly-owned subsidiary of the Company (the “Atiam Merger”). The aggregate amount paid by the Company with respect to all outstanding shares of capital stock of SCA (such amount, the “Atiam Merger Consideration”) was $2,000,000, consisting of (a) $850,000 in cash and (b) 515,697 unregistered shares of the Company’s common stock, which number of shares had a value of $1,150,000 based on the average closing price per share ($2.23) of Common Stock on OTCBB on the five consecutive trading days preceding the closing date. Upon the effectiveness of the Atiam Merger, each share of SCA Common Stock issued and outstanding immediately prior to the closing date was converted into the right to receive a pro rata portion of the Atiam Merger Consideration. The Company placed certificates representing 134,529 shares, or an amount equal to $300,000, of the Company’s common stock that otherwise would be payable to the Shareholders as Atiam Merger Consideration into an escrow account, which shares will be held in escrow for a period of one year to satisfy any indemnification claims by the Company or HBDC Sub under the Atiam Merger Agreement.
Through October 1, 2007, SCA operated through Atiam Technologies, L.P. Subsequent to October 1, 2007, SCA was merged into HBDC Sub, which was subsequently renamed Atiam Technologies LLC and operates as the Company’s Atiam business. The results of our Atiam business segment have been included in the Company’s statement of operations as of October 1, 2007. The Company’s Atiam business segment is a provider of comprehensive, web-based insurance administration software applications that support individual insurance products.

F-23


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
Note 3 — ACQUISITION OF ATIAM (continued)
The Company accounted for the acquisition of Atiam using the purchase method of accounting in accordance with Statement of Financial Accounting Standards No. 141 “Business Combinations”. Our calculation for the consideration paid for Atiam in connection with the Bilenia Agreement and the Atiam Merger Agreement in the aggregate was $3,080,744 and consisted of the following:
         
Cash payments to sellers
  $ 1,350,000  
Fair value of common stock issued to sellers
    1,650,006  
Estimated direct transaction fees and expenses
    80,738  
 
     
Estimated purchase price
  $ 3,080,744  
 
     
We estimated the fair values of Atiam’s assets acquired and liabilities assumed at the date of acquisition as follows:
         
Cash
  $ 608,534  
Accounts receivable
    643,017  
Prepaid expenses & other assets
    22,623  
Property and equipment, net
    158,819  
Other assets
    3,401  
Intangible assets
    2,097,672  
Accounts payable
    (34,278 )
Accrued expenses
    (122,675 )
Income taxes payable
    (157,288 )
Deferred revenue
    (120,000 )
Long and short term capital lease obligations
    (19,081 )
 
     
 
  $ 3,080,744  
 
     
Intangible assets acquired from Atiam were assigned the following values: value of client contracts and relationships other than license with an assigned value of $1,089,223 amortized straight line over five years; value of purchased software for sale and licensing value with an assigned value of $644,449 amortized straight line over five years; and employment and non-compete agreements acquired with an assigned value of $364,000 amortized straight line over three years. Intangible assets acquired from Atiam had the following unamortized values as of December 31, 2008: value of client contracts and relationships other than licensing of $816,916; value of purchased software for sale and licensing value of $483,337; and employment and non-compete agreements acquired of $212,319.

F-24


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
Note 3 — ACQUISITION OF ATIAM (continued)
The following table summarizes the required disclosures of the pro forma combined entity, as if the acquisition of Atiam occurred at January 1, 2007.
         
    For the Year
    Ended
    December 31,
    2007
 
       
Revenues, net
  $ 23,710,061  
Net loss
    (14,042,239 )
Net loss per common share — basic and diluted
  $ (0.42 )
In connection with the Atiam acquisition, Atiam entered into three-year employment agreements with four key employees of Atiam effective October 1, 2007. These employment agreements provide that these four key employees will be compensated at an aggregate annual base salary of $700,000 with bonus compensation at the discretion of the Company’s board. These agreements may be terminated by the Company for “cause” (as such term is defined in the agreements) and without “cause” upon 30 days notice. These agreements may be terminated by the Company without “cause”, in which case the terminated employee will be entitled to their base salary for a period ranging from six to twelve months. These agreements also contain non-competition and non-solicitation provisions for the duration of the agreements plus a period ranging from six to twelve months after termination of employment.
NOTE 4 — PROPERTY AND EQUIPMENT
Property and equipment consisted of the following:
                         
    Useful Life     At December 31,     At December 31,  
    (Years)     2008     2007  
Computer equipment and software
    3     $ 1,326,541     $ 967,347  
Phone equipment and software
    3       726,535       726,535  
Office equipment
    4.6       57,066       89,485  
Office furniture and fixtures
    6.7       388,934       575,450  
Leasehold improvements
    9.8       232,411       349,225  
 
                   
 
            2,731,487       2,708,042  
 
                       
Less accumulated depreciation
            (1,567,539 )     (1,115,562 )
 
                   
 
                       
 
          $ 1,163,947     $ 1,592,480  
 
                   
For the years ended December 31, 2008 and 2007, depreciation expense was $759,457 and $605,536, respectively.

F-25


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 5 — INTANGIBLE ASSETS
Intangible assets consisted of the following:
                         
    Useful Life (Years)   At December 31,   At December 31,
    Weighted average   2008   2007
     
ISG intangible assets acquired
    4.7     $ 4,964,338     $ 4,964,338  
Atiam intangible assets acquired
    4.7       2,097,672       2,097,672  
Software development costs for internal use
    2.6       660,680       981,521  
Software development costs for external marketing
    2.0       174,296        
Internet domain
    3.0       161,200       161,200  
(www.healthbenefitsdirect.com)
                       
             
 
            8,058,186       8,204,731  
Less: accumulated amortization
            (4,859,779 )     (3,108,771 )
             
 
                       
 
          $ 3,198,407     $ 5,095,960  
             
For the years ended December 31, 2008 and 2007, amortization expense was $1,808,688 and $1,681,231 respectively.
Amortization expense subsequent to the period ended December 31, 2008 is as follows:
         
2009
  $ 1,456,453  
2010
    1,028,646  
2011
    453,258  
2012
    260,050  
 
     
 
 
  $ 3,198,407  
 
     

F-26


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 6 — UNEARNED COMMISSION ADVANCES
The Company has agreements with certain of its insurance carriers whereby the Company’s insurance carriers advance the Company first year premium commissions before the commissions are earned. The unearned portion of premium commissions has been included in the consolidated balance sheet as a liability for unearned commission advances. These advance agreements represent a material source of cash to fund the Company’s operations. Unearned commission advances are recognized as commission revenue after we receive notice that the insurance company has received payment of the related premium. In the event that the insurance company does not receive payment of the related premium pertaining to a commission advance the insurance company generally deducts the unearned commission advance from its commission payments to the Company.
The Company’s advance agreement with Golden Rule Insurance Company (“Golden Rule”) is contractually limited to a maximum of $9,000,000, can be terminated by either party at any time, and in the event of termination the Company’s outstanding advance balance (including interest, if any) can be called by Golden Rule with seven days written notice. The Company’s advance agreement with Golden Rule expired on December 31, 2008 and thereafter Golden Rule will no longer advance first year premium commissions to the Company. As of December 31, 2008 the Company’s outstanding advance balance with Golden Rule was $2,317,003. Subsequent to December 31, 2008 in connection with the Company’s execution of a client transition agreement with eHealthInsurance Services, Inc. (“eHealth”), eHealth paid Golden Rule $966,097, which represented a partial repayment of the Company’s outstanding advance balance owed to Golden Rule, from amounts that otherwise would have been due the Company from eHealth. In addition eHealth assumed approximately $794,000 of the Company’s outstanding advance balance with Golden Rule as of the date of the eHealth transaction.
The Company’s advance agreement with Humana, Inc. (“Humana”) allows the insurance carrier to terminate future advances and convert the outstanding advance balance into a promissory note, which if not repaid within 30 days, would incur interest expense. As of December 31, 2008 the Company’s outstanding advance balance with Humana was $353,808. Subsequent to December 31, 2008 in connection with the eHealth transaction eHealth assumed $370,794 of the Company’s outstanding advance balance with Humana as of the date of the eHealth transaction. Effective January 31, 2009 Humana notified the Company that it will no longer advance first year premium commissions and charged back to the Company the remaining unearned commission advance as of January 31, 2009.
As of December 31, 2008 the Company’s outstanding advance balance with Time Insurance Company (marketed under the name Assurant Health) (“Assurant”) was $236,064. Subsequent to December 31, 2008 in connection with the eHealth transactions eHealth assumed approximately $220,000 of the Company’s outstanding advance balance with Assurant as of the date of the eHealth transactions.
See Note 14 — Subsequent Events.
NOTE 7 — RELATED PARTY TRANSACTIONS
On March 30, 2007, the Company’s Co-Chairman and former CEO, Alvin H. Clemens, participated in a private placement along with other accredited and institutional investors wherein he purchased 1,000,000 shares of the Company’s Common Stock and a warrant to purchase 500,000 shares of the Company’s Common Stock for a total purchase price of $2,225,000.

F-27


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 7 — RELATED PARTY TRANSACTIONS (continued)
On March 30, 2007, Co-Investment Trust II, L.P., designee of Cross Atlantic Capital Partners, Inc.; participated in a private placement along with other accredited and institutional investors wherein it purchased 5.0 million investment units for a purchase price of $5,000,000. Mr. Tecce, who is one of our directors effective August 2, 2007, is a managing director and counsel to Cross Atlantic Capital Partners, Inc. Mr. Caldwell, who is also one of our directors effective April 1, 2008, is a shareholder, director and officer of Co-Invest II Capital Partners, Inc., which is the general partner of Co-Invest Management II, L.P., which is the general partner of The Co-Investment Fund II, L.P and is the Chairman and Chief Executive Officer of Cross Atlantic Capital Partners, Inc.
On March 31, 2008, Co-Investment Trust II, L.P., designee of Cross Atlantic Capital Partners, Inc. participated in a private placement along with other accredited and institutional investors wherein it purchased 5.0 million investment units for a purchase price of $4,000,000.
See Note 8 — Shareholders’ Equity.
As of December 31, 2007, the Company recorded $28,500 due to related parties, which consisted of the following:
    Keystone Equities Group, L.P provided the Company investment advisory services in 2007 at a cost of $53,572. John Harrison, a director of the Company, is associated with Keystone Equities Group, L.P. The Company paid Keystone Equities Group, L.P $28,572 in 2007, recorded a related party liability of $25,000 as of December 31, 2007, which was subsequently paid in 2008.
 
    SendTec, Inc. (“SendTec”) provided certain marketing and advertising services in 2007 at a cost of $14,950. Paul Soltoff, a director of the Company, is the Chief Executive Officer of SendTec. The Company paid SendTec $32,741 in 2007 and recorded a related party liability of $3,500 as of December 31, 2007, which was subsequently paid in 2008.
As of December 31, 2008, the Company recorded $4,315 due to related parties, which consisted of director travel expense reimbursement to Cross Atlantic Capital Partners for Messrs. Caldwell and Tecce’s travel expense to board of director meetings.

F-28


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 8 — SHAREHOLDERS’ EQUITY
Common Stock
2007
On February 15, 2007, the Company granted 125,000 restricted shares of Common Stock to each of Charles A. Eissa, the Company’s President, and Ivan M. Spinner, the Company’s former Senior Vice President, in accordance with the terms of the Plan. The shares granted to Messrs. Eissa and Spinner were valued at $3.00 per share and vest as follows: 50,000 shares on February 15, 2008; 50,000 additional shares on February 15, 2009; 2,083 shares per month on the 15th day of each month thereafter beginning on March 15, 2009 through January 15, 2010; and 2,087 shares on February 15, 2010.
On March 30, 2007, the Company entered into Securities Purchase Agreements (“Purchase Agreements”) and completed a private placement with certain institutional and individual accredited investors and issued 5,000,000 shares of its Common Stock and warrants to purchase 2,500,000 shares of its Common Stock. Pursuant to the Purchase Agreements, the Company sold investment units (each, a “2007 Unit”) in the 2007 Private Placement at a per unit purchase price equal to $2.25. Each 2007 Unit sold in the 2007 Private Placement consisted of one share of Common Stock and a Warrant to purchase one-half (1/2) of one share of Common Stock at an initial exercise price of $3.00 per share, subject to adjustment. The gross proceeds from the 2007 Private Placement were $11,250,000. Alvin H. Clemens purchased 1,000,000 2007 Units in the 2007 Private Placement.
In connection with the 2007 Private Placement, the Company paid the placement agents an aggregate placement fee equal of $787,500 plus the reimbursement of certain expenses in the amount of $42,500. The Company also issued to the placement agents warrants (the “Placement Agent Warrants”) to purchase in the aggregate 350,000 shares of the Company’s Common Stock with an exercise price of $2.80 and exercisable from September 30, 2007 through March 30, 2010. The Company also incurred legal and other expenses in the amount of $65,240 in connection with the 2007 Private Placement.
The Purchase Agreements also provide a customary participation right, subject to exceptions and limitations, which provides for a designated investor to be able to participate in future financings for capital raising purposes occurring within two years of March 30, 2007 at a level based on such investor’s ownership percentage of the Company on a fully-diluted basis prior to such financing.
On October 1, 2007 the Company issued 739,913 shares of its Common Stock in connection with the Company’s acquisition of Atiam. See Note 3 —Acquisition of Atiam.

F-29


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 8 — SHAREHOLDERS’ EQUITY (continued)
On December 15, 2007 the Company issued 75,000 unrestricted shares of its Common Stock to certain directors of the Company in accordance with the Company’s Non Employee Director Compensation Plan, which were valued at $161,250 based on the $2.15 closing price of our Common Stock on the OTCBB on December 14, 2007.
2008
On January 3, 2008, the Company issued 75,000 shares of unrestricted Common Stock to certain directors in accordance with the Company’s Non Employee Director Compensation Plan, which was valued in aggregate at $129,000 based on the closing price per share ($1.72) of Common Stock on the OTCBB on January 3, 2008.
On February 15, 2008, Mr. Eissa and Mr. Spinner returned to the Company in aggregate 20,749 shares of the 100,000 shares of the Company’s Common Stock that vested to them on this date as consideration for the Company paying their estimated tax liabilities pursuant to the terms of their February 15, 2007 restricted stock grants. The shares were valued at $1.32 per share based on closing price of our Common Stock on the OTCBB on February 15, 2008.
On March 31, 2008, the Company entered into Securities Purchase Agreements (the “2008 Purchase Agreements”) with certain institutional and individual accredited investors (collectively, the “2008 Investors”) and completed a private placement (the “2008 Private Placement”) of an aggregate of 6,250,000 shares of our Common Stock and warrants to purchase 6,250,000 shares of our Common Stock. Pursuant to the 2008 Purchase Agreement, the Company sold investment units (each, a “2008 Unit”) at a per unit purchase price equal to $0.80. Each 2008 Unit sold in the 2008 Private Placement consisted of one share of Common Stock and a Warrant to purchase one share of Common Stock at an initial exercise price of $0.80 per share, subject to adjustment (the “2008 Warrant”). The gross proceeds from the 2008 Private Placement were $5,000,000 and we incurred $70,238 of legal and other expenses in connection with the 2008 Private Placement.
On March 31, 2008, 75,000 restricted shares of Common Stock issued to Ivan M. Spinner, the Company’s former Senior Vice President, were forfeited in accordance with the terms restricted stock grant. The forfeiture was accounted for as retirement of 75,000 shares valued at $225,000 based on the fair market value on the date of grant and recorded as a reduction to salaries, commission and related taxes, net effects are included in amortization of deferred compensation.
On April 1, 2008, the Company issued 99,010 restricted shares of its Common Stock to Mr. Edmond Walters upon the effective date of his becoming a director of the Company in accordance with the Company’s Non Employee Director Compensation Plan and the Company’s 2006 Omnibus Equity Compensation Plan. Mr. Walters was granted shares valued at $100,000 in aggregate based on the $1.01 closing price of our Common Stock on the OTCBB on April 1, 2008, and will vest as follows: 33,003 shares on April 1, 2008; 33,003 additional shares on April 1, 2009; 33,004 shares on April 1, 2010. Pursuant to the Company’s 2006 Omnibus Equity Compensation Plan, Mr. Walters has voting, dividend and distribution rights pertaining to his unvested shares, but he is restricted from selling or otherwise disposing of his restricted shares until vesting occurs.

F-30


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 8 — SHAREHOLDERS’ EQUITY (continued)
Stock Options
2007
On February 15, 2007, the Company and Daniel Brauser, the Company’s former Senior Vice President, entered into Amendment No. 1 (the “Amendment”) to Mr. Brauser’s option, dated November 10, 2005 (the “Brauser Option”). The Brauser Amendment was approved by the Company’s board of directors on February 15, 2007. Under the terms of the Brauser Option, Mr. Brauser has the right to purchase, at an exercise price of $2.50 per share, 500,000 fully-paid and non-assessable shares (the “Option Shares”) of the Company’s Common Stock.
Under the terms of the Brauser Option, the vesting schedule of the Option Shares was as follows: (a) 25% of the Option Shares on or after the first anniversary of the Brauser Option’s grant date; (b) 10,416 Option Shares on or after the last day of each month thereafter; and (c) 10,440 Option Shares on or after November 30, 2009. As of February 15, 2007, the Brauser Option was vested with respect to 145,832 Option Shares and remained unvested with respect to the remaining 354,168 Option Shares. The Amendment accelerates the vesting schedule of the Option Shares as follows: 25% of the Option Shares subject to the Brauser Option on the first anniversary of the Brauser Option’s date of grant; an additional 10,416 Option Shares on December 31, 2006; an additional 10,416 Option Shares on January 31, 2007; an additional 19,966 Option Shares on February 15, 2007; and an additional 30,382 Option Shares on the last day of each month thereafter beginning on February 28, 2007 through December 31, 2007.
The Amendment also provided that, in the event Mr. Brauser was removed as an officer or employee of the Company at any time on or before December 31, 2007, 100% of the Option Shares that are unexercisable as of the removal date will become fully vested upon such removal. Alternatively, in the event Mr. Brauser resigned as an employee of the Company at any time after June 30, 2007 but before December 31, 2007, 50% of the Option Shares that are unexercisable as of the resignation date would become exercisable upon such resignation.
Finally, the Amendment provides that, upon the termination of Mr. Brauser’s employment with the Company for any reason, the vested portion of the Option Shares as of the date of such termination will remain exercisable by Mr. Brauser for one year following such termination.
On September 10, 2007, the Company and Mr. Brauser entered into a Separation and Transitional Services Agreement, which, among other things, extended the exercisable period of Mr. Brauser’s exercisable options for an additional year. The Company recorded $106,925 of compensation expense as a result of the modification of the Brauser Option, which was valued as of September 10, 2007 using the Black-Scholes option-pricing model based on the following assumptions: expected volatility of 50%, risk free interest rate of 4.77%, expected life of 2 years and 0% assumed dividend yield.

F-31


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 8 — SHAREHOLDERS’ EQUITY (continued)
On December 7, 2007, the Company and Mr. Frohman entered into an Amendment to the Separation Agreement, which, among other things, extended the exercisable period of Mr. Frohman’s exercisable options for an additional year and terminated all future severance payments from the Company to Mr. Frohman. The Company recorded $105,501 of compensation expense as a result of the modification of Mr. Frohman’s options, which was valued as of December 7, 2007 using the Black-Scholes option-pricing model based on the following assumptions: expected volatility of 48%, risk free interest rate of 3.32%, expected life of 1 year and 0% assumed dividend yield.
During 2007, the Company issued options to purchase 190,550 shares of Common Stock to various employees at prices ranging from $2.13 to $3.00. These options vest one third on the first anniversary and an additional one third on each anniversary thereafter.
During 2007, 239,918 options were forfeited as a result of the termination of the employment of various employees in accordance with the terms of the stock options.
2008
On March 31, 2008, the board of directors of the Company adopted the Company’s 2008 Equity Compensation Plan (the “2008 Plan”), which plan was not subject to shareholder approval. An aggregate of 1,000,000 shares of the Company’s common stock was reserved for issuance under the 2008 Plan in addition to any authorized and unissued shares of common stock available for issuance under the Company’s 2006 Omnibus Equity Compensation Plan. The purpose of the 2008 Plan is to provide a comprehensive compensation program to attract and retain qualified individuals to serve as directors. The Company is authorized to award cash fees and issue non-qualified stock options under the 2008 Plan. The 2008 Plan is administered by the Company’s board of directors or the compensation committee established by the board.
Effective October 2, 2008, our shareholders approved an amendment and restatement of the 2008 Plan to (i) permit the grant of incentive stock options, (ii) provide our compensation committee with the flexibility to make grants that qualify as “qualified performance-based compensation” within the meaning of section 162(m) of the Internal Revenue Code of 1986, as amended (the “Code”), (iii) reflect the merger of the Health Benefits Direct Corporation 2006 Omnibus Equity Compensation Plan (the “2006 Plan”) with and into the 2008 Plan, (iv) amend the adjustment provision to make clarifying changes and (v) specify the maximum number of shares authorized for issuance under the 2008 Plan.
The 2008 Plan provides that the maximum aggregate number of shares of common stock that may be made with respect to grants, other than dividend equivalents, to any individual during any calendar year is 1,000,000 shares, subject to adjustment as described below. Grantees may not accrue dividend equivalents during any calendar year in excess of $1,000,000.

F-32


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 8 — SHAREHOLDERS’ EQUITY (continued)
On March 31, 2008, the Board approved the grant of 550,000 incentive stock options to Alvin H. Clemens, the Company’s former Chief Executive Officer and current Co-Chairman, under the Health Benefits Direct Corporation 2006 Plan, in consideration of Mr. Clemens’ resignation as Chief Executive Officer and the termination of his existing Amended and Restated Employment Agreement, effective on April 1, 2008. This option has a term of ten years, an exercise per share of $1.01 and will vest as follows: 300,000 shares on April 1, 2008; 20,833 on the first calendar day of each month from May 1, 2008 through March 1, 2009 and 20,837 shares on April 1, 2009. The Company recorded the entire fair value of this option as compensation expense as of June 30, 2008.
Also during 2008, the Company issued options under the 2006 Plan and 2008 Plan in aggregate to purchase 35,000 shares of Common Stock to employees at a weighted average option exercise price of $0.72. These options will vest one third on the first anniversary and an additional one third on each anniversary thereafter.
During 2008, a total of 1,125,700 options granted under the 2006 Plan and 2008 Plan were forfeited as a result of the resignation of a director and the termination of the employment of various employees in accordance with the terms of the stock options.
The Company recorded $1,387,686 and $1,377,880 in salaries, commission and related taxes pertaining to director and employee stock options and restricted and unrestricted stock grants in the year ended December 31, 2008 and 2007, respectively.

F-33


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 8 — SHAREHOLDERS’ EQUITY (continued)
A summary of the Company’s outstanding stock options as of and for the years ended December 31, 2008 and 2007 are as follows:
                         
    Number     Weighted        
    Of Shares     Average     Weighted  
    Underlying     Exercise     Average  
    Options     Price     Fair Value  
 
Outstanding at December 31, 2006
    4,881,268     $ 2.22     $ 0.83  
For the year ended December 31, 2007
                       
Granted
    190,550       2.83       1.41  
Exercised
                 
Forfeited
    239,918       2.50       0.03  
 
                       
Outstanding at December 31, 2007
    4,831,900       2.23       0.89  
For the year ended December 31, 2008
                       
Granted
    585,000       0.99       0.56  
Exercised
                 
Forfeited
    1,125,700       2.49       0.84  
 
                       
 
                 
Outstanding at December 31, 2008
    4,291,200       1.99       0.86  
 
                 
Outstanding and exercisable at December 31, 2008
    3,867,245     $ 1.98     $ 0.80  
 
                 
The weighted average fair value of option grants are estimated as of the date of grant using the Black-Scholes option-pricing model based on the following assumptions for options granted during the years ended December 31, 2008 and 2007:
                 
    For the Year Ended   For the Year Ended
    December 31, 2008   December 31, 2007
 
               
Expected volatility
    68 %     60 %
Risk-free interest rate
    1.41 %     4.67 %
Expected life in years
    5       5.0  
Assumed dividend yield
    0 %     0 %

F-34


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 8 — SHAREHOLDERS’ EQUITY (continued)
The following information applies to options outstanding at December 31, 2008:
                                             
Options Outstanding   Options Exercisable
                Weighted                
                Average   Weighted           Weighted
                Remaining   Average           Average
Exercise   Number of Shares   Contractual   Exercise           Exercise
Price   Underlying Options   Life   Price   Number Exercisable   Price
                                             
$ 0.24       15,000       4.9     $ 0.24           $  
  0.78       10,000       4.3       0.78              
  1.00       1,300,000       6.9       1.00       1,300,000       1.00  
  1.01       550,000       9.3       1.01       466,664       1.01  
  1.05       10,000       3.2       1.05              
  2.13       15,000       3.9       2.13       4,950       2.13  
  2.30       5,000       3.6       2.30       1,650       2.30  
  2.50       1,268,500       4.5       2.50       1,092,440       2.50  
  2.55       25,000       2.5       2.55       16,500       2.55  
  2.62       20,000       3.0       2.62       13,200       2.62  
  2.70       475,000       2.3       2.70       441,500       2.70  
  2.95       45,000       2.3       2.95       29,700       2.95  
  3.00       77,700       3.4       3.00       25,641       3.00  
  3.50       75,000       7.3       3.50       75,000       3.50  
  3.60       400,000       2.3       3.60       400,000       3.60  
                                             
          4,291,200                       3,867,245          
                                             
As of December 31, 2008, there were 7,000,000 shares of our common stock authorized to be issued under the 2008 Plan, of which 1,969,790 shares of our common stock remain available for future stock option grants.
The total intrinsic value of stock options granted during 2008 and 2007 was $0 and $0, respectively. The total intrinsic value of stock options outstanding and exercisable as of December 31, 2008 and December 31, 2007 was $0 and $0, respectively.
The value of equity compensation expense not yet expensed pertaining to unvested equity compensation was $412,478 as of December 31, 2008, which will be recognized over a weighted average 0.6 years in the future.

F-35


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 8 — SHAREHOLDERS’ EQUITY (continued)
Common Stock warrants
2007
In March 2007, in connection with the 2007 Private Placement, the Company issued warrants to purchase an aggregate of 2,500,000 shares of common stock at an exercise price of $3.00 per share to the participating investors in the 2007 Private Placement, which provides that the holder thereof shall have the right, at any time after March 30, 2007, but prior to the earlier of (i) ten business days’ after the Company has properly provided written notice to all such holders of a Call Event (as defined below) or (ii) the fifth anniversary of the date of issuance of the warrant, to acquire shares of Common Stock upon the payment of the exercise price. The Company also has the right, at any point after which the volume weighted average trading price per share of the Common Stock for a minimum of 20 consecutive trading days is equal to at least two times the Exercise Price per share, provided that certain other conditions have been satisfied to call the outstanding Warrants (a “Call Event”), in which case such Warrants will expire if not exercised within ten business days thereafter. The Warrants also include a cashless exercise and weighted average anti-dilution adjustment provisions for issuances of securities below the exercise price during the first two years following the date of issuance of the warrants, subject to customary exceptions.
Also in March 2007, in connection with the 2007 Private Placement, the Company issued to the placement agents warrants to purchase in the aggregate 350,000 shares of the Company’s Common Stock, which have an exercise price of $2.80 and are exercisable from September 30, 2007 through March 30, 2010.
During 2007, certain holders of the Company’s outstanding warrants exercised their warrants to purchase an aggregate of 300,000 shares of the Company’s common stock at an exercise price of $1.50 per share for an aggregate exercise price of $450,000.
2008
On March 31, 2008, in connection with the 2008 Private Placement the Company issued warrants to purchase 6,250,000 shares of its Common Stock at an exercise price of $0.80 per share to the participating investors in the 2008 Private Placement. The 2008 Warrants provide that the holder thereof shall have the right, at any time after March 31, 2008 but prior to the earlier of (i) ten business days’ after the Company has properly provided written notice to all such holders of a 2008 Call Event (as defined below) or (ii) the fifth anniversary of the date of issuance of the 2008 Warrant, to acquire shares of Common Stock upon the payment of $0.80 per Warrant Share (the “2008 Exercise Price”). The Company also has the right, at any point after which the volume weighted average trading price per share of the Common Stock for a minimum of 20 consecutive trading days is equal to at least two times the 2008 Exercise Price per share, provided that certain other conditions have been satisfied to call the outstanding 2008 Warrants (a “2008 Call Event”), in which case such 2008 Warrants will expire if not exercised within ten business days thereafter. The 2008 Warrants also include full ratchet anti-dilution adjustment provisions for issuances of Common Stock or Common Stock equivalents below $0.80 during the first two years following the date of issuance of the Warrants.

F-36


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 8 — SHAREHOLDERS’ EQUITY (continued)
Effective March 31, 2008, in connection with the 2008 Private Placement, the Company adjusted the 2007 Warrants pursuant to the weighted average anti-dilution adjustment provisions of the 2007 Warrants. The exercise price of the 2007 Warrants was adjusted from $3.00 to $2.48 and the number of issued, exercisable and outstanding 2007 Warrants was adjusted from 2,500,000 to 3,024,186.
During 2008, warrants to purchase 3,887,500 shares of its Common Stock at an exercise price of $1.50 per share expired in accordance with the terms of the Warrants.
A summary of the status of the Company’s outstanding stock warrants granted as of December 31, 2008 and changes during the period is as follows:
                 
            Weighted  
    Common     Average  
    Stock     Exercise  
    Warrants     Price  
Outstanding at December 31, 2006
    8,200,000     $ 1.50  
 
               
For the year ended December 31, 2007
               
Granted
    2,850,000       2.98  
Exercised
    (300,000 )     1.50  
 
           
Outstanding at December 31, 2007
    10,750,000       1.89  
 
               
For the year ended December 31, 2008
               
Granted
    6,250,000       0.80  
Adjustment to warrants issued in 2007 for the issuance of warrants in 2008
    524,186       2.48  
Exercised
           
Expired
    (3,887,500 )     1.50  
 
           
Outstanding at December 31, 2008
    13,636,686     $ 1.43  
 
           
 
               
Exercisable at December 31, 2008
    13,636,686     $ 1.43  
 
           

F-37


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 8 — SHAREHOLDERS’ EQUITY (continued)
The following information applies to warrants outstanding at December 31, 2008:
                 
    Common    
    Stock   Exercise
Year of Expiration   Warrants   Price
 
               
2009
    2,762,500     $ 1.50  
2010
    75,000       1.50  
2010
    350,000       2.80  
2011
    1,175,000       1.50  
2012
    3,024,186       2.48  
2013
    6,250,000     $ 0.80  
 
               
 
    13,636,686          
 
               
Outstanding warrants at December 31, 2008 have a weighted average remaining contractual life of 2.9 years.
Registration Rights
On March 30, 2007 and in connection with 2007 Private Placement, the Company and the participating investors entered into a Registration Rights Agreement (the “Registration Rights Agreement”). Under the terms of the Registration Rights Agreement, the Company agreed to prepare and file with the Commission, as soon as possible but in any event within 30 days following the later of (i) the date the Company is required to file with the Commission its Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006, or (ii) the date of the Registration Rights Agreement, a registration statement on Form SB-2 covering the resale of the shares and the warrant shares collectively, the “Registrable Securities”). Subject to limited exceptions, the Company also agreed to use its reasonable best efforts to cause the registration statement to be declared effective under the Securities Act of 1933 as amended (the “Securities Act”) as soon as practicable and agreed to use its reasonable best efforts to keep the registration statement effective under the Securities Act until the date that is two years after the date that the registration statement is declared effective by the Commission or such earlier date when all of the Registrable Securities covered by the Registration Statement have been sold or may be sold without volume restrictions pursuant to Rule 144(k) promulgated under the Securities Act. The Registration Rights Agreement also provides for payment of partial damages to the 2007 Private Placement investors under certain circumstances relating to failure to file or obtain or maintain effectiveness of the registration statement, subject to adjustment.
In connection with the 2007 Private Placement, the Company issued to the placement agents the Placement Agent Warrants. Under the terms of the Registration Rights Agreement, the holders of the Placement Agent Warrants have certain “piggyback” registration rights for the shares of Common Stock underlying the Placement Agent Warrants (the “Placement Agent Warrant Shares”).

F-38


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 8 — SHAREHOLDERS’ EQUITY (continued)
On May 2, 2007, the Company and Alvin H. Clemens entered into a Waiver of Registration Rights Agreement whereby Mr. Clemens agreed to waive his registration rights for the 500,000 warrants that he purchased in the 2007 Private Placement until the later of 60 days following the sale of substantially all of the shares he purchased in the 2007 Private Placement or six months following the effectiveness of the registration statement filed in connection with the 2007 Private Placement. On May 10, 2007, the Company and Mr. Clemens entered into a Consent and Waiver of Registration Rights Agreement whereby Mr. Clemens and the Company consented to the filing of an amendment to the registration statement filed in connection with the 2007 Private Placement to remove the 1,000,000 shares of Common Stock that Mr. Clemens purchased in the 2007 private placement from the registration statement until the six months following the effectiveness of such registration statement.
On June 1, 2007, the Commission declared effective the Company’s Registration Statement on Form SB-2 filed with the Commission on May 2, 2007 as amended.
In connection with the Bilenia Agreement, the Company and CCCC entered into the Bilenia Registration Rights Agreement. In connection with the Atiam Merger Agreement, the Company and Shareholders also entered into a Registration Rights Agreement (the “Shareholder Registration Rights Agreement”). See Note 3 — Atiam Acquisition.
On April 22, 2008, the Commission declared effective the Company’s Registration Statement on Form SB-2 filed with the Commission on February 1, 2008 as amended.
In connection with the signing of the 2008 Purchase Agreement, the Company and the 2008 Investors also entered into a Registration Rights Agreement (the “2008 Registration Rights Agreement”). Under the terms of the 2008 Registration Rights Agreement, the Company agreed to prepare and file with the Commission, as soon as possible but in any event within 30 days following the later of (i) the date the Company is required to file with the Commission its Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007, or (ii) the date of the Registration Rights Agreement, a registration statement on Form S-1 (the “2008 Registration Statement”) covering the resale of the Shares and the Warrant Shares collectively, the “2008 Registrable Securities”). Subject to limited exceptions, the Company also agreed to use its reasonable best efforts to cause the 2008 Registration Statement to be declared effective under the Securities Act of 1933 as amended (the “Securities Act”) as soon as practicable but, in any event, no later than 90 days following the date of the 2008 Registration Rights Agreement (or 150 days following the date of the 2008 Registration Rights Agreement in the event the 2008 Registration Statement is subject to review by the Commission), and agreed to use its reasonable best efforts to keep the 2008 Registration Statement effective under the Securities Act until the date that all of the 2008 Registrable Securities covered by the 2008 Registration Statement have been sold or may be sold without volume restrictions pursuant to Rule 144(b)(i)) promulgated under the Securities Act. The 2008 Registration Rights Agreement also provides for payment of partial damages to the Investors under certain circumstances relating to failure to file or obtain or maintain effectiveness of the 2008 Registration Statement, subject to adjustment.

F-39


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
Note 9 — CAPITAL LEASE OBLIGATIONS
The Company’s Atiam Business Segment has entered into several capital lease obligations to purchase equipment used for operations. The Company has the option to purchase the equipment at the end of the lease agreement for one dollar. The underlying assets and related depreciation were included in the appropriate fixed asset category, and related depreciation account.
Property and equipment includes the following amounts for leases that have been capitalized as of December 31, 2008 and 2007:
                         
    Useful Life (Years)     December 31, 2008     December 31, 2007  
 
                       
Computer equipment and software
    3     $ 328,074     $ 60,815  
Phone System
    3       15,011        
 
                   
 
            343,085       60,815  
 
                       
Less accumulated depreciation
            (68,090 )     (4,125 )
 
                   
 
          $ 274,995     $ 56,690  
 
                   
Future minimum payments required under capital leases at December 31, 2008 are as follows:
         
2009
  $ 115,973  
2010
    119,325  
2011
    99,705  
2012
    23,078  
 
     
 
       
Total future payments
    358,081  
Less amount representing interest
    59,272  
 
     
 
       
Present value of future minimum payments
    298,808  
Less current portion
    89,297  
 
     
 
       
Long-term portion
  $ 209,511  
 
     

F-40


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 10 — DEFINED CONTRIBUTION 401(k) PLAN
The Company implemented a 401(k) plan on January 1, 2007. Eligible employees contribute to the 401(k) plan. Employees become eligible after attaining age 19 and after 6 months of employment with the Company. The employee may become a participant of the 401(k) plan on the first day of the month following the completion of the eligibility requirements. Effective January 1, 2007 the Company implemented an elective contribution to the plan of 25% of the employee’s contribution up to 4% of the employee’s contribution (the “Contribution”). The Contributions are subject to a vesting schedule and become fully vested after one year of service, retirement, death or disability, whichever occurs first. The Company made contributions of $57,556 and $73,236 for the years ended December 31, 2008 and 2007.
NOTE 11 — RESTRICTED CASH, COMMITMENTS AND CONTINGENCIES
Employment and Separation Agreements
On March 31, 2008, in connection with our 2008 Private Placement and Mr. Clemens’ resignation as our Chief Executive Officer and appointment as Co-Chairman of our board of directors, Mr. Clemens’ amended and restated employment agreement was terminated effective upon his resignation on April 1, 2008. Also in connection with our 2008 Private Placement, the Company and Mr. Clemens agreed to enter into a new employment agreement within 15 days of the effective date of Mr. Clemens’ resignation as Chief Executive Officer, which agreement will provide for a one year term and a salary of $300,000, which salary shall be effective as of the date of Mr. Clemens’ resignation.
On March 31, 2008, following Mr. Clemens’ resignation as our Chief Executive Officer, Anthony R. Verdi, our Chief Financial Officer, was also appointed to the position of Chief Operating Officer, effective April 8, 2008. Mr. Verdi shall have the authority, as our Chief Operating Officer, to lead the Company as the principal executive officer in the absence of a Chief Executive Officer and Mr. Verdi shall have such authority until we appoint a new Chief Executive Officer or until such time as our board of directors determines otherwise.
Mr. Verdi’s amended and restated employment agreement, as amended on March 31, 2008, provides for an initial term of one year with automatic successive one-year renewals unless we or Mr. Verdi gives the other party 60 days’ written notice prior to the end of the then current term. Mr. Verdi’s base salary is $225,000 per year.

F-41


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 11 — RESTRICTED CASH, COMMITMENTS AND CONTINGENCIES (continued)
If we terminate Mr. Verdi’s employment for cause or Mr. Verdi terminates his employment agreement without good reason, Mr. Verdi will be entitled to receive (i) all accrued and unpaid salary and vacation pay through the date of termination and (ii) continued participation for one month in our benefit plans. Otherwise if we terminate Mr. Verdi’s employment or Mr. Verdi terminates his employment agreement for good reason including his permanent disability he will be entitled to receive 18 months’ base salary at the then current rate, payable in accordance with our usual practices, continued participation for 18 months in our benefit plans and payment, within a commercially reasonable time and on a prorated basis, of any bonus or other payments earned in connection with our bonus plan existing at the time of termination. In addition, if Mr. Verdi’s employment is terminated in accordance with the foregoing sentence within two months prior to, or 24 months following, a change in control (as described in the employment agreement), Mr. Verdi will be entitled to receive 18 months’ base salary at the then current rate upon the date of termination, regardless of our usual practices, and all stock options held by Mr. Verdi at the date of termination will immediately become 100% vested and all restrictions on such options will lapse.
If Mr. Verdi’s employment is terminated due to a permanent disability we may credit any such amounts against any proceeds paid to Mr. Verdi with respect to any disability policy maintained and paid for by us for Mr. Verdi’s benefit.
If Mr. Verdi dies during the term of his employment agreement, the employment agreement will automatically terminate and Mr. Verdi’s estate or beneficiaries will be entitled to receive (i) three months’ base salary at the then current rate, payable in a lump sum and (ii) continued participation for one year in our benefit plans.
Mr. Verdi was appointed to the Board on June 20, 2008.
Pursuant to a written employment agreement, which we amended on March 31, 2008, Mr. Charles Eissa serves as our President. Pursuant to his amended employment agreement, his annual base salary is $250,000 per year. He is entitled to receive such bonus compensation as a majority of the members of our board of directors may determine from time to time. Mr. Eissa’ s amended employment agreement is effective beginning on March 31, 2008 and expires on March 31, 2009, subject to automatic annual renewals.
In the event of Mr. Eissa’ s termination without cause or for good reason, he or his estate would receive his then current base annual salary, plus unpaid accrued employee benefits, which is primarily accrued vacation, plus the continuation of his employee benefits for a period of one year, less all applicable taxes. In the event of his voluntary termination, death or disability, he or his estate would receive unpaid accrued employee benefits, plus the continuation of his employee benefits for a period of 1 month, less all applicable taxes.

F-42


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 11 — RESTRICTED CASH, COMMITMENTS AND CONTINGENCIES (continued)
Restricted Cash and Operating Leases
On February 17, 2006, the Company entered into a lease agreement with FG2200, LLC, a Florida limited liability company, for approximately 50,000 square feet of office space at 2200 S.W. 10th Street, Deerfield Beach, Florida (the “Lease”). The initial term of the Lease commences on March 15, 2006 and terminates on March 31, 2016. The Company has the option to extend the term for two additional 36-month periods, as well as the right to terminate the Lease within the first five years. The monthly rent increases every 12 months, starting at $62,500 plus certain building expenses incurred by the landlord and ending at approximately $81,550 plus certain building expenses incurred by the landlord. In connection with the Lease, the Company provided a $1 million letter of credit to the landlord as a security deposit for the Company’s obligations under the Lease.
On February 21, 2008 the Company entered into a sub-lease agreement with a third party whereby the third party sub-leased approximately 5,200 square feet of our Deerfield Beach office space beginning March 1, 2008 through February 28, 2009. This sub-lease agreement was amended and restated on October 3, 2008 to increase the sub-leased square footage to 13,900 and extend the lease term through January 31, 2010.
On October 1, 2008 the Company entered into a sub-lease agreement with a third party whereby the third party sub-leased approximately 8,000 square feet of our Deerfield Beach office space beginning October 15, 2008 through January 31, 2010. In accordance with this sub-lease agreement the Company recognizes base rent, additional rent representing a portion of certain actual occupancy expenses for our Deerfield Beach office and certain telephony, technology and facility services provided to our sub-tenant.
On July 7, 2006, the Company entered into a lease agreement with Radnor Properties-SDC, L.P. (the “Landlord”) for the lease of 7,414 square feet of office space located in Radnor Financial Center, Building B, 150 Radnor-Chester Road, Radnor, Pennsylvania. The term of the lease commenced on November 1, 2006, which was the date the Company, with the Landlord’s prior consent, assumed possession of the premises and the date the Landlord tendered possession of the premises to the Company following the substantial completion of the improvements required to be made by the Landlord under the lease agreement, and will expire on the last day of the 125 th month following the commencement of the lease term. The annual rent increases every 12 months, starting at approximately $161,592 plus a proportionate share of landlord’s building expenses after the second month and ending at approximately $258,378 plus a proportionate share of landlord’s building expenses. Under the terms of the lease agreement, rent is waived for the first five months of the lease term with respect to 5,238 square feet and for the first twelve months for the remaining 2,176 square feet. The Company recorded an expense charge and liability for deferred rent in the amount of $38,578 as of December 31, 2006.

F-43


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 11 — RESTRICTED CASH, COMMITMENTS AND CONTINGENCIES (continued)
The Company paid to the Landlord a security deposit of $100,000 under the lease (the “Security Deposit”) during the third quarter of 2006, which is accounted for as a deposit in other assets. The Company will not earn interest on the Security Deposit. The Security Deposit will decrease and the Landlord will return to the Company $10,000 on the third anniversary of the commencement date of the lease and on each anniversary thereafter until the required Security Deposit has been reduced to $20,000. The Security Deposit will be returned to the Company 30 days after the end of the lease provided the Company has complied with all provisions of the lease.
Effective during the first quarter of 2007, the letters of credit pertaining to the lease for our Florida office and our New York office were collateralized in the form of a money market account, which as of December 31, 2008 and December 31, 2007 had a balance of $1,150,000. This money market account is on deposit with the issuer of the letters of credit and is classified as restricted cash on the Company’s balance sheet. The terms of the money market account allow the Company to receive interest on the principal but prohibits the Company from withdrawing the principal for the life of the letters of credit.
On March 7, 2006, the Company entered into a sublease for approximately 13,773 square feet of office space located on the 7th floor at 1120 Avenue of the Americas, New York, New York (“Sublease Agreement”). The initial term of the Sublease Agreement commences in March 2006, and terminates on December 31, 2010. The monthly rent increases every 12 months, starting at approximately $303,000 per annum plus a proportionate share of landlord’s building expenses and ending at approximately $341,000 per annum plus a proportionate share of landlord’s building expenses. In connection with the Sublease Agreement, the Company provided a $151,503 letter of credit to the landlord as a security deposit for the Company’s obligations under the sublease. On May 15, 2006 the Company received the landlord’s consent, dated April 18, 2006, to the Sublease Agreement. In March 2008, the Company closed its sales office located in New York. On April 17, 2008 the Company entered into a sub-lease agreement with a third party (“2008 Sublease Agreement”) whereby the third party will sub-lease the Company’s New York office space for the balance of the Company’s Sublease Agreement and pay the Company sub-lease payments essentially equal to the Company’s costs under the Sublease Agreement. The terms of the 2008 Sublease Agreement required the Company to make certain leasehold improvements. The third party commenced paying sub-sublease payments to the Company in September 2008 however the third party failed to pay their December 2008, January and February 2009 rent when due. The Company is a beneficiary to a letter of credit in the amount of $151,503, which is available for the Company to draw against in the event of the third party’s failure to pay their rent when due. Effective December 31, 2008, the Company has accrued $629,396 related to the non-cancelable lease for the abandoned facilities, which is net present value of the Company’s future lease payments due under the remaining Sublease Agreement term plus management’s estimate of utility payments, which is estimated to be $773,311, less management’s estimate of future sub-lease revenue under the 2008 Sublease Agreement secured by the letter of credit, which is estimated to be $120,023.
The Company leases certain real and personal property under non-cancelable operating leases. Rent expense was $2,482,008 and $1,710,010 for the years ended December 31, 2008 and 2007, respectively.

F-44


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 11 — RESTRICTED CASH, COMMITMENTS AND CONTINGENCIES (continued)
Future minimum payments required under operating leases, severance and employment agreements and service agreements at December 31, 2008 are as follows:
         
2009
  $ 2,114,929  
2010
    1,934,411  
2011
    1,602,323  
2012
    1,418,744  
2013
    1,191,826  
thereafter
    2,920,264  
 
     
 
       
Total
  $ 11,182,497  
 
     
Litigation
On August 7, 2008, a former employee of the Company (the “Plaintiff”) filed a putative collective action in the United States District Court for the Southern District of Florida, case no. 08-CV-61254-Ungaro-Simonton, alleging that the Company and a co-defendant, who is an officer of the Company, unlawfully failed to pay overtime to its insurance sales agents in violation of the Fair Labor Standards Act (“FLSA”). Plaintiff purported to bring claims on behalf of a class of current and former insurance sales agents who were classified as non-exempt by the Company and compensated at an hourly rate, plus commissions (“Agents”). On October 16, 2008, the Court conditionally certified a collective action under the FLSA covering all Agents who worked for the Company within the last three years. Plaintiff and all Agents who opt to participate in the collective action seek payment from the Company of compensation for all overtime hours worked at the rate of one and one-half times their regular rate of pay, liquidated damages, attorneys’ fees, costs, and interest. On March 2, 2009, the parties reached an agreement to settle this case. That settlement will be submitted to the court for necessary approval. As of December 31, 2008 the Company recorded $200,000 of expense in other general and administrative expense, which represents the estimated cost of the settlement.
On August 28, 2008, a former employee of the Company (the “Plaintiff”) filed a national class action complaint in the Seventeenth Judicial Circuit of Florida, Broward County, case no. 062008 CA 042798 XXX CE, alleging that the Company breached a contract with employees by failing to provide certain commissions and/or bonuses. The complaint also contains claims for an accounting and for declaratory relief relating to the alleged compensation agreement. Plaintiff purports to bring these claims on behalf of a class of current and former insurance sales agents. Plaintiff seeks payment from the Company of all commissions allegedly owed to him and the putative class, triple damages, attorneys’ fees, costs, and interest. The Company filed a motion to dismiss the complaint, which is set for hearing on November 13, 2008. The Company filed a motion to dismiss the complaint, which has not yet been heard by the court. The Company believes that these claims are without merit and intends to vigorously defend the litigation.

F-45


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 11 — RESTRICTED CASH, COMMITMENTS AND CONTINGENCIES (continued)
Guarantee of Indebtedness by the Company to Third Parties Pertaining to Unearned Commission Advances Paid to Non-employee ISG Agents
The Company is a party to sales and marketing agreements whereby the Company has guaranteed the repayment of unearned commission advances paid directly from third parties including certain of the Company’s insurance carriers to the Company’s non-employee ISG agents. Under these agreements certain third parties pay commissions directly to the Company’s non-employee ISG agents and such payments include advances of first year premium commissions before the commissions are earned. Unearned commission advances from the Company’s insurance carriers to the Company’s non-employee ISG agents are earned after the insurance company has received payment of the related premium. In the event that the insurance company does not receive payment of the related premium pertaining to an unearned commission advance the third parties generally deduct the unearned commission advance from its commission payments to the Company’s non-employee ISG agents in the form of charge-backs. In the event that commission payments from these third parties to the Company’s non-employee ISG agents do not exceed the charge-backs these third parties may deduct the unearned commission advance to non-employee ISG agents from their payments to the Company or demand repayment of the non-employee ISG agents’ unearned commission balance from the Company. The current amount of the unearned commission advances these third parties to the Company’s non-employee ISG agents, which is the maximum potential amount of future payments the Company could be required to make to these third parties, is estimated to be approximately $643,000 as of December 31, 2008. As of December 31, 2008 the Company has recorded a liability of $76,651 in accrued expenses for the estimated amount the Company anticipates it will pay pertaining to these guarantees. Unearned commission advances from these third parties are collateralized by the future commission payments to the non-employee ISG agents and to the Company. The Company has recourse against certain non-employee ISG agents in the event the Company must pay the unearned commission advances.
License Agreement with Realtime Solutions Group
On May 31, 2006, the Company entered into a Software and Services Agreement (the “License Agreement”) with Realtime Solutions Group, L.L.C. (“Realtime”), under which Realtime granted the Company a worldwide, transferable, non-exclusive, perpetual and irrevocable license to use, display, copy, modify, enhance, create derivate works within, and access Realtime Solutions Group’s Straight Through Processing software (“STP”) and all associated documentation, source code and object code, for use in the marketing, promotion and sale of health benefits or insurance products.
As consideration for the grant of the rights and licenses under the License Agreement, the Company paid to Realtime a $10,000 nonrefundable cash deposit and upon delivery of the STP software and other materials the Company will pay a license fee in the form of 216,612 unregistered shares of our common stock. Concurrent with entering into the License Agreement, HBDC and Realtime entered into a Registration Rights Agreement that provides for piggyback registration rights for the to be issued shares.
The Company may unilaterally terminate the License Agreement, with or without cause, at any time on 30 calendar day prior written notice to Realtime. The license rights in the software granted under the License Agreement survive any termination of the License Agreement in perpetuity.

F-46


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 11 — RESTRICTED CASH, COMMITMENTS AND CONTINGENCIES (continued)
As of December 31, 2008 the Company has not taken delivery of the STP software or issued Common Stock in connection with the License Agreement.
NOTE 12 — SEGMENT INFORMATION
The Company derives the results of the business segments directly from its internal management reporting system. The accounting policies the Company uses to derive business segment results are substantially the same as those the consolidated company uses. Business segment results are presented net of inter-segment amounts. Management measures the performance of each business segment based on several metrics, including earnings from operations. Management uses these results, in part, to evaluate the performance of, and to assign resources to, each of the business segments.
We acquired Atiam on October 1, 2007. The results of Atiam’s operations prior to our October 1, 2007 acquisition have been excluded from our financial statements. The results of our Atiam business segment have been included in the Company’s statement of operations as of October 1, 2007. Thus Atiam segment’s results from operations for years ended December 31, 2008 and 2007 are not comparable.
Selected operating results and total asset information for each business segment was as follows:
                                                 
    For the Twelve Months   For the Twelve Months
    Ended December 31, 2008   Ended December 31, 2007
    Telesales   Atiam   Total   Telesales   Atiam   Total
Revenue
  $ 18,549,515     $ 5,578,512     $ 24,128,027     $ 19,568,722       1,141,028     $ 20,709,750  
 
                                               
Gain (loss) from operations
  $ (8,231,905 )   $ (731,806 )   $ (8,963,711 )   $ (14,650,531 )     197,490     $ (14,453,041 )
                                                 
    December 31, 2008 December 31, 2007
Total assets
  $ 4,817,971     $ 3,891,082     $ 8,709,053     $ 12,492,533       3,802,121     $ 16,294,654  

F-47


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 13 — INCOME TAXES
The Company has net operating losses carry-forwards for federal income tax purposes of approximately $25,000,000 at December 31, 2008, the unused portion of which, if any, expires in years 2025 through 2028. The Company accounts for income taxes under Statement of Financial Accounting Standards No. 109, “Accounting for Income Taxes” “SFAS 109”. SFAS 109 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and the tax basis of assets and liabilities, and for the expected future tax benefit to be derived from tax losses and tax credit carry forwards. SFAS 109 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Internal Revenue Code Section 382 places a limitation on the amount of taxable income that can be offset by carry forwards after a change in control (generally greater than a 50% change in ownership).
The table below summarizes the differences between the Company’s effective tax rate and the statutory federal rate as follows for the periods ended December 31, 2008 and 2007:
                 
    2008     2007  
Computed “expected” benefit
  $ (3,141,629 )   $ (4,953,699 )
State tax benefit, net of federal effect
    (269,283 )     (424,603 )
Amortization of acquisition related assets
    724,266       489,211  
Other permanent differences
    57,489       13,737  
Increase in valuation allowance
    2,629,157       4,875,354  
 
           
 
  $     $  
 
           
Deferred tax assets and liabilities are provided for significant income and expense items recognized in different years for tax and financial reporting purposes. The components of the net deferred tax assets for the years ended December 31, 2008 and 2007 were as follows:
                 
    2008     2007  
Deferred tax assets:
               
Net operating loss carry forward
  $ 9,589,320     $ 5,668,883  
Unearned commission advances
    1,148,421       3,211,222  
Stock option and other compensation expense
    2,036,038       1,431,623  
Depreciation
    41,011        
All Other
    444,645       411,434  
 
           
Total deferred tax asset
    13,259,435       10,723,162  
Deferred tax liabilities:
               
Depreciation
    0       (37,196 )
Software development costs
    (317,291 )     (372,979 )
 
           
Net deferred tax asset
    12,942,144       10,312,987  
 
           
Less: Valuation allowance
    (12,942,144 )     (10,312,987 )
 
           
 
  $     $  
 
           
The Company fully reserved the net deferred tax asset due to the substantial uncertainty of the realization of any tax assets in future periods. The valuation allowance was increased by $2,629,157 from the prior year.

F-48


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 14 — SUBSEQUENT EVENTS
Expiration of Warrants
On January 10, 2009, warrants to purchase 2,762,500 shares of the Company’s Common Stock at an exercise price of $1.50 per share expired in accordance with the terms of the warrants.
Issuance of Stock, Amendments to Articles of Incorporation or Bylaws
On January 14, 2009, the Company entered into and, on January 15, 2009 completed, a private placement (the “2009 Private Placement”) with Co-Investment Fund II, L.P., a Delaware limited partnership (“Co-Investment” or the “Investor”), for an aggregate of 1,000,000 shares (each, a “Preferred Share”) of its Series A Convertible Preferred Stock, par value $0.001 per share (“Preferred Stock”), and warrants (“2009 Warrants”) to purchase 1,000,000 shares of its Preferred Stock (each, a “Preferred Warrant Share”), pursuant to the terms of the Securities Purchase Agreement (the “2009 Purchase Agreement”). The gross proceeds from the closing were $4 million and the Company intends to use the net proceeds of the Private Placement for working capital purposes.
Pursuant to the Purchase Agreement, the Company agreed to sell to Co-Investment 1,000,000 investment units (each, a “2009 Unit”) in the 2009 Private Placement at a per 2009 Unit purchase price equal to $4.00. Each 2009 Unit sold in the 2009 Private Placement consisted of one share of Preferred Stock and a Warrant to purchase one share of Preferred Stock at an initial exercise price of $4.00 per share, subject to adjustment (the “2009 Warrant”).
The Preferred Stock is entitled to vote as a single class with the holders of the Company’s common stock, with each Share of Preferred Stock having the right to 20 votes. Upon the liquidation, sale or merger of the Company, each Share of Preferred Stock is entitled to receive an amount equal to the greater of (A) a liquidation preference equal to two and a half (2.5) times the Preferred Stock original issue price, subject to certain customary adjustments, or (B) the amount such Share of Preferred Stock would receive if it participated pari passu with the holders of Common Stock on an as-converted basis. Each Share of Preferred Stock becomes convertible into 20 shares of Common Stock (the “Shares”), subject to adjustment and at the option of the holder of the Preferred Stock, immediately after stockholder approval of the Charter Amendment (as defined below). For so long as any shares of Preferred Stocks are outstanding, the vote or consent of the Holders of at least two-thirds of the Preferred Stock is required to approve (Y) any amendment to the Company’s certificate of incorporation or bylaws that would adversely alter the voting powers, preferences or special rights of the Preferred Stock or (Z) any amendment to the Company’s certificate of incorporation to create any shares of capital stock that rank senior to the Preferred Stock. In addition to the voting rights described above, for so long as 1,000,000 Share of Preferred Stocks are outstanding, the vote or consent of the holders of at least two-thirds of the Share of Preferred Stock is required to effect or validate any merger, sale of substantially all of the assets of the Company or other fundamental transaction, unless such transaction, when consummated, will provide the holders of Preferred Stock with an amount per share equal to two and a half (2.5) times the Preferred Stock original issue price.

F-49


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 14 — SUBSEQUENT EVENTS (continued)
The Company is also required, under the terms of the 2009 Purchase Agreement, to file a proxy statement (the “Proxy Statement”) and hold a special meeting of the Company’s stockholders (the “Special Meeting”) within 75 days of the effective date of the Purchase Agreement for the purpose of approving a certificate of amendment to the Company’s certificate of incorporation to increase the total number of the Company’s authorized shares of Common Stock from 90,000,000 to 250,000,000 (the “Charter Amendment”). Under the terms of the 2009 Purchase Agreement, Co-Investment has agreed to vote all Preferred Shares and shares of Common Stock beneficially owned by it in favor of the Charter Amendment at the Special Meeting.
The 2009 Warrants provide that the holder thereof shall have the right (A) at any time after the Stockholder Approval Deadline, but prior to the earlier of (i) ten business days’ after the Company has properly provided written notice to all such holders of a Call Event (as defined below), (ii) the date on which the Company’s stockholders approve the Charter Amendment (the “Stockholder Approval Date”) and (iii) January 14, 2014, to acquire 1,000,000 shares of Preferred Stock upon the payment of $4.00 per Preferred Warrant Share and (B) at any time after the Stockholder Approval Date, but prior to the earlier of (i) ten business days’ after the Company has properly provided written notice to all such holders of a Call Event (as defined below) and (ii) January 14, 2014, to acquire up to a total of 20,000,000 shares of Common Stock of the Company (each a “Warrant Share”) upon the payment of $0.20 per Warrant Share (the “Exercise Price”). The Company also has the right, at any point after the Stockholder Approval Date and after which the volume weighted average trading price per share of the Preferred Stock for a minimum of 20 consecutive trading days is equal to at least eight times the Exercise Price per share, provided that certain other conditions have been satisfied, to call the outstanding 2009 Warrants (a “Call Event”), in which case such 2009 Warrants will expire if not exercised within ten business days thereafter. The 2009 Warrants also include full ratchet anti-dilution adjustment provisions for issuances of securities below $0.20 per share of Common Stock during the first two years following the date of issuance of the 2009 Warrants, subject to customary exceptions.
Upon shareholder approval of the Charter Amendment at the Special Meeting and the filing of the Certificate of Amendment, all outstanding shares of Series A Preferred Stock will become immediately convertible, at the election of each holder of Preferred Shares, into twenty shares of the Company’s common stock and the 2009 Warrants issued in the 2009 Private Placement will automatically become exercisable for twenty shares of Common Stock.

F-50


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 14 — SUBSEQUENT EVENTS (continued)
In connection with the signing of the 2009 Purchase Agreement, the Company and the Investor also entered into a Registration Rights Agreement (the “2009 Registration Rights Agreement”). Under the terms of the 2009 Registration Rights Agreement, the Company agreed to prepare and file with the SEC, within 30 days following the receipt of a demand notice of a holder of Registrable Securities, a registration statement on Form S-1 (the “Registration Statement”) covering the resale of the Shares and the Warrant Shares (collectively, the “Registrable Securities”). Subject to limited exceptions, the Company also agreed to use its reasonable best efforts to cause the Registration Statement to be declared effective under the Securities Act of 1933, as amended (the “Securities Act”), as soon as practicable but, in any event, no later than 60 days following the date of the 2009 Registration Rights Agreement (or 120 days following the date of the 2009 Registration Rights Agreement in the event the Registration Statement is subject to review by the SEC), and agreed to use its reasonable best efforts to keep the Registration Statement effective under the Securities Act until the date that all of the Registrable Securities covered by the Registration Statement have been sold or may be sold without volume restrictions pursuant to Rule 144(b)(i) promulgated under the Securities Act. In addition, if the Company proposes to register any of its securities under the Securities Act in connection with the offering of such securities for cash, the Company shall, at such time, promptly give each holder of Registrable Securities notice of such intent, and such holders shall have the option to register their Registrable Securities on such additional registration statement. The 2009 Registration Rights Agreement also provides for payment of partial damages to the Investor under certain circumstances relating to failure to file or obtain or maintain effectiveness of the Registration Statement, subject to adjustment.
The Company also agreed, pursuant to the terms of the 2009 Purchase Agreement, that, except for the Follow-on Financing, for a period of 90 days after the effective date (the “ Initial Standstill ”) of the 2009 Purchase Agreement, the Company shall not, subject to certain exceptions, offer, sell, grant any option to purchase, or otherwise dispose of any equity securities or equity equivalent securities, including without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, capital stock and other securities of the Company (any such issuance, offer, sale, grant, disposition or announcement being referred to as a “ Subsequent Placement ”). Additionally, the Company has agreed with Co-Investment that, for an additional 90 day period following the Initial Standstill, it shall not engage in any Subsequent Placement without the prior written consent of Co-Investment, if such Subsequent Placement seeks to raise less than $15 million.
The 2009 Purchase Agreement also provides for a customary participation right for Co-Investment, subject to certain exceptions and limitations, which grants Co-Investment the right to participate in any future capital raising financings of the Company occurring prior to January 14, 2011. Co-Investment may participate in such financings at a level based on Co-Investment’s ownership percentage of the Company on a fully-diluted basis prior to such financing.
On January 14, 2009, the Company filed the Certificate of Designation with the Secretary of State of the State of Delaware. The Certificate of Designation was approved by the Company’s Board of Directors on January 12, 2009 and became effective upon filing. The Certificate of Designation provides for the terms of the Preferred Stock issued pursuant to the 2009 Purchase Agreement.

F-51


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 14 — SUBSEQUENT EVENTS (continued)
Cessation of Direct Marketing and Sales in the Telesales Call Center, Transactions with eHealth and Reduction in Staffing
During the first quarter of 2009, the Company ceased the direct marketing and sale of health and life insurance and related products to individuals and families in its Telesales call center. The Company continues to sell health and life insurance and related products to individuals and families through its non employee ISG agents. The Company’s Telesales business segment eliminated 43 positions including all of its licensed employee sales agents along with other Telesales service and support personnel and eliminated another 20 positions in Telesales through attrition.
On February 20, 2009 (the “Closing Date”), the Company entered into and completed the sale of the Company’s Telesales call center produced agency business (the “Agency Business”) to eHealth, an unaffiliated third party, pursuant to the terms of a Client Transition Agreement (the “Agreement”).
Pursuant to the Agreement the Company transferred to eHealth broker of record status and the right to receive commissions on certain of the in-force individual and family major medial health insurance policies and ancillary dental, life and vision insurance policies issued by Aetna, Inc., Golden Rule, Humana, PacifiCare, Inc., Assurant and United Healthcare Insurance Co. (collectively, the “Specified Carriers”) on which the Company was designated as broker of record as of the Closing Date (collectively, the “Transferred Policies” and each, a “Transferred Policy”). Certain policies and products were excluded from the transaction, including the Company’s agency business generated through its ISG agents, all short term medical products and all business produced through carriers other than the Specified Carriers. In addition, the Agreement also provides for the transfer to eHealth of certain lead information relating to health insurance prospects (the “Lead Database”). The estimated aggregate initial amount of consideration paid by eHealth pursuant to the Agreement is approximately $1,280,000. In addition, on the Closing Date, eHealth agreed to assume from the Company certain liabilities relating to historical commission advances on the Transferred Policies made by the Specified Carriers in an aggregate amount of approximately $1,385,000. In addition, eHealth has agreed to pay to HBDC II a portion of each commission payment received by eHealth and reported by the Specified Carrier relating to a Transferred Policy for the duration of the policy, provided that eHealth remains broker of record on such Transferred Policy.
Simultaneous with the execution of the Agreement, the Company and eHealth also entered into a Marketing and Referral Agreement, dated as of February 20, 2009 (the “ Referral Agreement ”). Pursuant to the terms of the Referral Agreement, eHealth agreed to construct one or more websites for the purpose of selling health insurance products (the “ Referral Sites ”) and to pay to HBDC II a portion of all first year and renewal commissions received by eHealth from policies sold through the Referral Sites that result from marketing to prospects using the Lead Database or other leads delivered by the Company to eHealth. The Referral Agreement is scheduled to terminate 18 months following the Closing Date and is terminable by the Company or eHealth upon material breach by the other party.

F-52


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 14 — SUBSEQUENT EVENTS (continued)
As a result of above, management anticipates a significant decline in future Telesales revenues as a result of the cessation of direct marketing and sales in Telesales and the eHealth transaction. Revenue from the five insurance carriers subject to the eHealth transactions accounted for 66% and 75% of the Company’s total revenue for the years ended December 31, 2008 and 2007. Management believes the reduction in future revenues will be mitigated if not more than offset by significant reductions in future expenses. During the year ended December 31, 2008, the Company incurred approximately $12,697,000 of expense in Telesales’ call center, which will be eliminated as a result of the cessation of direct marketing and sales activities, including approximately $7,668,000 of salaries, commissions and related taxes, approximately $4,013,000 of lead, advertising and other marketing, approximately $848,000 rent and other occupancy costs and approximately $168,000 of other general and administrative expense.
We have not completed a determination of the impairment of long term assets as a result of the cessation of direct marketing and sales and the Agreement. The long term assets, which may be impaired, and their net book value as of December 31, 2008 include property and equipment net of depreciation of approximately $434,000, intangible assets net of accumulated amortization acquired from ISG including value of purchased commission override revenue of $227,779 and value of acquired carrier contracts and agent relationships of $1,032,294. We anticipate completing an impairment determination during the first quarter of 2009.
Results of March 25, 2009 Special Shareholder Meeting
Effective March 25, 2009, our shareholders approved an amendment to our certificate of incorporation, as amended, to increase the number of authorized Common Shares from 90,000,000 shares to 200,000,000.
Amendments to Articles of Incorporation Pertaining to the Convertibility of Preferred Shares into Common Shares
As a result of shareholder approval of an amendment to our certificate of incorporation, as amended, to increase the number of authorized shares of Common Stock from 90,000,000 shares to 200,000,000 on March 25, 2009, the Company filed a Certificate of Amendment with the Secretary of State of the State of Delaware. The Certificate of Amendment was approved by the Company’s board of directors on January 12, 2009 and became effective upon filing on March 25, 2009. Upon the filing of the Certificate of Amendment, all outstanding shares of Series A Preferred Stock became immediately convertible, at the election of each holder of Preferred Shares, into twenty shares of the Company’s common stock and the 2009 Warrants issued in the 2009 Private Placement automatically became exercisable for twenty shares of Common Stock.
Anti-dilution Adjustment to 2007 Warrants and 2008 Warrants
Effective March 25, 2009, in connection with our shareholders’ approval of an amendment to our certificate of incorporation, the Company adjusted the 2007 Warrants pursuant to the weighted average anti-dilution adjustment provisions of the 2007 Warrants. The exercise price of the 2007 Warrants was adjusted from $2.48 to $1.51 and the number of issued, exercisable and outstanding 2007 Warrants were adjusted from 3,024,186 to 4,968,491.

F-53


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 14 — SUBSEQUENT EVENTS (continued)
Also effective March 25, 2009, in connection with our shareholders’ approval of an amendment to our certificate of incorporation, the Company adjusted the 2008 Warrants pursuant to the full ratchet anti-dilution adjustment provisions of the 2008 Warrants. The exercise price of the 2008 Warrants was adjusted from $0.80 to $0.20 and the number of issued, exercisable and outstanding 2008 Warrants were adjusted from 6,250,000 to 25,000,000.
Action of the Compensation Committee on February 5, 2009
On February 5, 2009, the Compensation Committee (the “Committee”) of the Company’s board of directors authorized and issued stock option grants and bonuses to each of Anthony R. Verdi, the Company’s Chief Financial Officer, Chief Operating Officer and acting principal executive officer, and Robert Oakes, a director of the Company and President of the Company’s Atiam Technologies LLC subsidiary.
The Committee approved a $100,000 cash bonus payable to Mr. Verdi in four equal monthly installments beginning in April 2009 and a $50,000 cash bonus payable to Mr. Oakes in February 2009. The Committee also authorized and issued to Mr. Verdi a stock option grant to purchase a total of 650,000 shares of the Company’s common stock, which vests as follows: 130,000 shares of Common Stock on each of May 31, 2009, September 30, 2009, May 31, 2010 and September 30, 2010; 65,000 shares of Common Stock on May 31, 2011; and 32,500 shares of Common Stock on each of September 30, 2011 and May 31, 2012.
The Committee authorized and issued to Mr. Oakes a stock option grant to purchase a total of 1,000,000 shares of the Company’s common stock, which vests as follows: 200,000 shares of Common Stock on each of May 31, 2009, September 30, 2009, May 31, 2010 and September 30, 2010; 100,000 shares of Common Stock on May 31, 2011; and 50,000 shares of Common Stock on each of September 30, 2011 and May 31, 2012.
Each of the options issued to Messrs. Verdi and Oakes have a five year term and an exercise price of $0.101, which is equal to closing price of one share of the Company’s common stock as quoted on the OTCBB on February 5, 2009.
Separation of Employment Agreement and General Release With Charles Eissa
On March 31, 2009, Charles Eissa, the Company’s President, and the Company agreed to a Separation of Employment and General Release Agreement whereby Mr. Eissa and the Company mutually agreed that Mr. Eissa’s employment terminated effective March 31, 2009 (“Separation Date”). Under the terms of the agreement the Company will continue to pay Mr. Eissa his current base salary for a period of fourteen (14) months after the Separation Date, less applicable tax withholding, which will be paid in equal installments in accordance with the Company’s normal payroll practices. The Company will provide Mr. Eissa with continued medical, dental and vision coverage at the level in effect as of the Separation Date until the end of the twelve (12)-month period following the Separation Date. In addition the Company agreed to vest effective with the Separation Date all remaining restricted common stock granted to Mr. Eissa on February 15, 2007 subject to the payment in cash of any withholding taxes to the Company, which would have vested between March 15, 2009 and February 15, 2010. Any stock option grants held by Mr. Eissa that are not vested as of the Separation Date shall be forfeited as of the Separation Date.

F-54


 

HEALTH BENEFITS DIRECT CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2008
NOTE 14 — SUBSEQUENT EVENTS (continued)
As of March 31, 2009 the Company and Mr. Eissa entered into a consulting agreement that outlines certain advisory services to be provided by Mr. Eissa to the Company.

F-55


 

ITEM 9.   CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINACIAL DISCLOSURE
NONE.
ITEM 9A(T).   CONTROLS AND PROCEDURES.
Disclosure Controls and Procedures.
     Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company. Under the supervision of our Chief Executive Officer and Chief Financial Officer, our management conducted an assessment of the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based on the results of such assessment, management have concluded that our disclosure controls and procedures as of the end of the period covered by this report have been designed and are functioning effectively to provide reasonable assurance that the information required to be disclosed by the Company in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and is accumulated and communicated to management, including the Company’s principal executive and principal financial officers, or person performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Internal Control over Financial Reporting.
     There have not been any changes in the Company’s internal control over financial reporting during the Company’s last fiscal year to which this report relates that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
     A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
     Management’s report on internal control over financial reporting is included in Item 8, Financial Statements , of this Annual Report on Form 10-K.
ITEM 9B.   OTHER INFORMATION.
On March 31, 2009, Charles Eissa, the Company’s President, and the Company agreed to a Separation of Employment and General Release Agreement whereby Mr. Eissa and the Company mutually agreed that Mr. Eissa’s employment terminated effective March 31, 2009 (“Separation Date”). Under the terms of the agreement the Company will continue to pay Mr. Eissa his current base salary for a period of fourteen (14) months after the effective date, less applicable tax withholding, which will be paid in equal installments in accordance with the Company’s normal payroll practices, beginning within thirty (30) days following the Separation Date. The Company will provide Mr. Eissa with continued medical, dental and vision coverage at the level in effect as of the Separation Date (or generally comparable coverage) for Employee, on the same terms as such coverage is available to employees of the Company generally, at the same premium rates and cost sharing as may be charged from time to time for employees of the Company generally, as if Employee had continued in employment until the end of the twelve (12)-month period following the Separation Date. In addition the Company agreed to vest effective on the Separation Date all remaining restricted common stock granted to Mr. Eissa on February 15, 2007 subject to the

98


 

payment in cash of any withholding taxes to the Company, which would have vested between March 15, 2009 and February 15, 2010. Any stock option grants held by Mr. Eissa that are not vested as of the Separation Date shall be forfeited as of the Separation Date and Employee shall have no further rights with respect thereto.
As of March 31, 2009 the Company and Mr. Eissa entered into a consulting agreement that outlines certain advisory services to be provided by Mr. Eissa to the Company.
As a result of shareholder approval of an amendment to our certificate of incorporation, as amended, to increase the number of authorized shares of Common Stock from 90,000,000 shares to 200,000,000 on March 25, 2009, the Company filed a Certificate of Amendment with the Secretary of State of the State of Delaware. The Certificate of Amendment was approved by the Company’s board of directors on January 12, 2009 and became effective upon filing on March 25, 2009. Upon the filing of the Certificate of Amendment, all outstanding shares of Series A Preferred Stock became immediately convertible, at the election of each holder of Preferred Shares, into twenty shares of the Company’s common stock and the 2009 Warrants issued in the 2009 Private Placement automatically became exercisable for twenty shares of Common Stock.

99


 

PART III
ITEM 10.   DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.
Directors, Executive Officers and Corporate Governance
      Donald R. Caldwell , 61, has served as one of our directors and as one of the Co-Chairmen of our board of directors since April 2008. Mr. Caldwell founded Cross Atlantic Capital Partners, Inc. in 1999, and presently serves as its Chairman and Chief Executive Officer. He has served as a Director at Rubicon Technology, Inc. since 2001, and at Diamond Management & Technology Consultants, Inc. (NASDAQ) since 1994. Mr. Caldwell is a Director and a member of the Compensation Committees of Quaker Chemical Corporation (NYSE), a provider of process chemicals and chemical specialties, and Voxware, Inc. (NASDAQ), a supplier of voice driven solutions. From 1996 to 1999, Mr. Caldwell was President and Chief Operating Officer and a Director of Safeguard Scientifics, Inc. Mr. Caldwell is a Certified Public Accountant in the State of New York.
      Alvin H. Clemens , 71, has served as one of our directors since November 2005 and has served as one of the Co-Chairmen since April 2008. Mr. Clemens has previously served as Executive Chairman of our board of directors from January 2006 to March 2008 and as our Chief Executive Officer from December 2006 to March 2008. Since 2001, Mr. Clemens has performed business and insurance industry consulting services in addition to managing his private investments. In 1998, he founded HealthAxis Inc., a publicly-traded company specializing in direct sales of insurance products utilizing the Internet, as a subsidiary of Provident American Corporation. In 1989, Mr. Clemens acquired a controlling interest in Provident American Corporation, an insurance holding company, and he served as its Chairman and Chief Executive Officer until 2001. In 1970, Mr. Clemens founded Academy Insurance Group, a company specializing in direct marketing of life and health insurance products. He currently serves on the board of trustees and the Building, Finance, and Executive Committees of The Pennsylvania State University.
      John Harrison , 65, has served as one of our directors since November 2005. He is a founding Partner and Executive Director of The Keystone Equities Group, Inc., a full service investment banking group and a registered NASD broker-dealer founded in 2003. Mr. Harrison also is a Managing Director of Covenant Partners, a hedge fund that invests in direct marketing services companies. In 1999, Mr. Harrison became a founding Partner of Emerging Growth Equities, Ltd., a full service investment banking and brokerage firm focused on raising capital for emerging technology companies addressing high-growth industry sectors. From 1985 to 2000, Mr. Harrison served as President of DiMark, a direct marketing agency that was subsequently acquired by Harte-Hanks in 1996. He also has held senior management positions with CUNA Mutual, RLI Insurance and CNA Insurance where he directed their direct marketing practice. Mr. Harrison was Chairman of the board of Professional Insurance Marketing Association (PIMA) and is on the advisory board of DePaul University’s Interactive and Direct Marketing Institute. He serves as a director of IXI Corporation, a database marketing company that uses proprietary wealth and asset information, and Solutionary, Inc., a full-service provider of managed security services.
      Warren V. Musser , 81, has served as one of our directors since January 2006 and as the Vice Chairman of our board of directors since March 2006. He also has served as President of The Musser Group, a financial consulting company, since 2001. Mr. Musser served as Chairman and Chief Executive Officer of Safeguard Scientifics, Inc. from 1953 until 2001. Mr. Musser is a director of Internet Capital Group, Inc. and Chairman of the board of directors of Telkonet, Inc. Mr. Musser serves on a variety of civic, educational and charitable boards of directors.
      Robert J. Oakes , 50, has served as one of our directors since August 2008. He has served as the President and CEO of our Atiam Technologies LLC subsidiary since our acquisition of the subsidiary on

100


 

October 1, 2007. From 1986 until 2007 Mr. Oakes was President and Chief Executive Officer of the general partner of Atiam Technologies L.P., a software development and servicing company that developed, expanded and serviced products to serve the insurance and financial services markets. Mr. Oakes founded Atiam in 1986 and led the company’s effort to design and develop its flagship product, InsPro . InsPro is a state-of-the-art Insurance, Marketing, Administration, and Claim System that provides end-to-end insurance processing, technology and support, for a broad range of life, health, and disability products.
      Sanford Rich , 50, has served as one of our directors since April 2006. He is currently the Managing Director, Investment Banking for Matrix USA LLC and has held this position since May 2008. From 1995 to May 2008 Mr. Rich was Director, Senior Vice President and Portfolio Manager at GEM Capital Management Inc. From 1993 to 1995, Mr. Rich was a Managing Director of High Yield Finance, Capital Markets & North American Loan Syndicate, Sales and Trading at Citicorp Securities. From 1985 to 1993, he served as Managing Director of Debt Capital Markets at Merrill Lynch. From 1978 to 1985, Mr. Rich held various Analyst positions in numerous companies, including Cypress Capital Management, Inc. (Vice President and Analyst from 1983 to 1985), FIAMCO (Distressed/High Yield Bond Analyst from 1981 to 1983), Progressive Corporation (Financial Analyst from 1980 to 1981) and Prescott, Ball and Turben (Distressed/High Yield Bond Analyst from 1978 to 1980).
      L.J. Rowell , 76, has served as one of our directors since April 2006. He is a past President (1984-1996), Chief Executive Officer (1991-1996) and Chairman of the Board (1993-1996) of Provident Mutual Life Insurance Company, where he also held various other executive and committee positions from 1980 until his retirement in 1996. Mr. Rowell currently serves on the boards of directors of the Southeast Pennsylvania Chapter of the American Red Cross, The PMA Group, the American College, The Foundation at Paoli, and The Milton S. Hershey Medical Center. Mr. Rowell also has served on the Board of Trustees of The Pennsylvania State University as a business and industry trustee since 1992. In 1991, he served as the Chairman of the Major Business Division for the United Way of Southeastern Pennsylvania. Mr. Rowell also has served as chairman of The American Red Cross Ad Blood Campaign and has previously served on its Major Contributions Donor Campaign.
      Paul Soltoff , 54, has served as one of our directors since November 2005. He also has served as Chairman and Chief Executive Officer of SendTec, Inc. since its inception in February 2000. From 1997 until February 2000, Mr. Soltoff served as Chief Executive Officer of Soltoff Direct Corporation, a specialized direct marketing consulting company. From September 2004 until October 2005, Mr. Soltoff served as a director of theglobe.com.
      Frederick C. Tecce , 73, has served as one of our directors since August 2007. He currently serves as of counsel with Buchanan Ingersoll & Rooney. He was an attorney with Klett Rooney Lieber & Schorling when it joined Buchanan in 2006. Mr. Tecce also serves as counsel to Cross Atlantic Capital Partners and has served on the investment committees of three of the funds managed by Cross Atlantic Partners. Mr. Tecce previously served as Senior Vice President and General Counsel of Academy Life Insurance Company. Mr. Tecce served on the transition team for Pennsylvania Governor Tom Ridge and was appointed by Governor Ridge to serve as a member of the board of the $50 billion Public School Employees Retirement System (PSERS), where he served as chairman of the Finance Committee until his retirement in September of 2001. He was appointed by U.S. Senator Rick Santorum to the Federal Judicial Nominating Committee where he served for several terms and also served on Dr. Robert Gallo’s Board of Visitors at the University of Maryland Institute for Human Virology. He has also served on the board of directors of several listed companies.

101


 

      Anthony R. Verdi , 60, has served as one of our directors since June 2008, as our Chief Financial Officer and Assistant Secretary since November 2005, as our Chief Operating Officer since April 2008 and from June 20, 2008 as Acting Principal Executive Officer. From 2001 until November 2005, Mr. Verdi has provided consulting services to life, health and property and casualty insurance company agency and venture capital clients. Mr. Verdi served as Chief Operating Officer of Provident and Chief Financial Officer of HealthAxis. From January 1990 until December 1998 Mr. Verdi served as Chief Financial Officer of Provident American Corporation. From July 1986 until January 1990, he was the Vice President and Controller of InterCounty Hospitalization and Health Plans, a nonprofit group medical insurer. From April 1971 until July 1986, he served in various finance and accounting capacities for the Academy Insurance Group, ultimately serving as the Assistant Controller.
      Edmond J. Walters , 47, has served as one of our directors since April 2008. Mr. Walters is Founder and Chief Executive Officer of eMoney Advisor, a wealth planning and management solutions provider for financial advisors that was founded in 2000 and is now a wholly-owned subsidiary of Commerce Bancorp. Prior to forming eMoney Advisor in 2000, Mr. Walters spent more than 20 years in the financial services industry, advising high net worth clients. From 1983 to 1992 he was associated with Kistler, Tiffany & Company in Wayne, PA. In 1992, Walters helped found the Wharton Business Group, a financial advising firm, in Malvern, PA.
Code of Business Conduct and Ethics
     We adopted an amended and restated Code of Business Conduct and Ethics on January 29, 2008. Our Code of Business Conduct and Ethics, in accordance with Section 406 of the Sarbanes-Oxley Act of 2002 and Item 406 of Regulation S-K, applies globally to our corporate directors, executive officers, senior financial officers, and other employees. Our Code of Business Conduct and Ethics is intended to promote honest and ethical conduct, full and accurate reporting, and compliance with laws as well as other matters. A printed copy of our Code of Business Conduct and Ethics may be obtained free of charge by writing to us at Health Benefits Direct Corporation, 150 N. Radnor-Chester Road, Suite B-101, Radnor, Pennsylvania 19087.
Corporate Governance and Committees
     Our board of directors currently is composed of Messrs. Caldwell, Clemens, Harrison, Musser, Oakes, Rich, Rowell, Soltoff, Tecce, Verdi and Waters. Mr. Clemens and Mr. Caldwell are the Co-Chairmen of our board of directors. Directors serve until the next annual meeting of stockholders, until their successors are elected or appointed or qualified, or until their prior resignation or removal. Our executive officers are appointed by, and serve at the discretion of, our board of directors. Our board of directors has established an audit committee, a compensation committee and a nominating and governance committee. Pursuant to our bylaws, our board of directors may from time to time establish other committees to facilitate the management of our business and operations.
Audit Committee
     The members of our audit committee are Messrs. Caldwell, Rich and Rowell. Mr. Rich chaired the committee during 2007 through March 31, 2008. Mr. Caldwell became chairman of the committee effective upon his appointment to the board on April 1, 2008. Our board of directors has determined that Mr. Caldwell is an “audit committee financial expert,” as such term is defined in Item 407(d)(5) of Regulation S-K promulgated by the Securities and Exchange Commission. Although our common stock is not listed on NASDAQ and, as a result, we are not subject to NASDAQ’s listing standards, we voluntarily strive to comply with such standards. Our board of directors, in applying the above-

102


 

referenced standards, has affirmatively determined that each of Messrs. Rich and Rowell are “independent”.
Compensation Committee
     The members of our compensation committee are Messrs. Harrison and Rich. Mr. Harrison chairs the committee.
Nominating and Governance Committee
     The members of our nominating and governance committee are Messrs. Rowell, Harrison and Soltoff. Mr. Rowell chairs the committee.
SECTION 16(A) BENEFICIAL OWNERSHIP COMPLIANCE
     Section 16(a) of the Securities Exchange Act of 1934, as amended, requires our executive officers and directors and persons who own more than 10% of our common stock to file reports of beneficial ownership and changes in beneficial ownership of our common stock and any other equity securities with the Securities and Exchange Commission. Executive officers, directors, and persons who own more than 10% of our common stock are required by Securities and Exchange Commission regulations to furnish us with copies of all Section 16(a) forms they file.
     Based solely on our review of the copies of Forms 3, 4, and 5 furnished to us, or representations from certain reporting persons that no Forms 3, 4 or 5 were required to be filed by such persons, we believe that all of our executive officers, directors, and persons who own more than ten percent of our common stock complied with all Section 16(a) filing requirements applicable to them during 2008 with the exception of: Robert Oakes, who inadvertently filed a late Form 3 to report his appointment to the board of directors on August 25, 2008; Edmond Walters, who inadvertently filed a late Form 3 to report his appointment to the board of directors on April 1, 2008 and a late Form 4 to report the purchase of 62,623 shares on July 15, 2008; and Charles Eissa, who inadvertently filed a late Form 4 to report the sale of 62,623 shares on July 15, 2008.

103


 

ITEM 11.   EXECUTIVE COMPENSATION
Summary Compensation Table
The following table summarizes the compensation paid to, awarded to or earned during the fiscal years ended December 31, 2008 and 2007 by our Chief Executive Officer and each of our two other most highly compensated executive officers whose total salary and bonus exceeded $100,000 for services rendered to us in all capacities during 2008. The executive officers listed in the table below are referred to in this report as our “named executive officers”. There were no non-equity incentive plan compensation or non-qualified deferred compensation earnings for any of the named executive officers for the fiscal years ended December 31, 2008 and December 31, 2007.
                                                         
                                            All Other    
                            Stock Awards   Option Awards   Compensation    
Name and Principal Position   Fiscal Year   Salary ($)   Bonus ($)   ($)   ($) (8)   ($) (9)   Total ($)
 
 
                                                       
Alvin H. Clemens (1)
    2008       343,269                   313,542       32,649       689,460  
Co-Chairman & fomer Chief Executive
    2007       360,577                   41,250       39,301       441,127  
Officer
                                                       
 
                                                       
Charles Eissa (2)
    2008       264,423             150,000 (7)     7,188       20,408       442,018  
President
    2007       278,846       50,000 (10)     131,250 (7)     3,750       10,189       474,035  
 
                                                       
Richard Arenschield (3)
    2008       18,500                               18,500  
Fomer Interim Chief Executive Officer
    2007                                      
 
                                                       
Anthony R. Verdi (4)
    2008       232,211                         14,556       246,767  
Principal Executive Officer, Chief
    2007       235,577       25,000 (10)           35,700       13,842       310,119  
Financial Officer & Chief Operating Officer
                                                       
 
                                                       
Robert J. Oakes (5)
    2008       250,000                         23,075       273,075  
President Atiam Technologies LLC
    2007                                      
 
                                                       
Ivan M. Spinner (6)
    2008       106,609             37,500 (7)     189,436       235,879       569,425  
Senior Vice President
    2007       356,731             131,250 (7)     156,186       13,727       657,893  
 
(1)   Mr. Clemens has served as Co-Chairman of our board since April 1, 2008. Mr. Clemens served as Executive Chairman of our board of directors from January 2006 to March 2008 and as our Chief Executive Officer from December 2006 to March 2008 .
 
(2)   Mr. Eissa was appointed as our President on November 18, 2005. Mr. Eissa served as Chief Operating Officer from November 18, 2005 to March 31, 2008.
 
(3)   Mr. Arenschield was appointed as our interim Chief Executive Officer on April 1, 2008 and resigned on April 3, 2008.
 
(4)   Mr. Verdi was appointed as our Chief Financial Officer on November 10, 2005, Chief Operating Officer on April 1, 2008 and Acting Principal Executive Officer on June 20, 2008.
 
(5)   Mr. Oakes was appointed as President of our subsidiary Atiam Technologies, LLC on October 1, 2007 concurrently with the closing of our acquisition of Atiam.
 
(6)   Mr. Spinner was appointed as our Senior Vice President on April 3, 2006 concurrently with the closing of our acquisition of ISG. Mr. Spinner’s employment terminated on March 31, 2008.

104


 

(7)   Represents the dollar amount recognized for financial statement reporting purposes with respect to the applicable fiscal year in accordance with SFAS 123(R), under the modified prospective method. On February 15, 2007, we made restricted stock grants of 125,000 shares of our common stock to each of Mr. Eissa and Mr. Spinner in accordance with the terms of our 2006 Omnibus Equity Compensation Plan. These grants are subject to certain restrictions, including a restriction on transfer prior to the shares becoming fully vested. Mr. Eissa’s shares will vest as follows: 50,000 shares on the first anniversary of the grant date; 50,000 additional shares of the second anniversary of the grant date; 2,083 shares per month on the 15th day of each month beginning on March 15, 2009 through January 15, 2009; and 2,087 on the third anniversary of the grant date. Mr. Spinner’s shares vested as follows: 50,000 shares on the first anniversary of the grant date. Mr. Spinner’s remaining 75,000 unvested shares were forfeited effective with his termination. The value of the restricted stock grants were based on the closing price per share ($3.00) of our common stock on the OTCBB on the date of the grant. Stock award expense for the most recently completed two fiscal years pertaining to named executive officers is based on the value of the restricted stock grants amortized straight line over their vesting period.
 
(8)   Represents the dollar amount recognized for financial statement reporting purposes with respect to the applicable fiscal year in accordance with SFAS 123(R) under the modified prospective method. Stock option expense for the two most recently completed fiscal years pertaining to the named executive officers is based on the estimated fair value of the stock option as of the date of grant using the Black-Scholes option-pricing model amortized over the vesting period of the option or the duration of employment, whichever is shorter. Fair value is estimated based on an expected life of five years, an assumed dividend yield of 0% and the assumptions below.
                                                                                 
                    % of Fair                                        
                    Value                                        
            Amount   Expensed in                                        
            Expensed in   Financial                           Closing            
            Financial   Statements   Fair Value at   Number of   Option   Stock Price            
            Statements   Based on   Date of Grant   Options   Exercise   on the Date   Date of   Expected   Risk Free
Name   Fiscal Year   $   Vesting   ($)   Granted (#)   Price ($)   of Grant ($)   Grant   Volatility   Interest Rate
 
 
                                                                               
Alvin H. Clemens
    2008       313,542       100 %     313,542       550,000       1.01       1.01       4/1/2008       67.35 %     1.42 %
 
    2007       41,250       27.5 %                                                        
 
                                                                               
Richard Arenschield
    2008                                                        
 
                                                                               
Charles Eissa
    2008       7,188       47.9 %                                                        
 
    2007       3,750       25.0 %                                                        
 
    2006       3,889       25.9 %                                                        
 
    2005       173       1.2 %     15,000       500,000       2.50       1.00       11/10/2005       25 %     3.75 %
 
                                                                               
Anthony R. Verdi
    2008                                                                      
 
    2007       35,700       34.0 %                                                        
 
    2006       67,959       64.7 %                                                        
 
    2005       1,341       1.3 %     105,000       350,000       1.00       1.00       11/10/2005       25 %     3.75 %
 
                                                                               
Ivan M. Spinner
    2008       189,436       44.5 %                                                        
 
    2007       156,186       36.7 %                                                        
 
    2006       79,759       18.8 %     425,381       150,000       3.50       3.50       4/3/2006       111 %     4.55 %
     Effective January 1, 2006, we adopted the provisions of SFAS No. 123(R) under the modified prospective method. SFAS No. 123(R) eliminates accounting for share-based compensation transactions using the intrinsic value method prescribed under APB Opinion No. 25, “Accounting for Stock Issued to Employees,” and requires instead that such transactions be accounted for using a fair-value-based method. Under the modified prospective method, we are required to recognize compensation cost for share-based payments to employees based on their grant-date fair value from the beginning of the fiscal period in which the recognition provisions initially are applied. For periods prior to adoption, the financial statements are unchanged, and the pro forma disclosures previously required by SFAS No. 123, as amended by SFAS No. 148, will continue to be required under SFAS No. 123(R) to the extent those

105


 

amounts differ from those in the Statement of Operations. Expense in 2006 pertaining to employee stock options for all named executive officers other than Mr. Spinner is recorded in salaries, commissions and related taxes. Expense pertaining to Mr. Spinner’s stock option is recorded in depreciation and amortization expense as part of the value of the employment and non-compete agreement acquired as a result of our acquisition of ISG.
 
(9)   All other compensation paid to our named executive officers in the fiscal year ended December 31, 2008 consisted of the following:
                                                 
    Payments for   Company Paid           Company   Company Paid    
    Personal Use of   Health, Life and           Matching of   Entertainment    
    Auto and   Disabilitly           Employee 401(k)   and Meals ($)    
Name   Equipment ($) (a)   Insurance ($) (b)   Severance ($) (c)   Contributions (d)   (e)   Total ($)
 
 
                                               
Alvin H. Clemens
    13,200       19,449                         32,649  
 
                                               
Charles Eissa
    9,150       7,850             2,172       1,236       20,408  
 
                                               
Anthony R. Verdi
    10,500       1,915             2,142             14,556  
 
                                               
Robert J. Oakes
          20,970             2,104             23,075  
 
                                               
Ivan M. Spinner
    3,554       4,406       226,385       1,294       240       235,879  
 
(a)   Payments for personal use of auto and equipment represent the taxable portion of monthly auto allowances and company payments for cell phones and other equipment for the portion of our named executive officers’ personal use of automobiles, cell phones and other equipment. The portion of the $12,000 pertaining to business travel was considered a reimbursement for business expenses and excluded from compensation.
 
(b)   Company-paid health, life and disability insurance represents the cost of company-paid insurance premiums covering the named executive officers and, in the case of health insurance premiums, their dependents. We pay 100% of these insurance premiums for the named executive officers. Health insurance premiums vary based on several factors, including the age of the named executive officer and the number of their covered dependents.
 
(c)   Severance represents payments to Mr. Spinner for salary, auto and equipment allowances paid subsequent to his termination.
 
(d)   The Company implemented a 401(k) plan on January 1, 2007 and implemented an elective contribution to the Plan of 25% of the employee’s contribution up to 4% of the employee’s compensation, which were fully vested for the above named Executive Officers.
 
(e)   Company-paid lunches for the named executive officers.
 
(10)   Messrs. Eissa and Verdi each received a one time bonus in 2007.

106


 

Outstanding Equity Awards at Fiscal Year-End
     The following table sets forth information for the outstanding equity awards held by our named executive officers for the year ended December 31, 2008. The information below pertains to stock options, which were granted under the 2005 Incentive Stock Plan and the 2006 Omnibus Equity Compensation Plan, and restricted stock grants, which were granted in accordance with the terms of our 2006 Omnibus Equity Compensation Plan. The number of shares of stock that have not vested pertains to the February 15, 2007 restricted stock grant to the named executive officers below. The market value of the number of shares of stock that have not vested was based on the closing price per share ($0.08) of our common stock on the OTCBB on December 31, 2008.
                                                         
    Option Awards   Stock Awards
                    Equity                            
                    Incentive                            
                    Plan Awards:                           Market
    Number of   Number of   Number of                   Number of   Value of
    Securities   Securities   Securities                   Shares or   Shares or
    Underlying   Underlying   Underlying                   Units of   Units of
    Unexercised   Unexercised   Unexercised   Option           Stock That   Stock That
    Options   Options   Unearned   Exercise   Option   Have Not   Have Not
    (#)   (#)   Options   Price   Expiration   Vested   Vested
Name   Exercisable   Unexercisable   (#)   ($)   Date   (#)   ($)
 
 
                                                       
Richard Arenschield
                                         
 
                                                       
Alvin H. Clemens
    466,664 (1)     83,336               1.01       4/1/2018              
 
    300,000 (2)                 1.00       11/22/2015              
 
                                                       
Charles Eissa
    385,400 (3)     114,600             2.50       11/9/2015       75,000       6,000  
 
                                                       
Anthony R. Verdi
    350,000 (4)                 1.00       11/09/2015              
 
                                                       
Robert J. Oakes
                                         
 
                                                       
Ivan M. Spinner
                                         
 
(1)   Vesting occurs as follows; 300,000 shares were vested on April 1, 2008, 20,833 vested on May 1, 2008 and 20,833 shares vested or will vest on the first of each month thereafter through March 1, 2009, and 20,837 shares will vest on April 1, 2009.
 
(2)   Vesting occurs as follows; 200,000 shares vested on May 23, 2006, 150,000 shares on November 23, 2006, 12,500 shares on December 31, 2006 and on the last day of each month thereafter until November 30, 2007.
 
(3)   Vesting occurs as follows; 125,000 shares vested on November 10, 2006, 10,416 shares on December 31, 2006 and on the last day of each month thereafter until October 31, 2007, and 10,440 shares on December 31, 2008(?).
 
(4)   Vesting occurs as follows; 100,000 shares vested on May 10, 2006, 125,000 shares on November 10, 2006, 10,416 shares on December 31, 2006 and on the last day of each month thereafter until October 31, 2007, and 10,424 shares on December 31, 2008(?).

107


 

Employment, Severance and Other Agreements
Richard Arenschield
     On March 31, 2008, Mr. Clemens resigned as Chief Executive Officer, effective upon the later of April 1, 2008 and the business day immediately following the date on which we filed our Annual Report on Form 10-KSB with the SEC for the fiscal year ended December 31, 2007. Richard Arenschield was approved and appointed by our board of directors to serve as the interim Chief Executive Officer, effective immediately upon the April 2, 2008 effective date of Mr. Clemens’ resignation. Under the terms of a verbal agreement, Mr. Arenschield will be entitled to receive compensation for his services as interim Chief Executive Officer in the amount of $150,000 for a term of six months, payable in accordance with our ordinary payroll procedures, and an additional amount of $50,000 for living expenses, payable in accordance with a schedule to be determined by the board of directors. Mr. Arenschield resigned from the position of interim Chief Executive Officer on April 3, 2008.
Alvin H. Clemens and Ivan M. Spinner
     On November 27, 2007 we entered into amended and restated employment agreements with each of Alvin H. Clemens and Ivan M. Spinner. The employment agreements replaced and superseded the executives’ existing employment agreements. On March 28, 2008, Mr. Spinners’ employment as our Executive Vice President was terminated without cause. In accordance with Mr. Spinner’s amended and restated employment agreement Mr. Spinner is entitled to continue to receive his salary and benefits for a period of 18 months after his termination.
     On March 31, 2008, in connection with our March 31, 2008 private placement and Mr. Clemens’ resignation as our Chief Executive Officer and appointment as Co-Chairman of our Board of Directors, Mr. Clemens’ amended and restated employment agreement was terminated effective upon his resignation on April 1, 2008. In consideration of Mr. Clemens’ resignation as Chief Executive Officer and the termination of his existing Amended and Restated Employment Agreement, Mr. Clemens received incentive stock options to purchase 550,000 shares of our common stock. These options have a term of ten years and have an exercise per share equal to $1.01. The Company and Mr. Clemens had attempted to negotiate a new employment agreement governing the terms of Mr. Clemens’ position as Co-Chairman of the Board, which would provide Mr. Clemens with a one year term and a salary of $300,000 effective as of the date of Mr. Clemens’ resignation. The Company continues to pay Mr. Clemens a salary at an annualized rate of $300,000, together with employee benefits through March 31, 2009. Mr. Clemens employment, salary and benefits cease on March 31, 2009, after which point he will be compensated under our Non Employee Director Compensation Plan.

108


 

Charles A. Eissa
     Pursuant to a written employment agreement, Mr. Eissa serves as our President and Chief Operating Officer. Pursuant to his employment agreement, his annual base salary was $214,200 per year through April, 1, 2006, was then increased to $250,000 through March 19, 2007 and then increased to $300,000 thereafter. He is entitled to receive such bonus compensation as a majority of our board of directors may determine from time to time. Mr. Eissa’s employment agreement automatically renewed on November 18, 2007.
     In connection with the March 31, 2008 private placement, Mr. Eissa’s employment agreement was amended effective March 31, 2008 to revise Mr. Eissa’s annual base salary to $250,000 and to amend the term of his employment agreement to a one year term commencing March 31, 2008.
     On February 2, 2009, Mr. Eissa’s employment agreement was amended to amend the term of his employment agreement to a term of 13 months commencing on March 31, 2008 and ending on April 30, 2009 .
     In the event of Mr. Eissa’s termination without cause or for good reason, he or his estate would receive his then current base annual salary, plus unpaid accrued employee benefits, which is primarily accrued vacation, plus the continuation of his employee benefits for a period of 1 year, less all applicable taxes. In the event of his voluntary termination, death or disability, he or his estate would receive unpaid accrued employee benefits, plus the continuation of his employee benefits for a period of 1 month, less all applicable taxes.
     All shares of common stock held by Mr. Eissa (together with the shares held by his respective affiliates) are subject to lock-up provisions that provide restrictions on the future sale of common stock by the holders and their transferees. These lock-up provisions provide, in general, that these shares may not directly or indirectly be offered, sold, offered for sale, contracted for sale, hedged, or otherwise transferred or disposed of, for a period of twelve (12) months following the purchase of such shares in the private placement, and for an additional twelve (12) months thereafter each holder may only sell up to 50% of his portion of these shares. We filed a registration statement with the SEC, which was subsequently declared effective, covering the resale of the shares of common stock held by Mr. Eissa.
Anthony R. Verdi
     Pursuant to an amended and restated employment agreement Mr. Verdi serves as our Chief Financial Officer and Chief Operating Officer. Pursuant to his amended and restated employment agreement, his annual base salary was $225,000 per year through April, 1, 2006, was then increased to $250,000 through March 31, 2009 and, if not terminated, will automatically renew for one year periods. He is entitled to receive such bonus compensation as a majority of our board of directors may determine from time to time.
     In connection with the March 31, 2008 private placement, Mr. Verdi’s employment agreement was amended effective March 31, 2008 to revise Mr. Verdi’s annual base salary to $225,000 and to amend the term of his employment agreement to a one year term commencing March 31, 2008.
     In the event of Mr. Verdi’s termination without cause or for good reason, he or his estate would receive his then current base annual salary, plus unpaid accrued employee benefits, which is primarily accrued vacation, plus the continuation of his employee benefits for a period of 18 months, less all applicable taxes. In the event of his voluntary termination, death or disability, he or his estate would

109


 

receive unpaid accrued employee benefits, plus the continuation of his employee benefits for a period of 1 month, less all applicable taxes.
Robert J. Oakes
     Pursuant to a written employment agreement with Atiam Technologies, LLC Mr. Oakes serves as Atiam Technologies LLC’s President and Chief Executive Officer. Pursuant to his employment agreement, his annual base salary is $250,000 per year through October 1, 2010. He is entitled to receive such bonus compensation as may be determined by the Compensation Committee of the board of directors and such fringe benefits as are available to other executives of Health Benefits Direct Corporation. Mr. Oakes employment agreement shall be automatically extended for an additional one year term on October 1, 2010 and annually thereafter unless either party provides written notification to the other party of non-renewal no later than 60 days prior to the termination date of the agreement.
     In the event of Mr. Oakes’s termination without cause or for good reason, he or his estate would receive his then current base annual salary, plus unpaid accrued employee benefits, which is primarily accrued vacation, plus the continuation of his employee benefits for a period of 12 months, less all applicable taxes. In the event of his voluntary termination, death or disability, he or his estate would receive unpaid accrued employee benefits, plus the continuation of his employee benefits for a period of one month, less all applicable taxes.
     Pursuant to Mr. Oakes employment agreement, he is subject to a non competition and non-solicitation provision for a period of three years after October 1, 2007 or a period of one year following his termination, whichever is shorter.

110


 

Compensation of Directors
     The following table sets forth information concerning the compensation of all individuals who served on our board of directors during the fiscal year ended December 31, 2008. There were no non-equity incentive plan compensation or nonqualified deferred compensation earnings to any of our directors for the year ended December 31, 2008. Directors who are employees receive no additional or special compensation for serving as directors. All director compensation for Messrs. Clemens, Oakes and Verdi is included in the Summary Compensation Table.
                                         
    Fees Earned                    
    or           Option   All Other    
    Paid in Cash   Stock Awards   Awards   Compensation   Total
Name   ($)(1)   ($)(2)   ($)(3)   ($)(4)   ($)
 
 
                                       
Donald Caldwell
                             
 
                                       
John Harrison
    11,500       25,800       23,250       11,538       72,088  
 
                                       
C. James Jensen
    6,000       17,200       258,423             281,623  
 
                                       
Warren V. Musser
    9,000       17,200                   26,200  
 
                                       
Sanford Rich
    15,000       25,800       176,197       13,644       230,641  
 
                                       
L.J. Rowell
    13,500       25,800       176,197             215,497  
 
                                       
Paul Soltoff
    10,500       17,200       23,250             50,950  
 
                                       
Frederick Tecce
                             
 
                                       
Edmond Walters
    9,000       33,333                   42,333  
 
(1)   Represents board and committee meeting and retainer fees paid to our directors under our Non-Employee Director Compensation Plan.

111


 

(2)   Represents the dollar amount recognized for financial statement reporting purposed with respect to the applicable fiscal year n accordance with SFAS 123(R). Stock award expense paid to our directors under our Non Employee director Compensation Plan for the most recently completed fiscal year pertaining to directors, which is detailed by director in the following tables, was based on the closing price per share ($1.72) of our common stock on the OTCBB on the date of the grant.
                                 
    Date of   Number of Shares of           Aggregate Value of
    Stock Grant   Common Stock Granted   Value Per Share   Stock Granted
 
                               
Donald Caldwell
                       
 
                               
John Harrison
    1/3/2008       15,000     $ 1.72     $ 25,800  
 
                               
C. James Jensen (5)
    1/3/2008       10,000       1.72       17,200  
 
                               
Warren V. Musser
    1/3/2008       10,000       1.72       17,200  
 
                               
Sanford Rich
    1/3/2008       15,000       1.72       25,800  
 
                               
L.J. Rowell
    1/3/2008       15,000       1.72       25,800  
 
                               
Paul Soltoff
    1/3/2008       10,000       1.72       17,200  
 
                               
Frederick C. Tecce
                       
 
                               
Edmond Walters
    4/1/2008       99,010       1.01       100,000  
 
(3)   Represents the dollar amount recognized for financial statement reporting purposes with respect to the applicable fiscal year in accordance with SFAS 123(R). Stock option expense for the most recently completed fiscal year pertaining to directors is based on the estimated fair value as of the date of grant using the Black-Scholes option-pricing model based on the terms of each option amortized over the vesting period of the option or the duration of board membership, whichever is shorter. Fair value was estimated based on an assumed dividend yield of 0% and the assumptions below.
                                                                                         
            Fair Value                                            
    Amount   Expensed in                                            
    Expensed in   Financial                                            
    Financial   Statements   Fair Value   Number of   Option   Stock Price                   Risk Free   Expected   Assumed
    Statements   Based on   of Option   Options   Exercise   on the Date   Date of   Expected   Interest   Life in   Dividend
Name   ($)   Vesting   Award ($)   Granted (#)   Price ($)   of Grant ($)   Grant   Volatility   Rate   years   Yield
 
                       
John Harrison
    23,250       31 %     75,000       250,000       1.00       1.00       11/22/2005       25 %     3.75 %     4.5       0 %
                       
C. James Jensen
    258,423       44 %     587,324       200,000       3.60       3.60       04/27/2006       113 %     4.66 %     5       0 %
                       
Warren V. Musser
          0 %     193,264       250,000       1.00       1.00       01/11/2006       103 %     3.75 %     5       0 %
 
          0 %     896,542       425,000       2.70       2.90       03/14/2006       105 %     3.75 %     5       0 %
                       
L. J. Rowell
    176,197       30 %     587,324       200,000       3.60       3.60       04/27/2006       113 %     4.66 %     5       0 %
                       
Sanford Rich
    176,197       30 %     587,324       200,000       3.60       3.60       04/27/2006       113 %     4.66 %     5       0 %
                       
Paul Soltoff
    23,250       31 %     75,000       250,000       1.00       1.00       11/23/2005       25 %     3.75 %     4.5       0 %
 
(4)   Mr. Harrison provided marketing consulting services to the Company pursuant to a verbal agreement from January 29, 2007 through March 31, 2008. Mr. Rich provided management consulting services from January 28, 2008 through March 6, 2008.

112


 

(5)   Mr. Jensen resigned from the board effective March 26, 2008.
The following table sets forth information concerning the aggregate number of options available for non-employee directors as of December 31, 2008.
         
    Aggregate Number of
    Options Available as of
    December 31, 2008
 
       
Donald Caldwell
     
 
       
John Harrison
    250,000  
 
       
C. James Jensen
     
 
       
Warren V. Musser
    675,000  
 
       
Sanford Rich
    200,000  
 
       
L.J. Rowell
    200,000  
 
       
Paul Soltoff
    150,000  
 
       
Frederick C. Tecce
     
 
       
Edmond Walters
     
Director Compensation Plan.
     Directors who are employees receive no additional or special compensation for serving as directors. Non employee directors receive the following compensation under the terms of our Non Employee Director Compensation Plan:
    Each non employee director will receive the following cash compensation
    $5,000 annual retainer for each director
 
    $2,000 annual retainer for the Audit Committee Chairperson
 
    $1,000 annual retainer for the Compensation Committee Chairperson
 
    $1,000 annual retainer for the Nominating and Governance Committee Chairperson
 
    $1,000 meeting fee for each board meeting attending in person
 
    $500 meeting fee for each committee meeting attending in person or via teleconference.

113


 

    Each non employee director will receive the following equity compensation:
    Upon election to the Board a newly elected director will receive a grant of restricted shares of Common stock under the 2008 Equity Compensation Plan with an aggregate fair market value of $100,000, as determined by the closing market price of the Company’s Common Stock on the date of the directors election to the Board., which shall vest in the following increments: (i) one-third on the date of the director’s election to the Board; (ii) one-third on the date of the first anniversary of the director’s election to the Board; (iii) one-third on the date of the second anniversary of the director’s election to the Board.
 
    On a date specified by the Compensation Committee of the Board each director who serves as a director on that specified date will receive an annual grant of 10,000 fully vested shares of Common Stock granted under the 2008 Equity Compensation Plan.
 
    On a date specified by the Compensation Committee of the Board each director who serves as a chairperson of a committee of the Board on that specified date will receive an annual grant of 5,000 fully vested shares of Common Stock granted under the 2008 Equity Compensation Plan.
     We also purchase directors and officers liability insurance for the benefit of our directors and officers as a group. We also reimburse our directors for their reasonable out-of-pocket expenses incurred in attending meetings of our board of directors or its committees. No fees are payable to directors for attendance at specially called meetings of the board.

114


 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.
Security Ownership of Certain Beneficial Owners and Management
     The following table shows information known by us with respect to the beneficial ownership of our Shares as of March 20, 2009, for each of the following persons:
    each of our directors;
 
    our named executive officers;
 
    all of our directors, director nominees and executive officers as a group; and
 
    each person or group of affiliated persons or entities known by us to beneficially own 5% or more of our Shares.
     The number of Shares beneficially owned, beneficial ownership and percentage ownership are determined in accordance with the rules of the Securities and Exchange Commission (the “SEC”). Under these rules, beneficial ownership includes any Shares as to which the individual or entity has sole or shared voting power or investment power and includes any Shares that an individual or entity has the right to acquire beneficial ownership of within 60 days of March 20, 2009 through the exercise of any warrant, stock option or other right. In computing the number of Shares beneficially owned by a person and the percentage ownership of that person, Shares underlying options and warrants that are exercisable within 60 days of March 20, 2009 are considered to be outstanding. To our knowledge, except as indicated in the footnotes to the following table and subject to community property laws, where applicable, the persons named in this table have sole voting and investment power with respect to all Shares shown as beneficially owned by them. The following table is based on 41,279,645 Common Shares and 1,000,000 Preferred Shares outstanding as of March 20, 2009. Unless otherwise indicated, the address of all individuals and entities listed below is Health Benefits Direct Corporation, 150 N. Radnor-Chester Road, Suite B-101, Radnor, Pennsylvania 19087.
                         
    Number of           Percent
    Shares           of Shares
    Beneficially           Beneficially
Name of Beneficial Owner   Owned   Title of Class   Owned
Directors and Executive Officers:
                       
 
                       
Alvin H. Clemens
    5,083,918 (1)   Common Stock     11.5 %
Donald R. Caldwell
    11,955,715 (2)   Common Stock     25.5 %
 
    2,000,000 (3)   Series A Preferred Stock     100 %
Charles A. Eissa
    1,633,570 (4)   Common Stock     3.9 %
Warren V. Musser
    1,135,000 (5)   Common Stock     2.7 %
Robert J. Oakes
    398,899 (6)   Common Stock     1.0 %
John Harrison
    466,750 (7)   Common Stock     1.1 %
L.J. Rowell
    400,600 (8)   Common Stock     1.0 %
Paul Soltoff
    355,000 (9)   Common Stock     *  
Sanford Rich
    305,000 (8)   Common Stock     *  
Frederick C. Tecce
    12,105,715 (11)   Common Stock     25.8 %
 
    2,000,000 (3)   Series A Preferred Stock     100 %

115


 

                         
    Number of           Percent
    Shares           of Shares
    Beneficially           Beneficially
Name of Beneficial Owner   Owned   Title of Class   Owned
Anthony R. Verdi
    435,000 (11)   Common Stock     1.0 %
Edmond Walters
    161,633     Common Stock     *  
 
                     
All directors and executive officers as a group (12 persons)
    22,471,085 (1)(2)(4)(5)(6)(7)(8)(9)(10)(11)(12)   Common Stock     43.1 %
 
    2,000,000 (3)   Series A Preferred Stock     100 %
 
                       
Holders of More than Five Percent of Our Common Stock:
                       
 
                       
The Co-Investment Fund II, L. P.
    11,955,715 (12)   Common Stock     25.5 %
 
    2,000,000 (3)   Series A Preferred Stock     100 %
Cumberland Associates LLC
    3,339,113 (13)   Common Stock     7.8 %
Gerald Unterman
    3,104,838 (14)   Common Stock     7.3 %
 
*   Less than 1%
 
(1)   Includes 1,000,000 shares held by The Clemens-Beaver Creek Limited Partnership, of which Alvin H. Clemens is the general partner. Mr. Clemens disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein. Also includes 100,000 shares held by Mr. Clemens’s minor children. Also includes 850,000 shares underlying options and 804,838 shares underlying warrants, all of which are exercisable within 60 days of March 20, 2009. Also includes 500,000 shares underlying warrants held by the Clemens-Beaver Creek Limited Partnership.
 
(2)   Includes 6,350,877 shares and 5,604,838 shares underlying warrants that are exercisable within 60 days of March 20, 2009 and are beneficially owned by Co-Investment Trust II, L. P. (the “Fund”), designee of Cross Atlantic Capital Partners, Inc. Mr. Caldwell is a managing partner of Cross Atlantic Capital Partners, Inc. Mr. Caldwell is also a shareholder, director and officer of Co-Invest II Capital Partners, Inc., which is the general partner of Co-Invest Management II, L.P., which is the general partner of the Fund. Mr. Caldwell disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
 
(3)   Includes 1,000,000 Preferred Shares underlying warrants, all of which are exercisable within 60 days of March 20, 2009. Represents securities owned by the Fund, the designee of Cross Atlantic Capital Partners, Inc., of which Frederick C. Tecce is the managing director and of which Donald R. Caldwell is managing partner. Mr. Caldwell is also a shareholder, director and officer of Co-Invest II Capital Partners, Inc., which is the general partner of Co-Invest Management II, L.P., which is the general partner of the Fund. Mr. Tecce and Mr. Caldwell disclaim beneficial ownership of these securities, except to the extent of their pecuniary interest therein.
 
(4)   Includes 437,480 shares underlying options, all of which are exercisable within 60 days of March 20, 2009. Excludes 62,250 shares underlying options that are not exercisable within 60 days of March 20, 2009.

116


 

(5)   Includes 440,000 shares underlying warrants and 675,000 shares underlying options, all of which are exercisable within 60 days of March 20, 2009.
 
(6)   Excludes 1,000,000 shares of underlying options that are not exercisable within 60 days of March 20, 2009.
 
(6)   Includes 250,000 shares underlying options and 86,750 shares underlying warrants, all of which are exercisable within 60 days of March 20, 2009.
 
(7)   Includes 200,000 shares underlying options that are exercisable within 60 days of March 20, 2009.
 
(8)   Includes 150,000 shares underlying options and 25,000 shares underlying warrants, all of which are exercisable within 60 days of March 20, 2009.
 
(9)   Includes 25,000 shares underlying warrants that are exercisable within 60 days of March 20, 2009.
 
(10)   Includes 50,000 shares underlying warrants that are exercisable within 60 days of March 20, 2009. Also includes 6,450,877 shares and 5,604,838 shares underlying warrants that are exercisable within 60 days of March 20, 2009 and are beneficially owned by the Fund, designee of Cross Atlantic Capital Partners, Inc. Mr. Tecce is a managing partner of Cross Atlantic Capital Partners, Inc. Mr. Tecce disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
 
(11)   Includes 350,000 shares underlying options and 25,000 shares underlying warrants, all of which are exercisable within 60 days of March 20, 2009.
 
(12)   Includes 5,604,838 shares underlying warrants that are exercisable within 60 days of March 20, 2009. Excludes 650,000 shares of underlying options that are not exercisable within 60 days of March 20, 2009.
 
(13   Includes 1,522,352 shares underlying warrants that are exercisable within 60 days of March 20, 2009.
 
(14)   According to Schedule 13G filed with the Commission by Mr. Unterman on April 18, 2007. Includes 1,104,839 shares underlying warrants that are exercisable within 60 days of March 20, 2009.

117


 

Equity Compensation Plan Information
     The following table shows certain information concerning our common stock to be issued in connection with our equity compensation plans as of December 31, 2008:
EQUITY COMPENSATION PLAN
                         
                    Number of
    Number of           Securities Remaining
    Securities to be   Weighted-   Available for Future
    Issued upon   Average Exercise   Issuance
    Exercise of   Price of   Under Equity
    Outstanding   Outstanding   Compensation Plans
    Options,   Options,   (Excluding Securities
    Warrants   Warrants and   Reflected in the first
Plan Category   and Rights   Rights   Column)
 
                       
Equity compensation plans approved by security holders
    17,927,886     $ 1.42       1,969,790  
 
                       
Equity compensation plans not approved by security holders
    0       0       0  
 
                       
Total
    17,927,886     $ 1.42       1,969,790  
     A description of the material terms of our equity compensation plans can be found in Note 8 — Shareholders Equity — Stock Options in the notes to the consolidated financial statements contained in Item 8 of this Annual Report on Form 10-K.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.
Transactions With Related Persons
     From the beginning of our last fiscal year until the date of this annual report on Form 10-K, there has been no transaction, nor is there any transaction currently proposed, to which we were, are, or would be a participant, in which the amount involved exceeded or would exceed the lesser of $120,000 or one percent of the average of our total assets at year end for the last two completed fiscal years and in which any of our directors or executive officers, any holder of more than 5% of our common stock or any member of the immediate family of any of these persons or entities had or will have a direct or indirect material interest, other than the compensation and compensation arrangements (including with respect to equity compensation and board compensation) described below.

118


 

     We believe that we have executed all of the transactions described below on terms no less favorable to us than we could have obtained from unaffiliated third parties. It is our intention to ensure that all future transactions between us and our officers, directors and principal stockholders and their affiliates are approved by a majority of our board of directors, including a majority of the independent and disinterested members of our board of directors, and are on terms no less favorable to us than those that we could obtain from unaffiliated third parties.
     We have engaged in the following transactions regarding sales of our common stock with our executive officers and directors, and with the beneficial holders of 5% or more of our common stock:
    On March 31, 2008, we completed a private placement of an aggregate of 6,250,000 shares of our common stock and warrants exercisable for 5,000,000 shares of our common stock. We sold 6,250,000 investment units in the private placement, each investment unit consisting of one share of our common stock and a warrant to purchase one share of common stock for an aggregate purchase price of $5,000,000. In connection with this private placement:
    Co-Investment Trust II, L.P., designee of Cross Atlantic Capital Partners, Inc., purchased 5.0 million investment units for a purchase price of $4,000,000. Mr. Tecce, who is one of our directors, is a managing partner of Cross Atlantic Partners, Inc. Mr. Caldwell, who is also one of our directors, is a shareholder, director and officer of Co-Invest II Capital Partners, Inc., which is the general partner of Co-Invest Management II, L.P., which is the general partner of The Co-Investment Fund II, L.P.
 
    Cumberland Associates LLC, a holder of more than 5% of our shares of common stock, purchased 1.25 million investment units in the private placement for a purchase price of $1,000,000.
    On January 15, 2009, we completed a private placement with Co-Investment Fund II, L.P., for an aggregate of 1,000,000 shares of our Series A Convertible Preferred Stock and warrants to purchase 1,000,000 shares of our Series A Convertible Preferred Stock.
    The preferred stock is entitled to vote as a single class with the holders of the Company’s common stock with each share of preferred stock having the right to 20 votes. Upon the liquidation, sale or merger of the Company, each share of preferred stock is entitled to receive an amount equal to the greater of (A) a liquidation preference equal to two and a half (2.5) times the preferred stock original issue price, subject to certain customary adjustments, or (B) the amount such share of preferred stock would receive if it participated pari passu with the holders of Common Stock on an as-converted basis. Each Share of preferred stock becomes convertible into 20 shares of common stock (the “ Shares ”), subject to adjustment and at the option of the holder of the preferred stock, immediately after stockholder approval of the amendment to our company’s charter. For so long as any shares of preferred stocks are outstanding, the vote or consent of the holders of at least two-thirds of the preferred stock is required to approve (Y) any amendment to the Company’s certificate of incorporation or bylaws that would adversely alter the voting powers, preferences or special rights of the preferred stock or (Z) any amendment to the Company’s certificate of incorporation to create any shares of capital stock that rank senior to the preferred stock. In addition to the voting rights described above, for so long as 1,000,000 Share of preferred stocks are outstanding, the vote or consent of the holders of at least two-thirds of the share of preferred stocks is required to effect or validate any merger, sale of substantially all of the assets of the Company or

119


 

      other fundamental transaction, unless such transaction, when consummated, will provide the holders of preferred stock with an amount per share equal to two and a half (2.5) times the preferred stock original issue price.
    The warrants provide that the holder thereof shall have the right (A) at any time after the Stockholder Approval Deadline, but prior to the earlier of (i) ten business days’ after the Company has properly provided written notice to all such holders of a Call Event (as defined below), (ii) the date on which the Company’s stockholders approve the Charter Amendment (the “ Stockholder Approval Date ”) and (iii) January 14, 2014, to acquire 1,000,000 shares of Preferred Stock upon the payment of $4.00 per Preferred Warrant Share and (B) at any time after the Stockholder Approval Date, but prior to the earlier of (i) ten business days’ after the Company has properly provided written notice to all such holders of a Call Event (as defined below) and (ii) January 14, 2014, to acquire up to a total of 20,000,000 shares of Common Stock of the Company (each a “ Warrant Share ”) upon the payment of $0.20 per Warrant Share (the “ Exercise Price ”). The Company also has the right, at any point after the Stockholder Approval Date and after which the volume weighted average trading price per share of the Preferred Stock for a minimum of 20 consecutive trading days is equal to at least eight times the Exercise Price per share, provided that certain other conditions have been satisfied, to call the outstanding Warrants (a “ Call Event ”), in which case such Warrants will expire if not exercised within ten business days thereafter. The Warrants also include full ratchet anti-dilution adjustment provisions for issuances of securities below $0.20 per share of Common Stock during the first two years following the date of issuance of the Warrants, subject to customary exceptions.
Director Independence
     Although our common stock is not listed on NASDAQ and, as a result, we are not subject to NASDAQ’s listing standards, we voluntarily strive to comply with such standards. As required under the NASDAQ listing standards, a majority of the members of a listed company’s board of directors must qualify as “independent,” as affirmatively determined by a company’s board of directors. Our board of directors, in applying the standards for independence as defined by Rule 4200(a)(15) of the NASDAQ listing standards and Rule 10A-3(b)(1)(ii) promulgated by the Securities and Exchange Commission, has affirmatively determined that Messrs. Harrison, Rich, Rowell, Tecce and Soltoff are “independent” directors.
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
     A summary of the fees of Sherb & Co., LLP for the years ended December 31, 2008 and 2007 are set forth below:
                 
    2008 Fees   2007 Fees
Audit Fees(1)
  $ 96,285     $ 79,000  
Audit-Related Fees(2)
    15,000       730  
Tax Fees(3)
    15,000        
All Other Fees
           
Total Fees
  $ 126,285     $ 79,730  
 
(1)   Audit fees for the fiscal years ended December 31, 2008 and 2007 were for professional services rendered for the audits and interim quarterly reviews of our consolidated

120


 

    financial statements and services that are normally provided in connection with statutory and regulatory filings or engagements.
 
(2)   Audit-related fees for the fiscal year ended December 31, 2008 were for professional services rendered for the audit of the Company’s 401(k) plan. Audit-related fees for the fiscal year ended December 31, 2007 were for out of pocket expenses incurred for the audit of our consolidated financial statements.
 
(3)   Tax fees were for tax compliance, tax advice and tax planning.
Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Auditors .
     The audit committee pre-approves all audit and permissible non-audit services provided by the independent registered public accounting firm. These services may include audit services, audit-related services, tax services and other services.

121


 

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
     The following documents are filed as part of this Form 10-K:
     1.  Financial Statements . See Financial Statements on page 43 of this Annual Report on Form 10-K.
     2.  Financial Statement Schedules . None, as all information required in these schedules is included in the consolidated financial statements or the notes thereto.
     3.  Exhibits . The Exhibits listed below are filed or incorporated by reference as part of this Annual Report on Form 10-K. Where so indicated by footnote, exhibits which were previously filed are incorporated by reference. For exhibits incorporated by reference, the location of the exhibit in the previous filing is indicated below.
     
Exhibit    
Number   Description
 
   
2.1
  Agreement and Plan of Merger, dated November 23, 2005, among Darwin Resources Corp., Health Benefits Direct Corporation, and HBDC II, Inc. (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on November 30, 2005).
 
   
2.2
  Agreement and Plan of Merger, dated as of September 21, 2007, by and among the Company, HBDC Acquisition, LLC, System Consulting Associates, Inc. and the shareholders of System Consulting Associates, Inc. party thereto (incorporated by reference from Exhibit 2.1 to the Company’s current report on From 8-K, filed with the Commission on September 26, 2007).
 
   
3.1
  Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on November 22, 2005).
 
   
3.2
  Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the Commission on December 3, 2007).
 
   
3.3
  Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Registrant’s Current Report on Form 8-K filed with the Commission on November 30, 2005).
 
   
3.4
  Certificate of Merger of HBDC II, Inc. with and into Health Benefits Direct Corporation (incorporated by reference to Exhibit 3.4 to the Registrant’s Current Report on Form 8-K filed with the Commission on November 30, 2005).
 
   
3.5
  Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.5 to the Registrant’s Registration Statement on Form SB-2, filed with the Commission on February 1, 2008).
 
   
3.6
  Certificate of Designation with respect to shares of Series A Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on January 21, 2009).
 
   
3.7**
  Certificate of Amendment to Certificate of Incorporation.

122


 

     
Exhibit    
Number   Description
 
   
4.1
  Form of Common Stock Purchase Warrant Certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on November 30, 2005).
 
   
4.2
  Warrant to Purchase Common Stock issued to Alvin H. Clemens (incorporated by reference to Exhibit 4.2 to the Registrant’s Annual Report on Form 10-KSB for the fiscal year ended December 31, 2005, filed with the Commission on March 31, 2006).
 
   
4.3
  Securities Purchase Agreement, dated March 30, 2007, by and between Health Benefits Direct Corporation and the Investors party thereto (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on March 30, 2007).
 
   
4.4
  Registration Rights Agreement, dated March 30, 2007, by and between Health Benefits Direct Corporation and the Investors party thereto (incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K, filed with the Commission on March 30, 2007).
 
   
4.5
  Form of Warrant (incorporated by reference to Exhibit 4.3 to the Registrant’s Current Report on Form 8-K, filed with the Commission on March 30, 2007).
 
   
4.6
  Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.4 to the Registrant’s Current Report on Form 8-K, filed with the Commission on March 30, 2007).
 
   
4.7
  Registration Rights Agreement, dated October 1, 2007, by and between Health Benefits Direct Corporation and Computer Command and Control Company (incorporated by reference from Exhibit 4.1 to the Company’s current report on From 8-K, filed with the Commission on October 4, 2007).
 
   
4.8
  Registration Rights Agreement, dated October 1, 2007, by and among Health Benefits Direct Corporation and Robert J. Oakes, Jeff Brocco, Tim Savery and Lisa Roetz (incorporated by reference from Exhibit 4.2 to the Company’s current report on From 8-K, filed with the Commission on October 4, 2007).
 
   
4.9
  Securities Purchase Agreement, dated March 31, 2008, by and between Health Benefits Direct Corporation and the Investor party thereto (incorporated by reference from Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on March 31, 2008).
 
   
4.10
  Securities Purchase Agreement, dated March 31, 2008, by and between Health Benefits Direct Corporation and the Investors party thereto (incorporated by reference from Exhibit 4.2 to the Registrant’s Current Report on Form 8-K, filed with the Commission on March 31, 2008).
 
   
4.11
  Form of Warrant (incorporated by reference to Exhibit 4.3 to the Registrant’s Current Report on Form 8-K, filed with the Commission on March 31, 2008).
 
   
4.12
  Form of Registration Rights Agreement, dated March 31, 2008, by and among Health Benefits Direct Corporation and the Investors party thereto (incorporated by reference from Exhibit 4.4 to the Company’s current report on From 8-K, filed with the Commission on March 31, 2008).

123


 

     
Exhibit    
Number   Description
 
   
4.13
  Form of Registration Rights Agreement, dated March 31, 2008, by and among Health Benefits Direct Corporation and the Investors party thereto (incorporated by reference from Exhibit 4.3 to the Company’s current report on From 8-K, filed with the Commission on March 31, 2008).
 
   
4.14
  Board Representation Agreement, date March 31, 2008, between the Company and The Co-Investment Fund II, L.P. (incorporated by reference from Exhibit 4.5 to the Registrant’s Current Report on Form 8-K, filed with the Commission on March 31, 2008).
 
   
10.1
  Health Benefits Direct Corporation 2005 Incentive Stock Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on November 30, 2005).
 
   
10.2
  Health Benefits Direct Corporation 2005 Non-Employee Directors Stock Option Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K/A filed with the Commission on December 22, 2005).
 
   
10.3
  Health Benefits Direct Corporation Compensation Plan for Directors (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on March 20, 2006).
 
   
10.4
  Lease Agreement, dated February 9, 2004, between Case Holding Co. and Platinum Partners, LLC (incorporated by reference to Exhibit 10.7 to the Registrant’s Form 8-K filed with the Commission on November 30, 2005).
 
   
10.5
  Lease between Health Benefits Direct Corporation and FG2200, LLC, effective March 15, 2006 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on March 6, 2006).
 
   
10.6
  Employment Agreement, dated November 18, 2005, between Health Benefits Direct Corporation and Charles A. Eissa (incorporated by reference to Exhibit 10.14 to the Registrant’s Current Report on Form 8-K filed with the Commission on November 30, 2005).
 
   
10.7
  Amendment 2008-1 to Employment Agreement, dated March 31, 2008, between Health Benefits Direct Corporation and Charles A. Eissa (incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed with the Commission on March 31, 2008).
 
   
10.8
  Form of Director and Officer Indemnification Agreement (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on January 17, 2006).
 
   
10.9
  Securities Contribution Agreement, dated September 9, 2005, among Health Benefits Direct Corporation, Marlin Capital Partners I, LLC, Scott Frohman, Charles A. Eissa, Platinum Partners II LLC and Dana Boskoff (incorporated by reference to Exhibit 10.22 to the Registrant’s Current Report on Form 8-K filed with the Commission on November 30, 2005).

124


 

     
Exhibit    
Number   Description
 
   
10.12
  Merger Agreement, dated April 3, 2006, among Health Benefits Direct Corporation, ISG Merger Acquisition Corp., Insurance Specialist Group Inc. and Ivan M. Spinner (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on April 6, 2006).
 
   
10.13
  Employment Agreement, dated April 3, 2006, between HBDC II, Inc. and Ivan M. Spinner (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on April 6, 2006).
 
   
10.14
  Health Benefits Direct Corporation 2006 Omnibus Equity Compensation Plan (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on May 2, 2006).
 
   
10.15
  Health Benefits Direct Corporation 2006 Omnibus Equity Compensation Plan Form of Nonqualified Stock Option Grant (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on May 2, 2006).
 
   
10.16
  Health Benefits Direct Corporation 2008 Equity Compensation Plan (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on March 31, 2008).
 
   
10.17
  Health Benefits Direct Corporation 2008 Equity Compensation Plan Form of Nonqualified Stock Option Grant (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on March 28, 2008).
 
   
10.18
  Sublease, dated March 7, 2006, between Health Benefits Direct Corporation and World Travel Partners I, LLC Form of Nonqualified Stock Option Grant (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on May 19, 2006).
 
   
10.19
  First Amendment to Sublease, dated April 18, 2006, between Health Benefits Direct Corporation ad World Travel Partners I, LLC (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on May 19, 2006).
 
   
10.20
  Letter Agreement, dated April 18, 2006, among World Travel Partners I, LLC, Health Benefits Direct Corporation, and 1120 Avenue of the Americas, LLC (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on May 19, 2006).
 
   
10.21
  Software and Services Agreement, dated May 31, 2006, among Health Benefits Direct Corporation, Insurint Corporation, and Realtime Solutions Group, L.L.C. (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on June 2, 2006).
 
   
10.22
  Lease, dated July 7, 2006, between Health Benefits Direct Corporation and Radnor Properties-SDC, L.P. (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on July 10, 2006).
 
   
10.23
  Separation Agreement, dated December 7, 2006, between Health Benefits Direct Corporation and Scott Frohman (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on December 11, 2006).

125


 

     
Exhibit    
Number   Description
 
   
10.24
  Amendment No. 1 to Option, dated as of February 15, 2007, delivered by Health Benefits Direct Corporation to Daniel Brauser (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on February 16, 2007).
 
   
10.25
  Consent and Lock-Up Agreement, dated April 5, 2007, between Health Benefits Direct Corporation and Scott Frohman (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on April 6, 2007).
 
   
10.26
  Agreement to Transfer Partnership Interests, dated October 1, 2007, by and among HBDC Acquisition, LLC and the former partners of BileniaTech, L.P. (incorporated by reference from Exhibit 10.1 to the Company’s current report on From 8-K, filed with the Commission on October 4, 2007).
 
   
10.27
  Amended and Restated Employment Agreement, dated November 27, 2007, between Health Benefits Direct Corporation and Alvin H. Clemens (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on December 3, 2007).
 
   
10.28
  Amended and Restated Employment Agreement, dated November 27, 2007, between Health Benefits Direct Corporation and Anthony R. Verdi (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the Commission on December 3, 2007).
 
   
10.29
  Amendment 2008-1 to Amended and Restated Employment Agreement, dated March 31, 2008, between Health Benefits Direct Corporation and Anthony R. Verdi (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed with the Commission on March 31, 2008).
 
   
10.30
  Amended and Restated Employment Agreement, dated November 27, 2007, between Health Benefits Direct Corporation and Ivan M. Spinner (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed with the Commission on December 3, 2007).
 
   
10.31**
  Client Transition Agreement, between Health Benefits Direct Corporation, HBDC II, Inc. and eHealthInsurance Services, Inc.
 
   
14
  Amended and Restated Code of Business Conduct and Ethics (incorporated by reference to Exhibit 14.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on February 4, 2008).
 
   
21**
  Subsidiaries of Health Benefits Direct Corporation.
 
   
23.1**
  Consent of Sherb & Co., LLP.
 
   
31.1**
  Section 302 Certification of Principal Executive Officer.
 
   
31.2**
  Section 302 Certification of Principal Financial Officer.

126


 

     
Exhibit    
Number   Description
 
   
32.1**
  Section 906 Certification of Principal Executive Officer and Principal Financial Officer.
 
**   Filed herewith

127


 

SIGNATURES
     Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
         
  HEALTH BENEFITS DIRECT CORPORATION
 
 
  By:   /s/ Anthony R. Verdi    
    Anthony R. Verdi   
    Principal Executive Officer, Chief Financial
Officer and Chief Operating Officer 
 
 
     Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
         
/s/ ANTHONY R. VERDI
 
Anthony R. Verdi
  Chief Financial Officer, Chief Operating Officer and Director (Principal Executive Officer, Principal Financial and Accounting Officer)   March 31, 2009
 
       
 
 
  Co-Chairman    March 31, 2009 
Alvin H. Clemens
       
 
       
/s/ DONALD R. CALDWELL
 
  Co-Chairman    March 31, 2009 
Donald R. Caldwell
       
 
       
/s/ WARREN V. MUSSER
 
  Director    March 31, 2009 
Warren V. Musser
       
 
       
/s/ JOHN HARRISON
 
  Director    March 31, 2009 
John Harrison
       
 
       
/s/ ROBERT J. OAKES
 
  Director    March 31, 2009 
Robert J. Oakes
       
 
       
/s/ PAUL SOLTOFF
 
  Director    March 31, 2009 
Paul Soltoff
       

128


 

         
/s/ SANFORD RICH
 
  Director    March 31, 2009 
Sanford Rich
       
 
       
 
 
  Director    March 31, 2009 
L.J. Rowell
       
 
       
/s/ FREDERICK C. TECCE
 
  Director    March 31, 2009 
Frederick C. Tecce
       
 
       
/s/ EDMOND WALTERS
 
  Director    March 31, 2009 
Edmond Walters
       

129


 

EXHIBIT INDEX
     
Exhibit    
Number   Description
 
   
2.1
  Agreement and Plan of Merger, dated November 23, 2005, among Darwin Resources Corp., Health Benefits Direct Corporation, and HBDC II, Inc. (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on November 30, 2005).
 
   
2.2
  Agreement and Plan of Merger, dated as of September 21, 2007, by and among the Company, HBDC Acquisition, LLC, System Consulting Associates, Inc. and the shareholders of System Consulting Associates, Inc. party thereto (incorporated by reference from Exhibit 2.1 to the Company’s current report on From 8-K, filed with the Commission on September 26, 2007).
 
   
3.1
  Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on November 22, 2005).
 
   
3.2
  Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the Commission on December 3, 2007).
 
   
3.3
  Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Registrant’s Current Report on Form 8-K filed with the Commission on November 30, 2005).
 
   
3.4
  Certificate of Merger of HBDC II, Inc. with and into Health Benefits Direct Corporation (incorporated by reference to Exhibit 3.4 to the Registrant’s Current Report on Form 8-K filed with the Commission on November 30, 2005).
 
   
3.5
  Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.5 to the Registrant’s Registration Statement on Form SB-2, filed with the Commission on February 1, 2008).
 
   
3.6
  Certificate of Designation with respect to shares of Series A Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on January 21, 2009).
 
   
3.7**
  Certificate of Amendment to Certificate of Incorporation.
 
   
4.1
  Form of Common Stock Purchase Warrant Certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on November 30, 2005).
 
   
4.2
  Warrant to Purchase Common Stock issued to Alvin H. Clemens (incorporated by reference to Exhibit 4.2 to the Registrant’s Annual Report on Form 10-KSB for the fiscal year ended December 31, 2005, filed with the Commission on March 31, 2006).

130


 

     
Exhibit    
Number   Description
 
   
4.3
  Securities Purchase Agreement, dated March 30, 2007, by and between Health Benefits Direct Corporation and the Investors party thereto (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on March 30, 2007).
 
   
4.4
  Registration Rights Agreement, dated March 30, 2007, by and between Health Benefits Direct Corporation and the Investors party thereto (incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K, filed with the Commission on March 30, 2007).
 
   
4.5
  Form of Warrant (incorporated by reference to Exhibit 4.3 to the Registrant’s Current Report on Form 8-K, filed with the Commission on March 30, 2007).
 
   
4.6
  Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.4 to the Registrant’s Current Report on Form 8-K, filed with the Commission on March 30, 2007).
 
   
4.7
  Registration Rights Agreement, dated October 1, 2007, by and between Health Benefits Direct Corporation and Computer Command and Control Company (incorporated by reference from Exhibit 4.1 to the Company’s current report on From 8-K, filed with the Commission on October 4, 2007).
 
   
4.8
  Registration Rights Agreement, dated October 1, 2007, by and among Health Benefits Direct Corporation and Robert J. Oakes, Jeff Brocco, Tim Savery and Lisa Roetz (incorporated by reference from Exhibit 4.2 to the Company’s current report on From 8-K, filed with the Commission on October 4, 2007).
 
   
4.9
  Securities Purchase Agreement, dated March 31, 2008, by and between Health Benefits Direct Corporation and the Investor party thereto (incorporated by reference from Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on March 31, 2008).
 
   
4.10
  Securities Purchase Agreement, dated March 31, 2008, by and between Health Benefits Direct Corporation and the Investors party thereto (incorporated by reference from Exhibit 4.2 to the Registrant’s Current Report on Form 8-K, filed with the Commission on March 31, 2008).
 
   
4.11
  Form of Warrant (incorporated by reference to Exhibit 4.3 to the Registrant’s Current Report on Form 8-K, filed with the Commission on March 31, 2008).
 
   
4.12
  Form of Registration Rights Agreement, dated March 31, 2008, by and among Health Benefits Direct Corporation and the Investors party thereto (incorporated by reference from Exhibit 4.4 to the Company’s current report on From 8-K, filed with the Commission on March 31, 2008).
 
   
4.13
  Form of Registration Rights Agreement, dated March 31, 2008, by and among Health Benefits Direct Corporation and the Investors party thereto (incorporated by reference from Exhibit 4.3 to the Company’s current report on From 8-K, filed with the Commission on March 31, 2008).

131


 

     
Exhibit    
Number   Description
 
   
4.14
  Board Representation Agreement, date March 31, 2008, between the Company and The Co-Investment Fund II, L.P. (incorporated by reference from Exhibit 4.5 to the Registrant’s Current Report on Form 8-K, filed with the Commission on March 31, 2008).
 
   
10.1
  Health Benefits Direct Corporation 2005 Incentive Stock Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on November 30, 2005).
 
   
10.2
  Health Benefits Direct Corporation 2005 Non-Employee Directors Stock Option Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K/A filed with the Commission on December 22, 2005).
 
   
10.3
  Health Benefits Direct Corporation Compensation Plan for Directors (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on March 20, 2006).
 
   
10.4
  Lease Agreement, dated February 9, 2004, between Case Holding Co. and Platinum Partners, LLC (incorporated by reference to Exhibit 10.7 to the Registrant’s Form 8-K filed with the Commission on November 30, 2005).
 
   
10.5
  Lease between Health Benefits Direct Corporation and FG2200, LLC, effective March 15, 2006 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on March 6, 2006).
 
   
10.6
  Employment Agreement, dated November 18, 2005, between Health Benefits Direct Corporation and Charles A. Eissa (incorporated by reference to Exhibit 10.14 to the Registrant’s Current Report on Form 8-K filed with the Commission on November 30, 2005).
 
   
10.7
  Amendment 2008-1 to Employment Agreement, dated March 31, 2008, between Health Benefits Direct Corporation and Charles A. Eissa (incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed with the Commission on March 31, 2008).
 
   
10.8
  Form of Director and Officer Indemnification Agreement (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on January 17, 2006).
 
   
10.9
  Securities Contribution Agreement, dated September 9, 2005, among Health Benefits Direct Corporation, Marlin Capital Partners I, LLC, Scott Frohman, Charles A. Eissa, Platinum Partners II LLC and Dana Boskoff (incorporated by reference to Exhibit 10.22 to the Registrant’s Current Report on Form 8-K filed with the Commission on November 30, 2005).

132


 

     
Exhibit    
Number   Description
 
   
10.12
  Merger Agreement, dated April 3, 2006, among Health Benefits Direct Corporation, ISG Merger Acquisition Corp., Insurance Specialist Group Inc. and Ivan M. Spinner (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on April 6, 2006).
 
   
10.13
  Employment Agreement, dated April 3, 2006, between HBDC II, Inc. and Ivan M. Spinner (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on April 6, 2006).
 
   
10.14
  Health Benefits Direct Corporation 2006 Omnibus Equity Compensation Plan (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on May 2, 2006).
 
   
10.15
  Health Benefits Direct Corporation 2006 Omnibus Equity Compensation Plan Form of Nonqualified Stock Option Grant (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on May 2, 2006).
 
   
10.16
  Health Benefits Direct Corporation 2008 Equity Compensation Plan (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on March 31, 2008).
 
   
10.17
  Health Benefits Direct Corporation 2008 Equity Compensation Plan Form of Nonqualified Stock Option Grant (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on March 28, 2008).
 
   
10.18
  Sublease, dated March 7, 2006, between Health Benefits Direct Corporation and World Travel Partners I, LLC Form of Nonqualified Stock Option Grant (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on May 19, 2006).
 
   
10.19
  First Amendment to Sublease, dated April 18, 2006, between Health Benefits Direct Corporation ad World Travel Partners I, LLC (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on May 19, 2006).
 
   
10.20
  Letter Agreement, dated April 18, 2006, among World Travel Partners I, LLC, Health Benefits Direct Corporation, and 1120 Avenue of the Americas, LLC (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on May 19, 2006).
 
   
10.21
  Software and Services Agreement, dated May 31, 2006, among Health Benefits Direct Corporation, Insurint Corporation, and Realtime Solutions Group, L.L.C. (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on June 2, 2006).
 
   
10.22
  Lease, dated July 7, 2006, between Health Benefits Direct Corporation and Radnor Properties-SDC, L.P. (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on July 10, 2006).

133


 

     
Exhibit    
Number   Description
 
   
10.23
  Separation Agreement, dated December 7, 2006, between Health Benefits Direct Corporation and Scott Frohman (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on December 11, 2006).
 
   
10.24
  Amendment No. 1 to Option, dated as of February 15, 2007, delivered by Health Benefits Direct Corporation to Daniel Brauser (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on February 16, 2007).
 
   
10.25
  Consent and Lock-Up Agreement, dated April 5, 2007, between Health Benefits Direct Corporation and Scott Frohman (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Commission on April 6, 2007).
 
   
10.26
  Agreement to Transfer Partnership Interests, dated October 1, 2007, by and among HBDC Acquisition, LLC and the former partners of BileniaTech, L.P. (incorporated by reference from Exhibit 10.1 to the Company’s current report on From 8-K, filed with the Commission on October 4, 2007).
 
   
10.27
  Amended and Restated Employment Agreement, dated November 27, 2007, between Health Benefits Direct Corporation and Alvin H. Clemens (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on December 3, 2007).
 
   
10.28
  Amended and Restated Employment Agreement, dated November 27, 2007, between Health Benefits Direct Corporation and Anthony R. Verdi (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the Commission on December 3, 2007).
 
   
10.29
  Amendment 2008-1 to Amended and Restated Employment Agreement, dated March 31, 2008, between Health Benefits Direct Corporation and Anthony R. Verdi (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed with the Commission on March 31, 2008).
 
   
10.30
  Amended and Restated Employment Agreement, dated November 27, 2007, between Health Benefits Direct Corporation and Ivan M. Spinner (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed with the Commission on December 3, 2007).
 
   
10.31**
  Client Transition Agreement, between Health Benefits Direct Corporation, HBDC II, Inc. and eHealthInsurance Services, Inc.
 
   
14
  Amended and Restated Code of Business Conduct and Ethics (incorporated by reference to Exhibit 14.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on February 4, 2008).
 
   
21**
  Subsidiaries of Health Benefits Direct Corporation.
 
   
23.1**
  Consent of Sherb & Co., LLP.

134


 

     
Exhibit    
Number   Description
 
   
31.1**
  Section 302 Certification of Principal Executive Officer.
 
   
31.2**
  Section 302 Certification of Principal Financial Officer.
 
   
32.1**
  Section 906 Certification of Principal Executive Officer and Principal Financial Officer.
 
**   Filed herewith

135

Exhibit 3.7
CERTIFICATE OF AMENDMENT
TO
THE CERTIFICATE OF INCORPORATION
OF
HEALTH BENEFITS DIRECT CORPORATION
                HEALTH BENEFITS DIRECT CORPORATION , (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify:
                FIRST : That the board of directors of the Corporation (the “Board of Directors”), at a duly convened meeting of the Board of Directors, duly adopted a resolution declaring advisable the amendment of the Certificate of Incorporation of the Corporation, as amended (the “Certificate’), and submitted the same to the stockholders of the Corporation for approval. The resolution setting forth the proposed amendment is as follows:
                RESOLVED , that Article FOURTH be amended and restated in its entirety as follows:
     “ FOURTH: A. The total number of shares of stock which the Corporation shall have the authority to issue is 210,000,000. The Classes and aggregate number of shares of each class which the Corporation shall have authority to issue are as follows:
  1.   Two Hundred million (200,000,000) shares of Common Stock, par value $0.001 per share (the “Common Stock”); and
 
  2.   Ten million (10,000,000) shares of Preferred Stock, par value of $0.001 per share (the “Preferred Stock”).”
                SECOND : That the stockholders of the Corporation have duly approved the aforesaid amendment in accordance with the provisions of Section 242 of the DGCL.

 


 

               IN WITNESS WHEREOF, this Certificate of Amendment has been executed on behalf of the Company by its Chief Financial Officer and Chief Operating Officer this 25th day of March, 2009.
         
 
       
HEALTH BENEFITS DIRECT CORPORATION    
 
       
By:
 
  /s/ ANTHONY R. VERDI
 
 
   
Name: Anthony R. Verdi    
Title: Chief Financial Officer and Chief Operating Officer    

 

Exhibit 10.31
EXECUTION VERSION
CLIENT TRANSITION AGREEMENT
     This CLIENT TRANISITION AGREEMENT (the “ Agreement ”) is made and entered into as of February ___, 2009 between eHealthInsurance Services, Inc., a Delaware corporation (“ eHealth ”) and Health Benefits Direct Corporation, a Delaware corporation and its wholly owned subsidiary HBDC II, Inc, also a Delaware Corporation (collectively, “ HBDC ”).
RECITALS
     A. HBDC or an employee or former employee sales agent serves as broker of record for a number of individual and family major medical (“ IFP ”) health insurance policies and ancillary policies (e.g., dental, life and vision insurance) sold along or bundled with such policies (collectively, the “ Policies ”).
     B. HBDC desires to transfer to eHealth broker of record (“ BOR ”) status and the right to receive commissions on all of the in-force Policies issued by the Specified Carriers, including those issued after the date hereof, but excluding the Excluded Policies (collectively, the “ Transition Policies ”).
     C. eHealth desires to compensate HBDC, as described in this Agreement, for the transfer of BOR status and the right to receive commissions on the Transition Policies.
     NOW, THEREFORE, in consideration of the covenants, promises and representations set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:
ARTICLE I
DEFINITIONS
     1.1 Capitalized Terms . The following capitalized terms shall have the meanings set forth below:
          (a) “ Acquisition Proposal ” shall have the meaning set forth in Section 6.5 .
          (b) “ Action or Proceeding ” shall mean any action, suit, proceeding, arbitration or governmental or regulatory investigation or audit.
          (c) “ Agreement ” shall have the meaning set forth in the preamble above, together with all exhibits and schedules hereto.
          (d) “ Ancillary Agreements ” shall mean the Marketing and Referral Agreement and the Collateral Agreements.

 


 

          (e) “ Assumed Obligations ” shall have the meaning set forth in Section 2.5 .
          (f) “ Books and Records ” shall mean all papers and records (in paper or electronic format) in the care, custody or control of HBDC relating to the Transition Policies, including the applications for the Transition Policies, the full names, addresses (including Zip Code), e-mail addresses, dates of birth, gender and tobacco usage information (yes/no) of the holders of the Transition Policies, and any and all opt-out lists pertaining to the holders of the Transition Policies, in such electronic form and format as may be reasonably requested by eHealth.
          (g) “ BOR ” shall have the meaning set forth in Recital B .
          (h) “ Business ” shall have the meaning set forth in Section 4.1 .
          (i) “ Carrier Book ” shall mean with respect to a particular Specified Carrier all of the Transition Policies issued by that Specified Carrier.
          (j) “ Collateral Agreements ” shall have the meaning set forth in Section 2.4 .
          (k) “ Closing ” shall have the meaning set forth in Section 3.1 .
          (l) “ Closing Date ” shall have the meaning set forth in Section 3.1 .
          (m) “ Conflict ” shall mean any event that would constitute a conflict, breach, violation or default (with or without notice or lapse of time, or both) or give rise to a right of termination, cancellation, modification or acceleration of any obligation or loss of any benefit.
          (n) “ Confidentiality Agreement ” shall mean the Reciprocal Non-Disclosure Agreement between eHealth and HBDC dated April 1, 2008.
          (o) “ Contract ” shall mean any mortgage, indenture, lease, contract, purchase order, covenant or other agreement, instrument or commitment, permit, concession, franchise or license.
          (p) “ eHealth shall have the meaning set forth in the preamble above.
          (q) “ Estimated Lifetime Value ” shall mean with respect to a Specified Carrier’s Carrier Book the value of such Carrier Book as determined and agreed upon by eHealth and HBDC. The Estimated Lifetime Value shall equal the difference between (i) the anticipated regular commission payments to eHealth on the Specified Carrier’s Carrier Book for in-force Transition Policies between February 1, 2009 and January 31, 2014 as a result of the BOR Transfer relating to such Specified Carrier; and (ii) the amount of the Assumed Obligation for historical commission advances made by such Specified Carrier to HBDC (if any).
          (r) “ Exchange Act ” shall mean the Securities Exchange Act of 1934, as amended.
          (s) “ Excluded Liabilities ” shall have the meaning set forth in Section 2.6 .
          (t) “ Excluded Policies ” shall have the meaning set forth in Section 2.2.

-2-


 

          (u) “ Governmental Entity ” shall mean any U.S. or foreign, national, federal, state, municipal or local or other government, court, administrative agency or commission, court tribunal or judicial or arbitral body or other governmental body, authority, instrumentality, agency or commission.
          (v) “ HBDC ” shall have the meaning set forth in the preamble above.
          (w) “ IFP ” shall have the meaning set forth in Recital A .
          (x) “ Indemnification Claim ” shall have the meaning set forth in Section 8.3 .
          (y) “ Indemnification Objection Notice ” shall have the meaning set forth in Section 8.3 .
          (z) “ Initial BOR Transfer Payment ” shall mean, with respect to each Carrier Book that is a part of the BOR Transfer, twenty percent (20%) of the Estimated Lifetime Value of such Carrier Book.
          (aa) “ Lead ” shall mean shall mean health insurance prospect or member information belonging to HBDC.
          (bb) “ Lead Database ” shall mean the full names, addresses (including Zip Code), date of birth, gender and tobacco usage information (yes/no) and e-mail addresses of all of the Leads in the possession of HBDC or any Subsidiary of HBDC as of the first Closing, and any and all opt-out lists pertaining to such Leads, in such electronic form and format as may be reasonably requested by eHealth
          (cc) “ Liability ” shall mean any liability or obligation (whether known or unknown, whether asserted or unasserted, whether absolute or contingent, whether accrued or unaccrued, whether liquidated or unliquidated, whether incurred or consequential and whether due or to become due), including any liability for taxes.
          (dd) “ Lien ” shall mean any pledge, lien, security interest, charge, claim, equity, encumbrance, restriction on transfer, conditional sale or other title retention device or arrangement (including a capital lease), transfer for the purpose of subjection to the payment of any indebtedness, or restriction on the creation of any of the foregoing, whether relating to any property or right or the income or profits therefrom.
          (ee) “ Loss ” shall have the meaning set forth in Section 8.2 .
          (ff) “ Marketing and Referral Agreement ” shall mean the Marketing and Referral Agreement between eHealth and HBDC, the form of which is attached hereto as Schedule 1.1(ff) .
          (gg) “ Nasdaq ” means the Nasdaq Global Market.
          (hh) “ Officer’s Certificate ” shall have the meaning set forth in Section 7.2(d) .

-3-


 

          (ii) “ Ordinary Course of Business ” shall mean the ordinary course of business, consistent with past practice (including with respect to quantity and frequency).
          (jj) “ Person ” shall mean any individual, partnership, firm, corporation, association, trust, unincorporated organization or other entity, as well as any syndicate or group of any of the foregoing.
          (kk) “ Policies ” shall have the meaning set forth in Recital A .
          (ll) “ Purchaser Indemnified Parties ” shall have the meaning set forth in Section 8.2 .
          (mm) “ SEC ” means the Securities and Exchange Commission.
          (nn) “ Securities Act ” shall mean the Securities Act of 1933, as amended.
          (oo) “ Specified Carriers ” shall mean Aetna, Inc., Golden Rule Insurance Company (“ GRIC ”), Humana, Inc., PacifiCare, Inc., Time Insurance Company (marketed under the brand name Assurant Health) and United Healthcare Insurance Co..
          (pp) “ Subsidiary ” or “ Subsidiaries ” shall mean, with respect to any Person, any entity of which securities or other ownership interests having ordinary voting power to elect a majority of the board of directors or other persons performing similar functions are at any time directly or indirectly owned by such Person.
          (qq) “ Third Party Claim ” shall have the meaning set forth in Section 8.5 .
          (rr) “ Transition Assets ” shall mean the BOR Transfer, the Books and Records and the Lead Database.
          (ss) “ Transition Policies ” shall have the meaning set forth in Recital B .
     Other capitalized terms shall have the meaning ascribed to such terms in other portions of this Agreement.
     1.2 Construction .
          (a) As used in this Agreement, the words “include” and “including” and variations thereof will not be deemed to be terms of limitation, but rather will be deemed to be followed by the words “without limitation.”
          (b) Except as otherwise indicated, all references in this Agreement to “Articles,” “Schedules,” and “Sections” are intended to refer to Articles, Schedules, and Sections to this Agreement.
          (c) The headings in this Agreement are for convenience of reference only, will not be deemed to be a part of this Agreement, and will not be referred to in connection with the construction or interpretation of this Agreement.

-4-


 

ARTICLE II
CLIENT TRANSITION
     2.1 BOR Transfer/Books and Records . In one or more Closings and subject to the terms and conditions set forth in this Agreement (including the conditions to Closing set forth in Article VII ), HBDC shall transfer and assign to eHealth, or shall cause to be transferred and assigned to eHealth, free and clear of any and all Liens (other than Assumed Obligations) the following: (i) BOR status on, and all right to receive commissions on premiums paid for, all Transition Policies (collectively, the “ BOR Transfer ”); and (ii) the Books and Records. As more fully described in Article III , the BOR Transfer may take place in successive Closings on a Carrier Book basis.
     2.2 Excluded Policies. The Transition Policies shall not include, and HBDC shall not transfer and assign to eHealth, BOR status and the right to receive commissions on (a) any policy, including any ancillary policy, underwritten by a carrier other than a Specified Carrier; (b) the policies listed on Exhibit A to HBDC’s BOR letters to the Specified Carriers dated January 22, 2009; or (c) any policy identified as and for which commissions are paid by a Specified Carrier as a Short Term policy (collectively, the “ Excluded Policies ”).
     2.3 Transfer of Lead Database . In the first Closing, HBDC shall deliver, assign and transfer the Lead Database to eHealth in such electronic format as reasonably requested by eHealth.
     2.4 Assignments. HBDC shall deliver or cause to be delivered to eHealth, duly executed by HBDC, or any other Person required, such other good and sufficient instruments of assignment and transfer, in form and substance reasonably acceptable to eHealth, as shall be effective to vest in eHealth BOR status on, and all right to receive commissions on premiums paid for, all Transition Policies, including without limitation any BOR letter or other agreement or document requested by a Specified Carrier (such instruments being collectively referred to herein as the “ Collateral Agreements ”).
     2.5 Assumed Obligations . As of the Closing of that portion of the BOR Transfer relating to a Specified Carrier’s Carrier Book, eHealth hereby agrees to assume the following, and only the following, obligations of HBDC to such Specified Carrier (collectively, the “ Assumed Obligations ”):
     eHealth shall assume the Liabilities of HBDC to the Specified Carrier up to the amounts set forth on Schedule 2.5 for historical commission advances on Transition Policies made by the Specified Carrier to HBDC (the “ Limited Commission Advance Liability ”). eHealth shall assume the Limited Commission Advance Liability only to the extent such Liability is offset against commission payments that would otherwise have been made to eHealth on the Transition Policies (excluding Excluded Policies) of the Specified Carrier and that such offset is consistent with such Specified Carrier’s commission advance offset practices with HBDC prior to the date of this Agreement.
     2.6 Liabilities Not Assumed . Other than the Assumed Obligations, eHealth shall not assume by virtue of this Agreement, and shall have no liability or obligation for, any Liability of HBDC or its Subsidiaries (the “ Excluded Liabilities ”), including (without limitation) the Excess GRIC

-5-


 

Liability and the other Liabilities listed below, and HBDC shall retain and pay, satisfy, discharge and perform all such Liabilities, including (without limitation) the following Excluded Liabilities:
          (a) The Liability of HBDC for commission advances other than as specifically set forth in Section 2.5 , including without limitation the Liability of HBDC to GRIC for commission advances or other amounts in excess of the amount set forth on Schedule 2.5 (the “ Excess GRIC Liability ”). .
          (b) Any Liability of HBDC as a result of any Action or Proceeding initiated at any time to the extent caused by any action or inaction that occurred or condition that existed on or prior to the Closing Date;
          (c) Any Liability of HBDC for costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby;
          (d) Any Liability of HBDC under any Contract;
          (e) Any Liability pertaining to HBDC’s business and arising out of or resulting from noncompliance on or prior to the Closing Date with any laws, statutes, ordinances, rules, regulations, orders, determinations, judgments or directives, whether legislatively, judicially or administratively promulgated;
          (f) Any Liability in respect of accounts payable, or payable obligations of HBDC (except as expressly set forth in Section 2.5 );
          (g) Any Liability for taxes of HBDC or any of its Subsidiaries for any taxable period or portion thereof, or relating or attributable to the Transition Policies or the Lead Database for any taxable period or portion thereof, ending on and including the Closing Date; eHealth will be liable for any taxes for any taxable period or portion thereof, or relating or attributable to the Transition Policies or the Lead Database for any taxable period or portion thereof, beginning on and including the day after the Closing Date; and
          (h) Any Liability of any Subsidiary of HBDC.
ARTICLE III
CLOSING AND CONSIDERATION
     3.1 Closing. Any Closing of the transactions contemplated by this Agreement (the “ Closing ”) will take place at the offices of eHealth, 440 East Middlefield Road, Mountain View, California 94043, commencing at 9:00 a.m., Pacific Standard Time, two business days following the satisfaction or written waiver of the last of the conditions of Closing as set forth in Article VII hereof, or on such other date and time as the parties may mutually determine (the “ Closing Date ”). If the conditions to Closing (as set forth in Article VII ), as they relate to that portion of the BOR Transfer relating to a Specified Carrier’s Carrier Book, are satisfied (or waived in writing), the parties shall hold successive Closings and each such Closing shall relate to that portion of the BOR Transfer that relates to such Carrier Book and for which the conditions to Closing are satisfied (or

-6-


 

waived in writing). Under such circumstances, the Books and Records relating to the Transition Policies (or holders thereof) of such Specified Carrier shall be assigned and transferred at the same Closing. The date of each successive closing shall be a Closing Date.
     3.2 Consideration . In addition to assuming Assumed Obligations, as consideration for the BOR Transfer (or portion thereof occurring at a Closing) and the covenants of HBDC:
          (a) Initial BOR Transfer Payment . eHealth shall pay to HBDC II (by wire transfer in accordance with written instructions delivered by HBDC to eHealth at a Closing) within 2 days after the Closing of a portion of the BOR Transfer relating to a Specified Carrier’s Carrier Book, the Initial BOR Transfer Payment relating to such Specified Carrier’s Carrier Book. Notwithstanding the foregoing, eHealth may pay $966,097 to GRIC in connection with the Closing of the BOR Transfer relating to GRIC, PacifiCare, Inc. and United Healthcare Insurance Co. Transition Policies (the “ GRIC Closing Payment ”). In the event eHealth makes such payment, the Initial BOR Transfer Payment that eHealth is required to make to HBDC II shall be reduced by the amount of the GRIC Closing Payment.
          (b) Transition Policy Commission Payments . Subject to the other provisions of this Agreement, and after the BOR Transfer relating to the Carrier Book of a Specified Carrier, eHealth shall pay to HBDC II an amount equal to forty-five percent (45%) of each commission payment received by eHealth and reported by the Specified Carrier as relating to a Transition Policy (a “ Transition Commission Payment ”) for the duration of the policy, provided that eHealth remains BOR on such Transition Policy. For purposes of calculating the Transition Commission Payment, eHealth shall not be deemed to receive any amount withheld by a Specified Carrier in satisfaction of an Assumed Obligation or an Excluded Liability.
     3.3 Insurance Licenses . HBDC II covenants that HBDC II holds a validly issued health insurance agency license in good standing and is authorized to sell health insurance products in all jurisdictions in the United States. HBDC II shall complete and return to eHealth a Form W-9 and the Affiliate Licensing Form attached hereto as Schedule 3.3 , along with copies of all of its licenses or other satisfactory evidence of licensure. HBDC II further agrees that within fifteen (15) days of its receipt of any additional health insurance agency license(s), it will notify eHealth in writing and provide eHealth with a copy of such license(s). HBDC II shall notify eHealth promptly in writing of any suspension, revocation, termination or non-renewal of any insurance license or the commencement of any proceeding therefore. HBDC II understands and agrees that it must comply with this Section 3.3 and that eHealth must be reasonably satisfied with HBDC II’s licensing documents and licensing status in order for HBDC to be paid Transition Commission Payments in accordance with Section 3.2(b) . Without limiting the foregoing, HBDC II shall not be entitled to receive Transition Commission Payments if it is not appropriately licensed in the relevant jurisdiction and eHealth shall not pay Transition Commission Payments retroactively. Accordingly, to be eligible for Transition Commission Payments for any calendar month, HBDC II must have submitted to eHealth the appropriate licensing documents no later than the 15 th day of such month. Notwithstanding, if eHealth is aware of a failure by HBDC II to comply with this Section 3.3 , eHealth will notify HBDC II in accordance with Section 10.1 of such failure and will not withhold Transition Commission Payments if such failure is cured by HBDC II within 15 days of notice by eHealth.

-7-


 

     3.4 Timing and Reporting of Transition Commission Payments . Transition Commission Payments are due and payable on a monthly basis, and shall be paid to HBDC on or before the thirtieth (30 th ) day following the last day of the month in which the Transition Commission Payment is earned. Transition Commission Payments will be paid by wire transfer in accordance with written instructions delivered by HBDC to eHealth at a Closing or as may be revised by HBDC from time to time. Transition Commission Payments are earned when eHealth receives a commission payment accurately reported by a Specified Carrier as a commission on a Transition Policy (a “ Transition Policy Commission ”). Transition Commission Payments shall be accompanied by a statement (a “ Transition Commission Payment Statement ”) in both paper and mutually agreeable electronic forms setting forth the calculation of the Transition Commission Payments. Subject to eHealth’s receipt of accurate, complete and timely commission payment data from each Specified Carrier, the Transition Commission Payment Statements shall include, at a minimum (a) the total compensation eHealth received from the Specified Carriers for the Transition Policies for the reported month, (b) the total Transition Commission Payments owed and paid to HBDC for such month, and (c) for each underlying Transition Policy, the name of the Specified Carrier, the commissions received from the Specified Carrier for the reported month, the number of holders of Transition Policies for which commissions were paid, and the name and address of the primary applicant underlying such Transition Policy.
     3.5 Transition Commission Payment Offset . eHealth shall be entitled to offset against amounts owed to HBDC the amount of any prior Transition Commission Payment made by eHealth to HBDC as a result of eHealth’s receipt of a Transition Policy Commission that a Specified Carrier contends was not owed or paid in error due to cancellation of the underlying health insurance policy or otherwise.
     3.6 Right to Audit. HBDC shall have the right to have HBDC employees and/or mutually agreeable external auditors audit the books and records of eHealth related to this agreement up to once a year, to determine eHealth’s compliance and adherence to Section 3.2 (Consideration), Section 3.4 (Timing and Reporting of Transition Commission Payments), = Section 3.5 (Transition Commission Payment Offset) and Section 6.14 (eHealth Receipt of Commission Payments) of this Agreement. HBDC shall give eHealth reasonable prior notice of any such audit, and shall abide by reasonable security and confidentiality procedures during the audit. HBDC shall bear the cost of such audit. eHealth shall have the same right to audit HBDC in accordance with this Section to determine HBDC’s compliance and adherence to Section 6.13 (HBDC Receipt of Commission Payments).
     3.7 Retention of Records. eHealth shall retain all records relating to its performance under this Agreement for six years, or for such period as may be required by applicable law.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF HBDC
     HBDC hereby represents and warrants to eHealth, subject to the specific exceptions disclosed in the disclosure letter and schedules thereto (each referencing or cross-referencing the appropriate Section and paragraph numbers of this Article IV as to which an exception exists and

-8-


 

which exceptions and other information provided in the disclosure letter and schedules thereto shall constitute representations and warranties under this Agreement) delivered by HBDC to eHealth, and dated as of the date hereof (the “ HBDC Disclosure Schedule ”), as follows:
     4.1 Organization .
          (a) Health Benefits Direct Corporation and HBDC II, Inc. (collectively HBDC) are both corporations duly organized, validly existing and in good standing under the laws of the State of Delaware. HBDC has the power and authority to own, lease and operate its assets and property and to carry on its business as now being conducted and is duly qualified or licensed to do business, to perform its obligations as BOR and to receive commission payments for the Transition Policies and is in good standing in each jurisdiction where the character of the properties owned, leased or operated by it or the nature of its activities makes such qualification or licensing necessary.
          (b) No other Subsidiary of HBDC is or has been engaged in the operation of the business relating to the sale of the Transition Policies (the “ Business ”) or has or ever had any right to receive commissions as a result of the sale of the Transition Policies. To the extent that any of the Transition Assets have been transferred to HBDC, such transfer was duly authorized by all required corporate action, did not result in a Conflict with any law, rule or regulation, did not breach, violate, create any default or event of default or otherwise result in a Conflict with any agreement, and did not result in the creation of any Lien. No such transfer resulted or will result in any claim that such transfer was invalid or conflicted with the rights of any creditor of HBDC or any other person or entity.
     4.2 Authority. HBDC has all requisite corporate power and authority to enter into this Agreement and the Ancillary Agreements and to consummate the transactions contemplated hereby and thereby. The execution and delivery of this Agreement and the Ancillary Agreements and the consummation of the transactions contemplated hereby and thereby have been duly authorized by all necessary corporate action on the part of HBDC, and no further action is required on the part of HBDC or any of HBDC’s stockholders to approve this Agreement, the Ancillary Agreements and the transactions contemplated hereby and thereby. This Agreement and the Ancillary Agreements and the transactions contemplated hereby and thereby have been approved by the Board of Directors of HBDC. This Agreement and the Ancillary Agreements and the transactions contemplated hereby and thereby are not required to be approved by the stockholders of HBDC or the Board of Directors or stockholders of any Subsidiary of HBDC. This Agreement has, and upon their execution the Ancillary Agreements will be, duly and validly executed and delivered by HBDC and constitute a valid and binding obligation of HBDC, enforceable against HBDC in accordance with their terms.
     4.3 No Conflict. The execution and delivery of this Agreement by HBDC does not, and the execution and delivery of the Ancillary Agreements and the performance of this Agreement and the Ancillary Agreements will not (a) conflict with or violate the certificate of incorporation or bylaws of HBDC or any Subsidiary of HBDC; (b) conflict with or violate any law, rule, regulation, order, judgment or decree applicable to HBDC or any Subsidiary of HBDC or by which any of their properties are bound or affected; (c) result in the creation of a Lien; or (d) result in any breach of or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or impair the rights of HBDC or alter the rights or obligations of any third party under, or give to others any rights of termination, amendment, acceleration or cancellation of, any note, bond,

-9-


 

mortgage, indenture, Contract, agreement, lease, license, permit, franchise, concession or other instrument or obligation (including any privacy policy or other privacy obligation pursuant to which any information to be transferred to eHealth has been collected), to which HBDC or any of its Subsidiaries is a party or by which the Transition Assets are bound or affected.
     4.4 Indebtedness; Guaranties . Except as set forth on Schedule 2.5 of this Agreement, neither HBDC nor any of its Subsidiaries has any Liability relating to any of the Transition Policies or Transition Assets. Neither HBDC nor any of its Subsidiaries is a guarantor or otherwise liable for any Liability or obligation of any other person or entity for any matter which relates to or affects or will affect the Transition Policies or Transition Assets or eHealth’s right to receive commissions as a result of the BOR Transfer.
     4.5 Absence of Changes. Since December 31, 2008 and except as contemplated by this Agreement, HBDC has conducted the Business only in the Ordinary Course of Business and, without limiting the generality of the foregoing:
          (a) HBDC has not pledged or otherwise encumbered any of the Transition Assets;
          (b) HBDC has not sold, assigned, licensed, leased, transferred or conveyed, or committed to sell, assign, license, lease, transfer or convey, any of the Transition Assets;
          (c) The Transition Policies have not been cancelled and HBDC has the right to receive commissions therefor;
          (d) No Action or Proceeding relating to the Business, the Transition Policies or the Transition Assets has been commenced or threatened, and to the knowledge of HBDC, no reasonable basis exists for any litigation, proceeding or investigation relating to the Business, the Transition Policies or the Transition Assets; and
          (e) There has been no agreement by HBDC, any of its Subsidiaries, or any employees, agents or affiliates of HBDC or any of its Subsidiaries to do any of the things described in the preceding clauses (a) through (d) (other than negotiations with eHealth and their representatives regarding the transactions contemplated by this Agreement).
     4.6 Legal and Other Compliance. The Business has been operated in material compliance with all applicable laws (including rules, regulations, codes, plans, injunctions, judgments, orders, decrees, rulings and charges thereunder) of federal, state, local and foreign governments (and all agencies thereof). No action, suit, proceeding, hearing, investigation, charge, complaint, claim, demand or notice has been filed or commenced, or to the knowledge of HBDC threatened against HBDC or any of its Subsidiaries, alleging any failure so to comply, nor to the knowledge of HBDC, is there any reasonable basis therefor.
     4.7 Liens. Except as set forth on Schedule 2.5 of this Agreement of the HBDC Disclosure Schedule, HBDC has good and valid title to each of the Transition Assets free and clear of any Liens. No Liens encumber any Transition Asset. No basis exists for the assertion of any claim which, if adversely determined, could result in a Lien on any Transition Asset. No Person other than HBDC possesses any claims or rights with respect to any Transition Asset.

-10-


 

     4.8 Litigation. There is no Action or Proceeding pending before any court or administrative agency against HBDC (or any Subsidiary or affiliate of HBDC or any officer or director of HBDC in their capacity as such) that relates directly or indirectly to the Business or any Transition Asset or that questions the validity of this Agreement or any Ancillary Agreement or of any action taken or to be taken pursuant to or in connection with this Agreement or any Ancillary Agreement. To the knowledge of HBDC, no such Action or Proceeding has been threatened, and HBDC is not aware of any reasonable basis for any such Action or Proceeding. There are no judgments, orders, decrees, citations, fines or penalties heretofore assessed against HBDC or any of its Subsidiaries affecting the Business, any Transition Policy or any Transition Asset under any federal, state, local or foreign law.
     4.9 Consents. No consent, waiver, approval, order or authorization of, or registration, declaration or filing with, or notification to, any Governmental Entity or any third party (including a Specified Carrier), including a party to any agreement with HBDC or any of its Subsidiaries (so as not to trigger a Conflict), is required by or with respect to HBDC or any of its Subsidiaries in connection with the execution and delivery of this Agreement or any Ancillary Agreement, or the consummation of the transactions contemplated hereby or thereby (including in order for eHealth to become BOR, and to receive commission payments, on the Transition Policies), except for the consents listed on Schedule 4.9 of the HBDC Disclosure Schedule. Schedule 4.9 of the HBDC Disclosure Schedule includes the reason any consents listed thereon are necessary.
     4.10 Books and Records/Lead Database. The Books and Records (a) are accurate in all material respects, (b) have been maintained in accordance with applicable laws and regulations and (c) are in HBDC’s possession or under its control. The Lead Database was obtained in compliance with all applicable laws, rules and regulations, and the use of the Lead Database by eHealth as contemplated by the Marketing and Referral Agreement will not cause eHealth to be in violation of any law, rule or regulation or cause a Conflict with any Contract of HBDC or any of its Subsidiaries.
     4.11 Solvency . Neither the HBDC nor any of its Subsidiaries has: (a) made a general assignment for the benefit of creditors, (b) filed any voluntary petition in bankruptcy or suffered the filing of any involuntary petition by its creditors, (c) suffered the appointment of a receiver to take possession of all, or substantially all, of its assets, (d) suffered the attachment or other judicial seizure of all, or substantially all, of its assets, (e) admitted in writing its inability to pay its debts as they come due, (f) made an offer of settlement, extension or composition to its creditors generally, or (g) taken any corporate action in furtherance of any of the foregoing. HBDC is, and after giving effect to the transactions to be effected pursuant to this Agreement (including the incurrence of all obligations being incurred in connection herewith), will be immediately following the Closing, Solvent. “ Solvent ” means, when used with respect to any Person, that, as of any date of determination: (i) the fair saleable value of such Person’s assets, as of such date, exceeds the value of its liabilities, including all contingent and other liabilities, (ii) such Person will not have, as of such date, an unreasonably small amount of capital for the businesses in which it is engaged or in which management has indicated it intends to engage, and (iii) such Person will be able to pay its liabilities, including all contingent and other liabilities, as they mature. For purposes of this definition: (1) “ fair saleable value ” means the aggregate amount of net consideration (as of any date of determination and giving effect to reasonable and customary costs of sale or taxes, where the probable amount of any such taxes is identified by such Person) that could be expected to be realized from an interested purchaser by a seller, in an arm’s length transaction under present conditions in a current market for the sale of assets of a comparable business enterprise, where both parties are

-11-


 

aware of all relevant facts and neither party is under any compulsion to act, where such seller is interested in disposing of the entire operation as a going concern, presuming the business will be continued in its present form and character, and with reasonable promptness, not to exceed one year; (2) “ liabilities, including all contingent and other liabilities ” have the meanings that are generally determined in accordance with applicable federal laws governing determinations of the insolvency of debtors; (3) “ contingent and other liabilities ” means the contingent and other liabilities known to such Person; and (4) “ not have an unreasonably small amount of capital for the businesses in which it is engaged or in which management has indicated it intends to engage ” and “ able to pay its liabilities, including all contingent and other liabilities, as they mature ” mean that such Person will be able to generate enough cash from operations, asset dispositions, refinancing, or a combination thereof, to meet its obligations (including all contingent and other liabilities) as they become due.
     4.12 Complete Copies of Materials. HBDC has made available to eHealth complete and correct copies of each document referenced in the HBDC Disclosure Schedule.
     4.13 Liabilities After a Closing . Following the Closing of the BOR Transfer with respect to a Specified Carrier’s Carrier Book, eHealth will have no Liability to such Specified Carrier (including interest, penalties or other Liabilities stemming from the commission advance agreements between HBDC and such Specified Carrier) other than the Assumed Obligation to such Specified Carrier and Liabilities eHealth would owe to such Specified Carrier had the transactions contemplated by this Agreement not occurred.
ARTICLE V
REPRESENTATIONS AND WARRANTIES OF EHEALTH
     eHealth hereby represents and warrants to HBDC as follows:
     5.1 Organization and Standing. eHealth is a corporation duly organized, validly existing and in good standing under the laws of Delaware.
     5.2 Authority. eHealth has all requisite corporate power and authority to enter into this Agreement and any Ancillary Agreement to which it is a party and to consummate the transactions contemplated hereby and thereby. The execution and delivery by eHealth of this Agreement and such Ancillary Agreements have been duly authorized by all necessary corporate action on the part of eHealth. This Agreement, and upon their execution any Ancillary Agreement executed by eHealth will be, duly executed and delivered by eHealth and constitute valid and binding obligations of eHealth, enforceable against it in accordance with their terms.
     5.3 No Conflict. Except in each case where such conflict, violation or default will not have a material adverse effect on the legality, validity or enforceability of eHealth’s obligations under this Agreement or any Ancillary Agreement, neither the execution and delivery of this Agreement or any Ancillary Agreement to which eHealth is a party, nor the consummation of the transactions contemplated hereby and thereby, will conflict with or result in any violation of, or default under (with or without notice or lapse of time, or both) (a) any provision of the Certificate of Incorporation and Bylaws, each as amended through the date hereof, of eHealth, (b) any judgment, order, decree, statute, law, ordinance, rule or regulation applicable to eHealth or its properties or assets, or (c) any

-12-


 

contract, agreement, commitment or undertaking to which eHealth is a party or to which it or any of its assets or properties are subject or bound.
     5.4 Consents. Other than with respect to consents, waivers, approvals, orders or authorizations of, or registrations, declarations or filings with, or notifications to, the SEC and/or Nasdaq, no consent, waiver, approval, order or authorization of, or registration, declaration or filing with, or notification to, any Governmental Entity is required by or with respect to eHealth for the execution and delivery of this Agreement, the Ancillary Agreements or the transactions contemplated hereby and thereby.
     5.5 Solvency . Neither the eHealth nor any of its Subsidiaries has: (a) made a general assignment for the benefit of creditors, (b) filed any voluntary petition in bankruptcy or suffered the filing of any involuntary petition by its creditors, (c) suffered the appointment of a receiver to take possession of all, or substantially all, of its assets, (d) suffered the attachment or other judicial seizure of all, or substantially all, of its assets, (e) admitted in writing its inability to pay its debts as they come due, (f) made an offer of settlement, extension or composition to its creditors generally, or (g) taken any corporate action in furtherance of any of the foregoing. eHealth is, and after giving effect to the transactions to be effected pursuant to this Agreement (including the incurrence of all obligations being incurred in connection herewith), will be immediately following the Closing, Solvent. “Solvent” means, when used with respect to any Person, that, as of any date of determination: (i) the fair saleable value of such Person’s assets, as of such date, exceeds the value of its liabilities, including all contingent and other liabilities, (ii) such Person will not have, as of such date, an unreasonably small amount of capital for the businesses in which it is engaged or in which management has indicated it intends to engage, and (iii) such Person will be able to pay its liabilities, including all contingent and other liabilities, as they mature. For purposes of this definition: (1) “fair saleable value” means the aggregate amount of net consideration (as of any date of determination and giving effect to reasonable and customary costs of sale or taxes, where the probable amount of any such taxes is identified by such Person) that could be expected to be realized from an interested purchaser by a seller, in an arm’s length transaction under present conditions in a current market for the sale of assets of a comparable business enterprise, where both parties are aware of all relevant facts and neither party is under any compulsion to act, where such seller is interested in disposing of the entire operation as a going concern, presuming the business will be continued in its present form and character, and with reasonable promptness, not to exceed one year; (2) “liabilities, including all contingent and other liabilities” have the meanings that are generally determined in accordance with applicable federal laws governing determinations of the insolvency of debtors; (3) “contingent and other liabilities” means the contingent and other liabilities known to such Person; and (4) “not have an unreasonably small amount of capital for the businesses in which it is engaged or in which management has indicated it intends to engage” and “able to pay its liabilities, including all contingent and other liabilities, as they mature” mean that such Person will be able to generate enough cash from operations, asset dispositions, refinancing, or a combination thereof, to meet its obligations (including all contingent and other liabilities) as they become due.

-13-


 

ARTICLE VI
ADDITIONAL AGREEMENTS
     6.1 Access Pending the Closing. During the period commencing on the date of this Agreement and continuing through the earlier of the last Closing pursuant to this Agreement and the termination of this Agreement pursuant to Article IX , HBDC, upon reasonable prior notice from eHealth to HBDC, will (i) afford eHealth and its representatives, at all reasonable times during normal business hours, reasonable access to HBDC’s and its Subsidiaries’ personnel, professional advisors, properties, contracts, Books and Records and other documents and data relating to the Transition Policies, the Transition Assets and/or the Assumed Obligations, (ii) furnish eHealth and its representatives with copies of all Contracts, Books and Records, and other existing documents and data as eHealth may reasonably request, and (iii) furnish eHealth with such additional data and information as eHealth may reasonably request, in each case relating to the Transition Policies, Transition Assets or the Assumed Obligations. No information or knowledge obtained in any investigation pursuant to this Section 6.1 shall affect or be deemed to modify any representation or warranty contained herein or the conditions to the obligations of the parties hereto to consummate the transactions contemplated hereby.
     6.2 Operation of the Business by HBDC . During the period commencing on the date of this Agreement and continuing through the earlier of the Closing of the last BOR Transfer and any termination of this Agreement pursuant to Article IX , unless otherwise agreed in writing by eHealth, HBDC will except as otherwise allowed or required pursuant to the terms of this Agreement:
          (a) conduct the Business in the Ordinary Course of Business in a manner that enables HBDC to comply with subsections (b) and (c) below and its other obligations under this Agreement. The Parties understand and agree that HBDC shall not be obligated to market or sell new insurance policies after the date of this Agreement, except as set forth in the Marketing and Referral Agreement;
          (b) use commercially reasonable, good faith efforts to maintain the Transferred Policies where BOR status has not been transferred to eHealth; and
          (c) maintain the Books and Records and the Lead Database in the usual, regular and ordinary manner, on a basis consistent with prior years.
     6.3 Conduct Prior to Closing. Except as otherwise expressly permitted by this Agreement, between the date of this Agreement and continuing through the earlier of the Closing of the last BOR Transfer and any termination of this Agreement pursuant to Article IX , HBDC will not, take any action, or fail to take any action, as a result of which any of the changes or events described in Section 4.5 of this Agreement would reasonably be expected to occur. In addition, HBDC will not, and shall ensure that its Subsidiaries do not, without the prior written consent of eHealth:
          (a) take any action to impair, encumber, create a Lien against or otherwise adversely affect the Transition Assets or the Transition Policies;

-14-


 

          (b) other than as described on Schedule 4.5 to the HBDC Disclosure Schedule, propose or enter into a Contract with any person, other than eHealth, providing for the possible acquisition, transfer or disposition of the Business or any of the Transition Assets;
          (c) enter into any Contract relating to any of the Transition Policies, Transition Assets or Assumed Obligations;
          (d) take any action, or fail to take any action, which would result in any of the representations and warranties set forth in Article IV not being true and correct on and as of the Closing Date with the same force and effect as if such representations and warranties had been made on and as of the Closing Date;
          (e) take, or agree in writing or otherwise to take, any of the actions described in Sections 6.3(a) through (d) above, or any other action that would prevent HBDC from performing or cause HBDC not to perform its covenants hereunder.
     6.4 Confidentiality. eHealth and HBDC acknowledge that they have entered into a Confidentiality Agreement and a Nondisclosure and Nonuse Agreement dated November 6, 2008 (the “ NDA ”). The NDA shall terminate upon the initial Closing under this Agreement and the terms of the Confidentiality Agreement shall govern all information shared between eHealth and HBDC prior to the date of such initial Closing and all information shared after such Closing relating to this Agreement; provided, however, that the following information shall become “Confidential Information” (as such term is used in the Confidentiality Agreement) of eHealth under the Confidentiality Agreement and not “Confidential Information” of HBDC: (i) after the Closing of a portion of the BOR Transfer relating to a Carrier Book, all non-public information relating to the Transition Policies (and the holders thereof) that form a part of such Carrier Book and the Books and Records and Assumed Obligations (if any) relating to such Carrier Book; and (ii) after the first Closing relating to any portion of the BOR Transfer, the Lead Database. Without limiting the foregoing, (i) from and after the first Closing hereunder, HBDC shall not use or disclose the Lead Database (or any information contained therein) for any purpose other than in connection with the performance of its obligations under this Agreement or the Marketing and Referral Agreement; (ii) from and after the first Closing hereunder, HBDC shall not disclose the information on Transition Commission Payment Statements; and (iii) from and after the Closing of a portion of the BOR Transfer relating to a Carrier Book, HBDC shall not use or disclose the name, e-mail address or other contact information or personally identifiable information relating to any holder of a Transition Policy that forms a part of such Carrier Book other than in connection with the performance of its obligations under this Agreement or the Marketing and Referral Agreement.
     6.5 No Solicitation. From and after the date of this Agreement until the earlier to occur of the last Closing of a BOR Transfer or termination of this Agreement pursuant to its terms, HBDC, its Subsidiaries and HBDC’s and its Subsidiaries’ directors, officers, employees, representatives, investment bankers, agents and affiliates shall not, directly or indirectly (a) solicit or encourage submission of any Acquisition Proposal (as defined herein) by any person, entity, or group (other than eHealth and its affiliates, agents and representatives) or (b) participate in any discussions or negotiations with, or disclose any information concerning the Transition Assets, or afford access to the properties, books or records with respect to the Transition Assets, or otherwise assist or facilitate, or enter into any agreement or understanding with, any person, entity or group (other than eHealth

-15-


 

and its affiliates, agents, and representatives) in connection with any Acquisition Proposal. For purposes of this Agreement, an “ Acquisition Proposal ” means any proposal or offer relating to any sale, acquisition, purchase or license of all or any portion of the Transition Assets. HBDC will, and will cause its Subsidiaries to, immediately cease and cause to be terminated any and all existing activities, discussion, or negotiations with any parties conducted heretofore with respect to any of the foregoing. HBDC will promptly (A) notify eHealth if it or any of its Subsidiaries receives any written proposal or written inquiry or written request for information in connection with an Acquisition Proposal or potential Acquisition Proposal and (B) notify eHealth of the significant terms and conditions of any such Acquisition Proposal including the identity of the party making an Acquisition Proposal.
     6.6 Notification of Certain Matters. HBDC shall give prompt notice to eHealth of (a) the occurrence or non-occurrence of any event, the occurrence or non-occurrence of which is likely to cause any representation or warranty of HBDC contained in this Agreement to be untrue or inaccurate at or prior to a Closing, and (b) any failure of HBDC to comply with or satisfy any covenant, condition or agreement to be complied with or satisfied by it hereunder; provided, however, that the delivery of any notice pursuant to this Section 6.6 shall not (i) limit or otherwise affect any remedies available to the party receiving such notice or (ii) constitute an acknowledgment or admission of a breach of this Agreement. No disclosure by HBDC pursuant to this Section 6.6 , however, shall be deemed to amend or supplement the HBDC Disclosure Schedule or prevent or cure any misrepresentations, breach of warranty or breach of covenant.
     6.7 Public Disclosure. eHealth and HBDC shall consult with each other before issuing any press release or otherwise making any public statement with respect to this Agreement or any Ancillary Agreement, eHealth’s acquisition of the Transition Assets, the other party or parties hereto, or any Acquisition Proposal, and shall not issue any such press release or make any such public statement prior to such consultation, except as may be required by applicable law or, with respect to eHealth any rules of or listing agreement with a national securities exchange or Nasdaq. Notwithstanding the foregoing, neither eHealth or HBDC shall issue any press release relating to this Agreement, any Ancillary Agreement or HBDC’s relationship with eHealth without the other party’s prior written consent.
     6.8 Communication with and Service of Holders of Transition Policies . Except with respect to HBDC’s Ordinary Course of Business communications prior to the date of a BOR Transfer and any communications by eHealth after a BOR Transfer, eHealth and HBDC shall cooperate and consult with each other with respect to communications to the holders of Transition Policies. HBDC shall cooperate with eHealth as reasonably requested by eHealth in connection with any communications to holders of Transition Policies notifying them of the BOR Transfer. After the BOR Transfer, eHealth will perform all ongoing broker-related duties and services with respect to the holders of Transition Policies in accordance with industry standards.
     6.9 Consents. Unless otherwise notified by eHealth in writing, HBDC shall use its best efforts to obtain the consents, waivers and approvals necessary to effectuate the transactions contemplated by this Agreement, including under any contractual or other restrictions relating to the Transition Assets that are necessary to permit the transfer of such Transition Assets to eHealth in connection with this Agreement. eHealth shall reasonably cooperate with HBDC in its efforts to obtain such consents, waivers and approvals.

-16-


 

     6.10 Legal Requirements. Each of eHealth and HBDC will take all commercially reasonable actions necessary to comply promptly with all legal requirements which may be imposed on such party with respect to this Agreement and the transactions contemplated hereby and will promptly cooperate with and furnish information to any other party hereto in connection with any such requirements imposed upon such other party in connection herewith. Each party will take all commercially reasonable actions to obtain (and will cooperate with the other parties in obtaining) any consent, authorization, order or approval of, or any registration, declaration, or filing with, or an exemption by, any Governmental Entity, or other third party, required to be obtained or made by such party or its Subsidiaries in connection with this Agreement and consummating the transactions contemplated hereby or the taking of any action contemplated by this Agreement.
     6.11 Estimated Lifetime Value . eHealth and HBDC agree that, after the execution of this Agreement and prior to the Closing of the BOR Transfer with respect to any Carrier Book, eHealth and HBDC shall attempt in good faith to agree upon the Estimated Lifetime Value of such Carrier Book, subject to HBDC’s compliance with the provisions of this Agreement (including, without limitation, by providing eHealth with any information eHealth reasonably requests relating to such Estimated Lifetime Value) and to the relevant Specified Carrier’s provision of information reasonably requested by eHealth.
     6.12 Additional Documents and Further Assurances. At any time or from time to time after the Closing, at eHealth’s reasonable request and without any further consideration, HBDC shall and shall cause its Subsidiaries to: (a) execute and deliver to eHealth such other instruments of sale, transfer, conveyance, assignment and confirmation; (b) provide such materials and information; and (c) take such other actions, as eHealth may reasonably deem necessary or desirable in order more effectively to transfer, convey and assign to eHealth, to confirm eHealth’s title to, all of the Transition Assets, to put eHealth in actual possession and operating control of the Transition Assets, to assist eHealth in exercising all rights with respect thereto, to ensure that eHealth receives commissions on the Transition Policies at the same rate and in the same manner as such commissions were received prior to the date of this Agreement, and otherwise to cause HBDC to fulfill its obligations under this Agreement and the Ancillary Agreements. Without limiting the foregoing, HBDC agrees to maintain its books and records relating to the Transition Policies and to provide eHealth with reasonable access thereto.
     6.13 HBDC Receipt of Commission Payments . It is the intent of the parties to effect the BOR Transfer referenced in this Agreement such that eHealth shall receive all commission payments made on or after February 1, 2009 for Transition Policies that are in force on or after February 1, 2009 (the “ Transition Commissions ”). Accordingly, if HBDC receives any Transition Commissions from any Specified Carrier, HBDC shall immediately notify eHealth and pay to eHealth the full amount of such Transition Commission payment (without offset of any kind) and shall provide all statements or other documents received from the Specified Carrier in connection therewith. In accordance with Sections 3.2(b) and 3.4 , eHealth will thereafter remit to HBDC the Transition Commission Payments relating to such Transition Policies. If HBDC receives any Transition Commissions from any Specified Carrier prior to the Closing of the BOR Transfer with respect to such Specified Carrier’s Carrier Book, HBDC shall, in accordance with this Section 6.13 , pay to eHealth the full amount of such Transition Commissions at such Closing, and eHealth shall thereafter remit to HBDC the appropriate Transition Commission Payments in accordance with Sections 3.2(b) and 3.4 .

-17-


 

     6.14 eHealth Receipt of Commission Payments . It is the intent of the parties to effect the BOR Transfer referenced in this Agreement such that HBDC shall continue to receive all commission payments made on or after February 1, 2009 for Excluded Policies that are in force on or after February 1, 2009. Accordingly, if eHealth receives any commission payments for Excluded Policies from any Specified Carrier, eHealth shall immediately notify HBDC and pay to HBDC the full amount of such commission payment (without offset of any kind) for such Excluded Policies and shall provide all statements or other documents received from the Specified Carrier in connection therewith. If eHealth receives any commission payments for Excluded Policies from any Specified Carrier prior to the Closing of the BOR Transfer with respect to such Specified Carrier’s Carrier Book, eHealth shall, in accordance with this Section 6.14 , pay to HBDC the full amount of such commission payments for Excluded Policies at such Closing.
     6.15 Liens. HBDC covenants and agrees to satisfy when due all obligations of HBDC or its Subsidiaries that have resulted or result in the imposition of any Lien on any of the Transition Assets.
     6.16 Ancillary Agreements. Each of eHealth and HBDC shall execute and deliver the Ancillary Agreements required to be executed by them.
ARTICLE VII
CONDITIONS TO THE CLOSING
     7.1 Conditions to Obligations of Each Party. The respective obligations of eHealth and HBDC to effect the transactions contemplated hereby (including the Closing of each portion of the BOR Transfer relating to a Specified Carrier’s Carrier Book) shall be subject to the satisfaction, at or prior to the Closing, of the following conditions:
          (a) No Order . No Governmental Entity shall have enacted, issued, promulgated, enforced or entered any statute, rule, regulation, executive order, decree, injunction or other order (whether temporary, preliminary or permanent) which is in effect and which has the effect of making the transactions contemplated hereby illegal or otherwise prohibiting the consummation of the transactions contemplated hereby.
          (b) No Injunctions or Restraints; Illegality . No temporary restraining order, preliminary or permanent injunction or other order issued by any court of competent jurisdiction or other legal restraint or prohibition preventing the consummation of the transactions contemplated hereby shall be in effect, nor shall any proceeding brought by a Governmental Entity be seeking any of the foregoing be pending.
     7.2 Additional Conditions to the Obligations of eHealth. The obligation of eHealth to effect the transactions contemplated hereby shall be subject to the satisfaction at or prior to a Closing (including the Closing of each portion of the BOR Transfer relating to a Specified Carrier’s Carrier Book) of each of the following conditions, any of which may be waived, in writing, exclusively by eHealth:

-18-


 

          (a) Representations, Warranties and Covenants . (i) The representations and warranties of the HBDC contained in this Agreement shall be true and correct, in each case on the date of this Agreement and as of each Closing Date; and (ii) HBDC shall have performed and complied in all material respects with all covenants and obligations under this Agreement required to be performed or complied with by HBDC as of the Closing.
          (b) Governmental Approval . Approvals from any court, administrative agency, commission or other federal, state, county or local deemed appropriate or necessary by eHealth shall have been timely obtained.
          (c) Litigation . There shall be no Action or Proceeding of any nature pending or threatened against (i) HBDC, its properties or any of its officers or directors arising out of, or in any way connected with, the transactions contemplated by this Agreement or any Ancillary Agreement; or (ii) HBDC, its properties or any of its officers or directors arising out of, or in any way connected with, the Business or the Transition Assets that could reasonably be expected to impair eHealth’s rights in the Transition Assets in any material respect, or (iii) the Business or the Transition Assets that could reasonably be expected to impair eHealth’s rights in the Transition Assets in any material respect.
          (d) Officer’s Certificate . eHealth shall have received a certificate (“ Officer’s Certificate”) validly executed by the Chief Financial Officer of HBDC for and on its behalf, to the effect that, as of the Closing, each of the conditions set forth in this Section 7.2 have been satisfied (unless otherwise waived by eHealth in accordance with the terms hereof) and setting forth the amount of Transition Commissions received on any Transition Policies in the Carrier Book that relate to the Closing.
          (e) Certificate of Secretary of HBDC . eHealth shall have received a certificate, validly executed by the Secretary of HBDC, certifying as to the valid adoption of resolutions of the Board of Directors of HBDC approving this Agreement and the consummation of the transactions contemplated hereby.
          (f) BOR Transfer Letter . HBDC shall have delivered to the relevant Specified Carrier (in such form as the Specified Carrier may request) a request to transfer BOR status to eHealth.
          (g) Specified Carrier Consents . eHealth shall have received all consents, approvals and agreements as eHealth deems necessary or appropriate in connection with the portion of the BOR Transfer that is the subject of the Closing.
          (h) Financing . eHealth shall have received from HBDC written confirmation and/or documents reasonably satisfactory to eHealth demonstrating that HBDC has closed its most recent round of financing and that HBDC has sufficient cash to operate its business for at least six (6) months after the final Closing Date.
          (i) Third Party Consents . eHealth shall have received all other consents, waivers, approvals, Lien releases, licenses and assignments required in connection with the execution and delivery of this Agreement or any Ancillary Agreement, or to consummate the transactions contemplated hereby or thereby to eHealth’s satisfaction.

-19-


 

          (j) Reserved; Not used.
          (k) Estimated Lifetime Value . eHealth and HBDC shall have agreed upon the Estimated Lifetime Value of the Carrier Book that is the subject of the Closing and such agreement shall be evidenced in a writing executed by each of eHealth and HBDC.
          (l) Certifications of HBDC . eHealth shall have received such certifications and other documents in connection with the Closing of the transactions contemplated by this Agreement as eHealth shall reasonably request.
          (m) Deliveries . HBDC shall have delivered to eHealth executed copies of the Ancillary Agreements and a completed Form W-9 and shall have delivered, transferred or assigned (as the case may be) all of the Transition Assets related to the BOR Transfer that is the subject of the Closing.
          (n) Lead Database . HBDC shall have (i) delivered to eHealth the Lead Database in such manner as eHealth shall reasonably request; and (ii) implemented the links as set forth in the Marketing and Referral Agreement.
          (o) Excess GRIC Liability . As a condition to the Closing of the portion of the BOR Transfer relating to GRIC Transition Policies, the Excess GRIC Liability shall have been paid and eHealth and HBDC both shall have received evidence reasonably satisfactory to both eHealth and HBDC of such payment.
     7.3 Conditions to Obligations of HBDC. The obligations of HBDC to consummate and effect the transactions contemplated hereby (including the Closing of each portion of the BOR Transfer relating to a Specified Carrier’s Carrier Book) shall be subject to the satisfaction at or prior to the Closing of each of the following conditions, any of which may be waived, in writing, exclusively by HBDC:
          (a) Representations, Warranties and Covenants . (i) The representations and warranties of eHealth contained in this Agreement shall be true and correct in each case on the date of this Agreement and as of each Closing Date; and (ii) eHealth shall have performed and complied in all material respects with all covenants and obligations under this Agreement required to be performed or complied with by eHealth as of the Closing.
          (b) Deliveries . eHealth shall have delivered to HBDC executed copies of each Ancillary Agreement required to be executed by it.
          (c) Specified Carrier Consents . HBDC shall have received all Specified Carrier consents, approvals and agreements necessary to effect the BOR Transfer that is the subject of the Closing.
          (d) Estimated Lifetime Value . eHealth and HBDC shall have agreed upon the Estimated Lifetime Value of the Carrier Book that is the subject of the Closing and such agreement shall be evidenced in a writing executed by each of eHealth and HBDC.

-20-


 

          (e) Referral Website . eHealth shall have implemented the referral website described in the Marketing and Referral Agreement.
ARTICLE VIII
SURVIVAL OF REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION
     8.1 Survival of Representations and Warranties. The representations and warranties of HBDC contained in this Agreement or in any certificate or other instrument delivered pursuant to this Agreement, shall survive the Closing hereunder.
     8.2 Indemnification .
          (a) HBDC Indemnification . HBDC hereby agrees to indemnify and hold eHealth and eHealth, Inc. (eHealth’s parent corporation), and each of their stockholders, officers, directors, employees, agents, attorneys, representatives and affiliates (collectively, the “ Purchaser Indemnified Parties ”), harmless against all claims, losses, liabilities, damages, deficiencies, costs and expenses, including reasonable attorneys’ fees and expenses of investigation and defense (hereinafter individually a “ Loss ” and collectively “ Losses ”), incurred or sustained by such Persons, directly or indirectly, as a result of (i) any breach or inaccuracy of a representation or warranty of HBDC contained in this Agreement, the Ancillary Agreements, or in any certificate, instrument, or other document delivered by HBDC pursuant to this Agreement (without giving effect to any limitation as to “materiality,” “material adverse effect,” or similar qualifications set forth therein); (ii) any failure by HBDC to perform or comply with any covenant applicable to it contained in this Agreement or the Ancillary Agreements; and (iii) any Excluded Liability.
          (b) eHealth Indemnification . eHealth hereby agrees to indemnify and hold HBDC, and each of HBDC’s stockholders, officers, directors, employees, agents, attorneys, representatives and affiliates (collectively, the “ HBDC Indemnified Parties ”), harmless against all Losses, incurred or sustained by such Persons, directly or indirectly, as a result of (i) any breach or inaccuracy of a representation or warranty of eHealth contained in this Agreement or in any certificate, instrument, or other document delivered by eHealth pursuant to this Agreement (without giving effect to any limitation as to “materiality,” “material adverse effect,” or similar qualifications set forth therein); (ii) any failure by eHealth to perform or comply with any covenant applicable to it contained in this Agreement and to be performed by eHealth after the Closing.
     8.3 Indemnification Procedure. Any Person seeking indemnification pursuant to this Article VIII (the “Indemnified Party”) shall give notice of an Indemnification Claim (as defined below) by delivery of an Indemnification Certificate (as defined in the immediately succeeding sentence) to the party from whom indemnification is sought (the “ Indemnifying Party ”). For purposes hereof, “ Indemnification Certificate ” shall mean a certificate signed by any officer or duly authorized representative of an Indemnified Party (i) stating that the Indemnified Party has paid, sustained, incurred, or properly accrued, or reasonably anticipates that it will have to pay, sustain, incur, or accrue Losses, and (ii) specifying in reasonable detail the individual items of Losses included in the amount so stated, the date each such item was paid, sustained, incurred or properly accrued, or the basis for such anticipated liability, and the nature of the indemnification claim

-21-


 

hereunder. The Indemnifying Party may object to any Indemnification Claim set forth in an Indemnification Certificate by delivery to the Indemnified Party of a written statement of objection (an “ Indemnification Objection Notice ”) within twenty (20) calendar days’ of receipt of an Indemnification Certificate. “ Indemnification Claim ” shall mean any matter which an Indemnified Party has determined has given rise to a right of indemnification under this Agreement.
     8.4 Resolution of Conflicts; Arbitration.
          (a) If an Indemnifying Party delivers an Indemnification Objection Notice to the Indemnified Party in accordance with Section 8.3 , the Indemnifying Party and the Indemnified Party shall meet in good faith to attempt to agree upon the rights of the respective parties with respect to each Indemnification Claim. If the Indemnifying Party and the Indemnified Party should so agree, a memorandum setting forth such agreement shall be prepared and signed by both parties.
          (b) If no such agreement can be reached after good faith negotiation and prior to forty-five (45) calendar days after delivery of an Indemnification Objection Notice, either the Indemnifying Party or the Indemnified Party may demand arbitration of the matter unless the amount of the Loss that is at issue is the subject of pending litigation with respect to a Third Party Claim (as defined below), in which event arbitration shall not be commenced until such amount is ascertained or both parties agree to arbitration, and in either such event the matter shall be settled by arbitration conducted by one arbitrator mutually agreeable to the Indemnifying Party and the Indemnified Party. In the event that, within thirty (30) calendar days after submission of any dispute to arbitration, the Indemnifying Party and the Indemnified Party cannot mutually agree on one arbitrator, then, within fifteen (15) calendar days after the end of such thirty (30) calendar day period, the Indemnifying Party and the Indemnified Party shall each select one arbitrator. The two arbitrators so selected shall select the arbitrator.
          (c) Any such arbitration shall be held in Santa Clara County, California, under the rules then in effect of the American Arbitration Association. The arbitrator shall determine how all expenses relating to the arbitration shall be paid, including without limitation, the respective expenses of each party, the fees of the arbitrator and the administrative fee of the American Arbitration Association. The arbitrator shall set a limited time period and establish procedures designed to reduce the cost and time for discovery while allowing the parties an opportunity, adequate in the sole judgment of the arbitrator to discover relevant information from the opposing parties about the subject matter of the dispute. The arbitrator shall rule upon motions to compel or limit discovery and shall have the authority to impose sanctions, including attorneys’ fees and costs, to the same extent as a competent court of law or equity, should the arbitrator determine that discovery was sought without substantial justification or that discovery was refused or objected to without substantial justification. The decision of the arbitrator as to the validity and amount of any Indemnification Claim in such Indemnification Certificate shall be final, binding, and conclusive upon the Indemnifying Party and the Indemnified Party. Such decision shall be written and shall be supported by written findings of fact and conclusions that shall set forth the award, judgment, decree or order awarded by the arbitrator. Judgment upon any award rendered by the arbitrator may be entered in any court having jurisdiction. The foregoing arbitration provision shall apply to any dispute between an Indemnifying Party and any Indemnified Party pursuant to this Article VIII .

-22-


 

     8.5 Third Party Claims. In the event an Indemnified Party becomes aware of a third-party claim which such Indemnified Party reasonably believes may result in a demand for indemnification pursuant to this Article VIII (a “ Third Party Claim ”), the Indemnified Party shall notify the Indemnifying Party of such claim, and the Indemnifying Party shall be entitled, at its expense, to participate in, but not to determine or conduct, the defense of such claim. The Indemnified Party shall have the right, in its sole discretion, to conduct the defense of and settle any such Third Party Claim; provided, however, that except with the consent of the Indemnifying Party, no settlement of any such Third Party Claim shall alone be determinative of the amount of Losses relating to such matter. In the event that the Indemnifying Party has consented to any such settlement, the Indemnifying Party shall have no power or authority to object under any provision of this Article VIII to the amount of any claim by the Indemnified Party against the Indemnifying Party with respect to such settlement.
     8.6 Payment of Indemnification. In the event that (a) an Indemnifying Party shall not have timely objected to the amount claimed by an Indemnified Party for indemnification with respect to any Loss in accordance with the procedures set forth in Section 8.3 , or (b) an Indemnifying Party shall have delivered an Indemnification Objection Notice as to the amount of any indemnification requested by an Indemnified Party and either (i) the Indemnifying Party and the Indemnified Party shall have, subsequent to the giving of such notice, mutually agreed that the Indemnifying Party is obligated to indemnify the Indemnified Party for a specified amount, (ii) a final award shall have been rendered in an arbitration pursuant to Section 8.4 , or (iii) a final nonappealable judgment shall have been rendered by the court having jurisdiction over the matters relating to such Indemnification Claim by an Indemnified Party for indemnification from an Indemnifying Party, then the Indemnifying Party shall pay any such indemnification owed to the Indemnified Party within fifteen (15) calendar days of such mutual agreement or final nonappealable judgment, as applicable, by wire transfer in immediately available funds to an account directed by the Indemnified Party.
     8.7 Remedy. To the extent that an Indemnified Party may recover for Losses pursuant to Section 8.2 , such Indemnified Party agrees to take commercially reasonable steps to avoid and mitigate such Losses. In addition the amount of any claim for Losses shall be net of any amount actually recovered by an Indemnified Party pursuant to any insurance policy, provided, however, that the Indemnifying Party shall not be obligated to seek such recovery. HBDC and eHealth acknowledge that, except in the event of fraud, intentional misrepresentation or willful misconduct, the provisions of this Article VIII shall be their sole and exclusive remedy from and after the Closing for any claims arising under this Agreement; provided, however, the foregoing clause of this sentence shall not be deemed a waiver by eHealth of any right to specific performance or injunctive relief.
ARTICLE IX
TERMINATION, AMENDMENT AND WAIVER
     9.1 Termination. Except as provided in Section 9.2 , this Agreement may be terminated and the transactions contemplated hereby abandoned at any time prior to the first Closing hereunder:
          (a) By the mutual written agreement of the parties;

-23-


 

          (b) By either eHealth or HBDC, if (i) the first Closing has not occurred by March 15, 2009; provided , however , that the right to terminate this Agreement under this Section 9.1(b)(i) shall not be available to any party whose willful failure to fulfill any obligation hereunder or other breach of this Agreement has been the cause of, or resulted in, the failure of the Closing to occur on or before such date; (ii) there shall be in effect a final nonappealable order of a federal or state court preventing consummation of the transactions contemplated hereby; or (iii) there shall be any legal requirement enacted, promulgated or issued or deemed applicable to the transactions contemplated hereby by any Governmental Entity that would make consummation of the transactions contemplated hereby illegal;
          (c) By eHealth, if eHealth is not in material breach of its obligations under this Agreement and there has been a breach of any representation, warranty, covenant or agreement contained in this Agreement on the part of HBDC and (i) HBDC is not using its commercially reasonable efforts to cure such breach, or has not cured such breach within 15 days, after notice of such breach has been given by eHealth to HBDC in accordance with Section 10.1 ; provided , however , that, no cure period shall be required for any such breach which by its nature cannot be cured and (ii) as a result of such breach, one or more of the conditions set forth in Section 7.1 or Section 7.2 would not be satisfied at or prior to the Closing;
          (d) By HBDC, if it is not in material breach of its obligations under this Agreement and there has been a breach of any representation, warranty, covenant or agreement contained in this Agreement on the part of eHealth and (i) eHealth is not using its commercially reasonable efforts to cure such breach, or has not cured such breach within 15 days, after notice of such breach has been given by HBDC to eHealth in accordance with Section 10.1 ; provided , however , that, no cure period shall be required for any such breach which by its nature cannot be cured and (ii) as a result of such breach, one or more of the conditions set forth in Section 7.1 or Section 7.3 would not be satisfied at or prior to the Closing; or
     9.2 Effect of Termination. In the event of termination of this Agreement as provided in Section 9.1 , this Agreement shall forthwith become void and there shall be no liability or obligation on the part of any party hereto, or its affiliates, officers, directors or stockholders; provided that each party shall remain liable for any willful breaches of this Agreement prior to its termination; and provided further that, the provisions of Section 6.4 (confidentiality), Section 6.7 (public disclosure), Article X and this Section 9.2 of this Agreement shall remain in full force and effect and survive any termination of this Agreement. Notwithstanding the foregoing, nothing contained herein shall relieve any party from liability for any willful breach hereof.
     9.3 Amendment. This Agreement may be amended by the parties hereto at any time by execution of an instrument in writing signed on behalf of each of the parties hereto.
     9.4 Extension; Waiver. At any time prior to the Closing, eHealth, on the one hand, and HBDC, on the other hand, may, to the extent legally allowed, (a) extend the time for the performance of any of the obligations of the other party hereto, (b) waive any inaccuracies in the representations and warranties made to such party contained herein or in any document delivered pursuant hereto and (c) waive compliance with any of the agreements or conditions for the benefit of such party contained herein. Any agreement on the part of a party hereto to any such extension or waiver shall be valid only if set forth in an instrument in writing signed on behalf of such party.

-24-


 

ARTICLE X
GENERAL PROVISIONS
     10.1 Notices. All notices and other communications hereunder shall be in writing and shall be deemed given upon receipt if delivered personally or by commercial delivery service, or upon receipt or refusal of delivery if mailed by registered or certified mail (return receipt requested) or sent via facsimile (with acknowledgment of complete transmission from the recipient of such facsimile) to the parties at the following addresses (or at such other address for a party as shall be specified by like notice):
          (a) if to eHealth, to:
eHealthInsurance Services, Inc.
440 East Middlefield Road
Mountain View, California 94043
Attention: Bruce Telkamp, Executive Vice President
Telephone No.: 650.210.3131
Facsimile No.: 650.961.2141
          (b) if to HBDC, to:
Health Benefits Direct Corporation
Radnor Financial Center
150 North Radnor Chester Road, Suite B101
Radnor, PA 19087
Attn: Anthony R. Verdi, Chief Financial Officer
Telephone No.: 484.654.2206
Facsimile No.: 484.654.2212
and also under separate cover to
Health Benefits Direct Corporation
Radnor Financial Center
150 North Radnor Chester Road, Suite B101
Radnor, PA 19087
Attn: Francis L. Gillian III, Vice President / Controller
Telephone No.: 484.654.2203
Facsimile No.: 484.654.2209
     10.2 Expenses. All fees and expenses incurred in connection with this Agreement including, without limitation, all legal, accounting, financial advisory, consulting and all other fees and expenses of third parties (including without limitation brokerage or finders’ fees, agents’ commissions or any similar charges) incurred by a party hereto, in connection with the negotiation and effectuation of the terms and conditions of this Agreement and the transactions contemplated hereby, shall be the obligation of the respective party incurring such fees and expenses.

-25-


 

     10.3 Right of Offset . eHealth shall have the right to offset against amounts owed to HBDC pursuant to this Agreement or any Ancillary Agreement, any amount owed by HBDC to eHealth pursuant to the terms of this Agreement or an Ancillary Agreement.
     10.4 Entire Agreement; Assignment. This Agreement and Schedules hereto, the Ancillary Agreements, the HBDC Disclosure Schedule, the NDA, the Confidentiality Agreement and the documents and instruments and other agreements among the parties hereto referenced herein: (a) constitute the entire agreement among the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings both written and oral, among the parties with respect to the subject matter hereof and thereof; and (b) are not intended to confer upon any other person any rights or remedies hereunder. This Agreement shall not be assigned by operation of law or otherwise without the written consent of the other party hereto. Notwithstanding the foregoing, (i) eHealth may, without written consent, assign all of the rights and obligations under this Agreement in connection with any sale of eHealth whether by means of an asset sale, stock sale or merger; and (ii) after all Closings hereunder, HBDC may, without written consent, assign all of the rights and obligations under this Agreement in connection with the sale of HBDC.
     10.5 Severability. In the event that any provision of this Agreement or the application thereof, becomes or is declared by a court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement will continue in full force and effect and the application of such provision to other persons or circumstances will be interpreted so as reasonably to effect the intent of the parties hereto. The parties further agree to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the economic, business and other purposes of such void or unenforceable provision.
     10.6 Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of California, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws thereof.
     10.7 No Third Party Beneficiaries. This Agreement shall not confer any rights or remedies upon any person or entity other than the parties hereto and their respective successors and permitted assigns.
     10.8 Specific Performance. The parties hereto agree that irreparable damage will occur in the event that any of the provisions of this Agreement are not performed in accordance with their specific terms or are otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which they are entitled at law or in equity.
     10.9 Waiver of Jury Trial. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY AND ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE ACTIONS OF ANY PARTY HERETO IN NEGOTIATION, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT HEREOF.

-26-


 

     10.10 Counterparts . This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other party, it being understood that all parties need not sign the same counterpart. This Agreement may be executed and delivered by facsimile or electronic transmission.
*****

-27-


 

     IN WITNESS WHEREOF, eHealth and HBDC have caused this Client Transition Agreement to be signed as of the date first written above.
         
“EHEALTH”  EHEALTHINSURANCE SERVICES, INC.
a Delaware corporation
 
 
  By:      
                                                         
“HBDC”
         
  HEALTH BENEFITS DIRECT CORPORATION
a Delaware corporation
 
 
  By:      
                                                         
       
 
  HBDC II, INC.
a Delaware corporation
 
 
  By:      
                                                         
       
 

 

Exhibit 21
SUBSIDIARIES OF HEALTH BENEFITS DIRECT CORPORATION
Health Benefits Direct Corporation’s (“Registrant”) subsidiaries as of December 31, 2008, are listed below.
         
Subsidiary   Ownership   Jurisdiction
 
Insurance Specialist Group
  100% owned by Registrant   Florida
HBDC II, Inc.
  100% owned by Registrant   Delaware
Insurint Corporation
  100% owned by Registrant   Delaware
Platinum Partners, LLC
  100% owned by HBDC II, Inc.   Florida
Atiam Technologies LLC
  100% owned by Registrant   Delaware

 

Exhibit 23.1
1900 NW Corporate Boulevard, Suite E210
Boca Raton, Florida 33431
Tel. 561-886-4200
Fax. 561-886-3330
e-mail:info@sherbcpa.com
Offices
in New York
and Florida
Sherb & Co.
Certified Public Accountants
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors
Health Benefits Direct Corporation
We hereby consent to the incorporation by reference in the Registration Statements of Health Benefits Direct Corporation on Forms SB-2 and S-1 (Nos. 333-123081, 333-133182, 333-142556 and 333-149015) and on Form S-8 (No. 333-142036) and the related prospectuses of our audit report dated March 26, 2009 with respect to the consolidated balance sheet at December 31, 2008 and 2007 and consolidated statements of operations, changes in shareholders’ equity and cash flows of Health Benefits Direct Corporation for the years then in the Form 10-K.
     
Boca Raton, Florida
March 31, 2009
  /s/ Sherb & Co., LLP
Certified Public Accountants

 

Exhibit 31.1
CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Anthony R. Verdi, certify that:
     (1) I have reviewed this annual report on Form 10-K of Health Benefits Direct Corporation;
     (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     (3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     (4) The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:
          a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under the Company’s supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to the Company by others within those entities, particularly during the period in which this report is being prepared;
          b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
          c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this quarterly report the Company’s conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
          d) Disclosed in the report any change in the registrant’s internal control over financial reporting that has occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     (5) The registrant’s other certifying officer and I have disclosed, based on the Company’s most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 


 

          a) All significant deficiencies in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
          b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: March 31, 2009
         
   
/s/ Anthony R. Verdi    
Anthony R. Verdi   
Principal Executive Officer, Chief Financial Officer and Chief Operating Officer   

 

         
Exhibit 31.2
CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Anthony R. Verdi, certify that:
     (1) I have reviewed this annual report on Form 10-K of Health Benefits Direct Corporation;
     (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     (3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     (4) The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:
          a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under the Company’s supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to the Company by others within those entities, particularly during the period in which this report is being prepared;
          b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
          c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this quarterly report the Company’s conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
          d) Disclosed in the report any change in the registrant’s internal control over financial reporting that has occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     (5) The registrant’s other certifying officer and I have disclosed, based on the Company’s most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 


 

          a) All significant deficiencies in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
          b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: March 31, 2009
         
   
/s/ Anthony R. Verdi    
Anthony R. Verdi   
Principal Executive Officer, Chief Financial Officer and Chief Operating Officer   

 

         
EXHIBIT 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Health Benefits Direct Corporation (the “Company”) on Form 10-K for the year ended December 31, 2008 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Anthony Verdi, Principal Executive Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) of 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 31, 2009
         
   
/s/ Anthony R. Verdi    
Anthony R. Verdi   
Principal Executive Officer, Chief Financial Officer and Chief Operating Officer